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INTRODUCTION
In two outstanding respects morphine and related drugs are unique
among pharmacological agents. First* they exert a powerful and specific
effect upon the perception of pain of all types and* secondly they reliably and
predictably depress respiration. There is no other family of drugs with
strictly comparable effects. In their respiratory depressant effects*
particularly* they stand alone. These two properties - analgesia and
respiratory depression - appear in some way to be linked* and, as yet*
analgesic members of the group which are devoid of significant respiratory
depressant properties are not known (Eckenhoff and Oech, I960).
Another interesting property of this group of drugs is the development
of tolerance* with repeated administration* to certain of their important
pharmacological effects* and their liability to cause addiction and dependence
under certain conditions. In the human* following continued administration*
maximum tolerance develops to their most important clinical effects* namely*
narcosis* analgesia and respiratory depression (Reynolds and Randall* 1957).
In ordinary clinical practice, the respiratory depressant properties of
morphine and related drugs constitute a more serious limitation to their use
than the development of tolerance or the liability to addiction. Despite this,
there are surprisingly little quantitative data on the respiratory effects of
morphine in man. Further, although morphine has been used for a very
considerable period of time in the treatment of acute left ventricular failure*
only occasional studies have appeared in which measurements of the effects
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of the drug in this or other types of heart failure have been reported. Such
observations have* in general* been rather incomplete* and there is* as yet*
no satisfactory hypothesis which would account for the beneficial effects of
the drug in this condition.
A further point of interest is the comparative rarity of reports* in the
modern literature* of deaths or serious mishaps following the therapeutic use
of a drug which so regularly depresses respiration. The dangers of using
this drug in bronchial asthma* in cor pulmonale* in pulmonary emphysema
and in patients suffering from thoracic deformities with impaired pulmonary
ventilation are* of course* well documented (Katz and Chandler* 1948; Roussak*
1951; Samuelsson* 1952; Wilson* Hoseth and Dempsey* 1954). With a few
other exceptions (Jeghers and Brick* 1950) the clinical use of morphine would
seem* from the absence of reports to the contrary* not to carry serious
hazards. Notwithstanding* it seems legitimate to enquire whether the respiratory
depressant properties of the drug does involve* in actual clinical practice* a
measurable risk which might be precisely evaluated.
On the whole* the published literature on morphine has been more
concerned with studies bearing on the problem of drug addiction and with the
evaluation of the newer synthetic analgesics and opiate antagonists. Usually*
the presentation of respiratory data has been incidental to these other
objectives.
It seems a reasonable surmise that a drug with the remarkable and
pharmacologically unique property of depressing respiration in the conscious
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subject might be a useful tool for the study of the central control of
respiration. In 1962* when the writer became interested in the problem of
the control of breathing the use of morphine as an investigative tool appeared
worth considering. It was soon apparent* however* that the published data
on the respiratory effects of morphine were not adequate for the formulation
of any hypothesis which might usefully be tested by means of suitably designed
experiments. It is true that there was a nearly general consensus that the
respiratory centre was depressed by the drug. Despite this consensus* the
evidence available left unanswered many important questions* and* even the
idea itself has recently been called in question by a leading worker in the field
of narcotic pharmacology (Krueger* 1955).
It seemed to the writer that most of the uncertainty* particularly in
regard to studies on humans* could be attributed to faulty experimental design.
This criticism applies specially to the choice and standardisation of doses
used and the paucity of measurements or observations made.
It was decided* in consequence* to design an experiment de novo for
the quantitative study of the effects of morphine in man on respiration* oxygen
consumption and carbon dioxide output. As a result of encouraging results
from some preliminary studies performed during the Summer and Autumn of
1962* the details of the experimental design were decided later that year.
The goals of the project were laid down in advance as follows.
1. To measure in detail the effects of morphine on respiration* oxygen
consumption* carbon dioxide output and arterial gas tensions in normal
subjects and in individuals suffering from left ventricular failure.
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2. To determine the relationship of the effects noted to the size of dose
administered.
3. To formulate an hypothesis, on the basis of these observations, by which
the respiratory depressant and other observed effects of the drug might be
explained.
4. To find out whether or not the use of this drug would be likely to increase
understanding of the central mechanisms responsible for the control of
respiration.
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REVIEW OF LITERATURE ON THE PHARMACOLOGY
OF MORPHINE
I. HISTORICAL
The preparation of opium from the seed capsules of the poppy plant
°l
Fapaver sdmniferum has been practised since prehistoric times and its
y ~
medicinal use was known to the ancient Egyptian* Persian and Greek physicians.
Morphine, which comprises about 10% by weight of powdered opium is a
comparatively modern drug. Its isolation, in crude form, was first achieved
by Serturner in 1303 and, during the next two decades, its use in clinical
practice appears to have become fairly well known. It was first administered
on a large scale by the hypodermic route during the American Civil War when,
it is said, many addicts were produced as a result (Maurer and Vogel, 1954).
The use of the hypodermic needle was pioneered by Wood around 1853, this
worker's wife unfortunately becoming addicted to the drug in this way. The
first systematic quantitative studies on the respiratory depressant properties
of morphine appear to have been those of v. Bezold (1866), Gscheidlen (1869)
and Claud Bernard (1864), according to Krueger (1941). The view that the
drug depressed the respiratory centre appears first to have been suggested
by Gscheidlen (Krueger, 1941).
The extensive literature on morphine has been very well covered in a
number of reviews (Krueger, Eddy and Sumwalt, 1941; Wikler, 1950; Krueger,
1955; Reynolds and Randall, 1957; Eckenhoff and Oech, I960). The present
survey of the literature is more limited in scope than the aforementioned and
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has been undertaken also with somewhat different objectives. It will be
concerned, mainly, with an analysis of the published data, with particular
reference to man, on the effects of the drug on respiration and oxygen
consumption. For reasons which will later become apparent, the published
reports on possible stimulatory effects of the drug were closely studied.
Reports on the circulatory effects of morphine, both in laboratory animals
and in man, which appeared to have some relevance to the mechanism of
effect of the drug in individuals with left ventricular failure have also been
reviewed.
IX, THE HYPOTHESIS OF THE 'DUAL ACTION' OF MORPHINE
The view has been advanced that morphine has a dual effect consisting
of a mixture of simultaneous stimulation and depression on different parts
of the central nervous system (Tatum, Seevers and Collins, 1929; Seevers
and Deneau, 1962). The Erst reference to the diphasic action of morphine,
according to Krueger* Eddy and Sumwalt (1941), appears to be in the work of
v. Boeck and Bauer (1874), who categorise this action as a phase of stimulation
followed by a phase of depression.
The evidence that morphine has stimulant effects is not particularly
good. The idea is based mainly on the effect of the drug on the overt
behaviour of a few animal species and, also, on the observation that, in many
species, very large doses cause convulsions. Evidence that the drug has
stimulant effects upon non-addicted humans, is rather meagre, though not
entirely lacking.
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Signs of increased motor activity after morphine are observed in the
mouse* in the domestic cat and probably also in all feline species* and* to
some extent* in the dog. In the mouse a curious erection of the tail (Straub
reaction) is a fairly constant phenomenon occurring very soon after adminis¬
tration of morphine in suitable dose and associated with circling movements.
In the domestic cat motor restlessness associated with signs of sympathetic
activity* namely* pilo-erection and pupillary dilatation, very commonly
occurs after morphine. This phenomenon appears to be dose related. Tavat
and Ak ijasu (1956) report that doses less than 0.2 * 0.3 mg/kg did not produce
motor restlessness in the cat. This dose is at the upper limit of ordinarily
used therapeutic doses in man. Doses of this order and greater regularly
produced motor restlessness in their cats. Joel andArndts (1925) stated
that doses of 0.1 - 0.2 mg/kg caused definite depression in the cat* while
larger doses regularly produced excitement. Doses of 20 mg/kg or larger
caused convulsions. Guinard (1890) who used doses of 0.4 - 90 mg/kg
reported no obvious narcotic effects. Wikler (1944) reported that morphine
5 mg/kg given to intact cats intravenously initially caused a bradycardia*
slowing of respiration and marked sedation, the animal lying quietly on its
side and not responding to prodding* pinching or noise. Within 5-10
minutes* the pupils dilated widely and the animal became alert and stood up.
However, motor activity was poorly co-ordinated* the animal preferring to
lie or sit quietly and showed motor restlessness only if disturbed. Larger
doses caused spontaneous motor restlessness to appear immediately after
administration without any initial period of depression.
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Measurement of respiration and oxygen consumption in conscious cats
given morphine has only rarely been reported. Such studies have usually
shown an increase in minute ventilation and oxygen consumption (Krueger,
Eddy and Sumwalt, 1941).
Morphine given to conscious dogs does not cause overt excitement as
marked as that reported in cats. However* it has been noted that morphine
given to conscious dogs may fail to depress respiration or may even increase
this* even in the absence of any signs of overt excitement (Krueger* et al. 1941).
This is to be attributed, at least in part* to the role of respiration in this
species in promoting heat loss. At an appropriate environmental temperature
respiratory depression will occur (Wood and Cerna* 1892; Marshall and
Roaenf eld, 1937). Nevertheless a period of excitement following administration
of morphine has frequently been reported in the dog. Following intravenous
doses of 0.5 - 10 mg/kg (Schmidt and Livingstone, 1933) or of 2 mg/kg (Powers*
Reid and Gregersen* 1947) a brief period of restlessness and hyperventilation
lasting 1 - 2 minutes is regularly seen before longer lasting depression supervenes.
Recently* Dome r and Josselson (1984) has studied the occurrence of overt
excitement in dogs in relation to the dose of intravenous morphine administered.
Excitement did not occur after doses less than 0.5 mg/kg. Doses of 0.5 -
10 mg/kg caused the immediate appearance of behaviour which these workers
rather inappropriately call "sham rage" consisting of squealing, pawing and
snapping lasting 3 - 44 seconds* the duration being roughly parallel with the
size of dose. Hyperventilation* tachycardia and salivation appeared some
2-5 minutes later, following which the animal became calm and fell asleep if
unmolested.
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Large doses of morphine have caused the appearance of convulsions
in nearly all laboratory species studied. This has been generally interpreted
as evidence of stimulation. An increase in minute ventilation is associated
with these convulsant doses. In man* convulsions after morphine poisoning
are said to be rare (Krueger et al., 1941).
Documentary evidence that morphine exerts a stimulant effect upon
non~addicted humans is unsatisfactory. Statements based on heresay have
inferred that in some individuals excitement rather than sedation is produced
by the drug (Krueger et al.* 1941; Salter and White* 1949)* There seems
little doubt from the evidence of objective studies that* in clinical doses* the
drug exerts a predominantly quieting effect in man (Keats and Beecher* 1952;
Keats and Telford* I960; Smith and Beecher* 1962; Smith* Semke and Beecher*
1962). However* there is very good evidence that morphine sometimes
increases ventilation* oxygen consumption and cardiac output in man. Dripps
and Comroe (1945) reported that following intravenous administration of
morphine subjects often breathed more rapidly and deeply - this they attributed
to emotional factors. Starr* Gamble et al. (1937)* Dripps and Comroe (1945)
and Johnson (195B) report an occasional subject in whom measured minute
ventilation rose after administration of morphine. Huggins* Spencer* Geddes*
Deavers and Moyer (1957) report a fall in the arterial tension initially
after 15 mg morphine intravenously* probably indicating a period of hyperpnoea.
Drew, Dripps and Comroe (1946) measured the cardiac output in 7 normal
individuals during and 40 minutes after intravenous administration of morphine
15 mg. In 6 subjects cardiac output increased during the injection and at 40
minutes a slight increase over the control values persisted in 4 subjects.
Prime and Gray (1952) report a mean increase in cardiac output 1 hour after
pre-anaesthetic medication* presumably morphine and atrophine* which they
attribute* probably incorrectly* to apprehension. Fejfar, Bergmann, Fejfarova
and Valach (1957) reported that cardiac output rose significantly in 9 of 20
subjects suffering from mitral stenosis after intravenous morphine. Ventilation
had fallen markedly in all but two patients 10 minutes after injection of the drug.
Thomas* Malmcrona* Fillmore and Shillingford (1955) gave intravenous
morphine in doses of 3 - 10 mg to patients with recent acute myocardial
infarction. In 8 of 15 experiments cardiac output increased for part or the
whole of the period of observation.
The above review of the evidence indicates that current views of a dual or
diphasic action of morphine are not very soundly based on any reliable foundation
of experimental evidence. Nevertheless* the observations referred to above
that* in some circumstances* morphine produces hyperpnoea* excitement*
raised oxygen consumption and increased cardiac output cannot be ignored.
Neither can they be explained on the basis of present knowledge.
m. RESPIRATORY EFFECTS OF MORPHINE
The existence of the afore-mentioned effects which have been interpreted
by many as stimulatory should not be permitted to obscure the fact that, in the
majority of reported studies, morphine has been shown to exert a depressant
effect upon respiration. This effect is seen both in laboratory animals and in man.
It seems definite that, under suitable conditions, morphine will depress
respiration in man and in all ordinary laboratory species. The cat is, possibly,
an exception to this statement to the extent that it is more likely than other
laboratory animals to exhibit motor restlessness after morphine. Even so,
following the administration to conscious intact cats of doses of morphine
that are not too large, probably about 5 rng/kg (Wikler, 1944) respiratory
slowing and sedation appear immediately after injection, lasting for some
minutes (5 - 10') before overt excitement, with signs of sympathetic discharge,
appears. Tavat and Ak ^asu (1956) have found that the minimal dose which pro¬
duces overt excitement and motor restlessness in the cat is 0.2- 0.3 mg/kg.
It would appear crucial to measure the respiratory effects of doses of morphine
lower than this, but such experiments have not yet been done. On a weight
basis, this range includes amounts commonly used therapeutically in man
(14 - 21 mg/70 kg) and not known, except perhaps very rarely to cause excitement
in such individuals.
Since anaesthetised and decerebrate cats show respiratory depression
after morphine (Dripps and Dumke, 1943; Ngai, 1961) it seems very likely that
conscious cats also would so so if suitable doses were administered.
In rabbits* rats, primates and man respiratory depression regularly
occurs after administration of morphine, by any route. Dogs, also, suffer
respiratory depression after morphine. However, as pointed out in the
previous section, these effects may be masked by the influence of a warm
environment or by transient excitatory effects similar to those which occur
in cats. Even so, these excitatory effects also become less marked with
decreasing dose (Domer and Josselson, 1964).
The pre-war literature on the respiratory effects of morphine reviewed
by Krueger et al. (1941) is, subject to the preceding qualifications, consistent
with the view that the drug depresses respiration in all laboratory species
studied. Eater studies, although often reporting the collection of respiratory
data only as a subsidiary interest, support this view (Dripps and Dumke, 1943;
Hart and McCawley, 1944; Cook, Navis and Fellows, 1954j Miller, Gilfoil and
Shideman, 1955; Yim, Keaslitjg Gross and Mitchell, 1955; Ngai, 1961; Rubin,
Chernov, Miller and Mannering, 1964; Kokka, Elliott and Way, 1965).
Comparatively few attempts have been made to relate the excitatory or
respiratory depressant properties of morphine, in quantitative manner, to the
dose used.
As pointed out previously, Wikler (1944), Domer and Josselson (1964)
and Tavat and Ak ^asu (1956) have established a relationship between increasing
dose and the liability to cause overt excitement in the cat and dog.
Wright and Barbour (1935) state that, in the rabbit, the minimum dose
affecting minute volume of respiration was 0.5 mg/kg. The effect on
respiration increased sharply with increasing dose up to 2.0 mg/kg and more
gradually from this point to 10 mg/ kg. This would indicate that, over the
range used, depression in minute volume increased with the logarithm of the
dose administered.
Barlow (1933) also studied the effect of dose on respiratory depression
in the rabbit* with similar results. Respiratory depression increased rapidly
with increasing dose from the minimum of Q.26 mg/kg to 2.6 mg/kg. Larger
doses caused only slightly greater respiratory depression. The minute volume
actually increased after the smallest dose though the respiratory rate declined.
Earlier work cited by Krueger, Eddy and Sumwalt (1941) also suggested a
similar relationship between respiratory depression and the logarithm of the
dose. ■-»' '
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Barlow (1933) noted a similar relationship between dose and effect in
the rat. The range of doses studied was 2.1 *■ 63 mg/kg. The degree of
depression increased rapidly with increasing dose up to 15 mg/kg and thereafter
more gradually as the dose was increased further. The depression in
respiratory rate following 63 mg/kg was only 3% greater than that caused by
21 mg/kg.
Thus* in the older literature* quantitative data relating respiratory
effects to the size of the dose areifew, and. are available only for rat and
rabbit* the experimental animals which most reliably exhibit respiratory
depression after morphine.
Among more recent workerf* similar results have been reported.
Miller, Gilfoil and Shideman (1955) working with rabbits found that 4 mg/kg
produced a 50% reduction in minute volume of respiration. For doses up to
16 mg/kg the respiratory depression was proportional to the dose administered.
Doses larger than this were increasingly less effective in depressing respiration
Yim* Keasling, Gross and Mitchell (1955), also working with rabbits* found that
jW --
doses above .002 - . 004 millimols/kg produced no greater depression than
that (to 70% of control value) achieved by the aforementioned dose although
the larger doses did cause a longer lasting depression.
Kokka, Elliott and Way (1965) studied the dose/effect relationship
in great detail in conscious rats. They found that depression of ventilation
increased from 5 mg/kg through 10 - 20 mg/kg when the effect is reversed.
The depression caused by 20 mg/kg was in fact slightly less than that noted
after 10 mg/kg* This reversal of effect continued as the dose was increased
so that the respiratory depression after 40, 80 and 160 mg/kg was not as great
as that caused by 10 or 20 mg/kg. The oxygen uptake behaved in a similar
fashion.
Unfortunately, data as complete as that published by Kokka et al. (1965)
for the rat are not available for human subjects, Huggins, Spencer, Geddes,
Deavers and Moyer (1957) administered morphine intravenously to adult surgical
patients. The drug was given in increments of 15 mg and 15 - 20 minutes were
allowed to elapse before respiratory and other measurements were made.
There was a levelling off in minute volume depression at 75 mg and of tidal
volume at 30 mg. Doses up to 60 mg produced little change in respiratory
frequency. In some respects these results resemble those obtained in the
rabbit (Miller et al. 1955) and in the rat (Kokka et al. 1965); but on the whole
these findings are difficult to interpret and it seems doubtful whether repeated
injections of morphine in the manner described by these workers serve any
useful purpose in respiratory studies.
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Unfortunately, the majority of modern workers who have studied the
effect of morphine on human respiration have not standardised the doses used
or were, for other reasons - for example, the use of treatment groups too
small for analysis - unable to relate the size of dose to any changes observed
(Higgins and Means, 1915, Starr, Gamble, Margolies, Donal, Joseph and Eagle,
1937, Wangeman and Hawk, 1942; Dripps and Comroe, 1945; Johnson, 1951;
Eckenhoff, Helrich, Hege and Jones, 1955). The frequent neglect to standardise
the doses used is surprising.
It must be emphasised that the respiratory and other effects of morphine
demonstrated in animal experiments can seldom be usefully compared with the
human studies available. On the basis of body weight the doses used in animal
studies have been considerably larger than those used therapeutically or experi¬
mentally in the human. This cannot be interpreted as an indication that
experimental animals are usually more resistant to the depressant actions of
the drug than man. On the contrary, it is to be noted that the depression in
ventilation, where such depression occurs, is considerably greater than that
seen In human studies, including those to be presented later in the main body of
this report. Probably the greater difficulty of measuring pulmonary ventilation
in small animals has been responsible for the failure to detect significant changes
in ventilation of the order seen after the relatively smaller doses used in man.
Both in human and animal studies, the change in minute ventilation has,
in general, been the most reliable index of respiratory depression after morphine.
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In the rabbit, the respiratory rate has usually been markedly depressed by the
doses used (Cushny. 1913; Macht, 1915; Wright and Barbour. 1935; Hart and
McCawley. 1944; MiUer. Gilfoil and Shideman. 1955). In this animal, the
effects upon tidal volume have been very variable. By contrast, in their
Study on the rat, Kokka, Elliott and Way (1965) report that the smallest dose
used. 5 mg/kg, depressed minute ventilation by reducing the tidal volume,
without alteration of the respiratory rate. In human subjects, the changes in
respiratory rate and tidal volume have been very variable in all reported studies
(Higgins and Means, 1915, Wangeman and Hawk, 1942; Dripps and Comroe,
1945, Eas .agna and Beecher, 1954 a, b; Eckenhoff, Helrich, Hege and Jones,
1955; Orkin, Egge and Rovenstine, 1955; Eckenhoff and Oech, I960), with,
more often than not, no change which could be regarded as significant, in
respiratory rate or tidal volume. Although the statement that morphine
depresses all phases of respiration, namely, minute volume, respiratory
frequency and tidal volume,(Goodman and Gillman, 1955), is neither unreasonable
nor improbable there is little or no support for this belief in the published
studies on man or laboratory animals.
IV. EFFECT ON OXYGEN CONSUMPTION
The data on the effects of morphine upon oxygen consumption in laboratory
species are difficult to interpret. The best available study is the report by
Kokka* Elliott and Way (1955) on conscious male rats. In this study, measure¬
ments of respiration and oxygen consumption were made at 15 minute intervals
following drug administration. It was found that 5 mg/kg caused a small
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fall in oxygen uptake beginning at 30 minutes after injection and ending at
90 minutes. A more marked decline to 70% of the control value occurred
after doses of 10 - 20 mg/kg 60 minutes following injection. Doses larger than
20 mg/kg caused a reversal of effect so that 80 mg/kg had little effect upon
oxygen uptake and 160 mg/kg actually increased oxygen uptake after 60 minutes.
The pre-war literature reviewed by Krueger* Eddy and Sumwalt (1941)
is rather confusing. The majority of studies on the dog* according to these
authors* have shown a decrease of metabolism with doses of less than 20 mg/kg*
a decrease which was usually greater than 15%. They bdlieve that the different
doses used would explain some of the discrepancies in the literature* though
other factors* such as, biological variability* environmental conditions and
experimental procedures* seem to be involved. It is worthy of note that
Barbour* Gregg and Hunter (1930) found markedly raised basal metabolic rates
in 3 dogs after 6-10 weeks daily treatment with morphine*
Data in respect to other animal species are rather scanty. Pulewka (1927)
reporting 3 experiments in mice found a marked decline in oxygen consumption.
Wright and Barbour (1935) reported that oxygen uptake was not significantly
altered by morphine in rabbits. However* their published charts indicate that
oxygen consumption was slightly greater than the control values throughout the
post-drug period in one experiment with 0.5 mg/kg.
Thus, the older studies in laboratory species are not inconsistent with
the findings of Kokka, Elliott and Way (1965) that small doses of morphine depress
and larger doses* either cause no significant change, or increase oxygen uptake.
18
By contrast* the majority of experiments on human subjects have
demonstrated a fall in oxygen consumption following administration of morphine*
though not necessarily a significant one by the investigators' standards. The
extent of this decline in oxygen consumption has varied considerably (Higgins
and Means* 1915; Boothby and Rowntree* 1924; S<h oen, 1924; Bornstein and
Holm* 1926; Anderson, 1929; Stark, 1929; Herxheimer and Kost, 1932;
David* 1934; Starr, Gamble, Margolies, Donal, Joseph and Eagle, 1937;
Wangeman and Hawk, 1942; Johnson, 1951; Keats and Beecher, 1952). In
some individual experiments an increase in oxygen uptake was recorded
following drug administration, though this increase was usually either considered
non-significant or not commented upon (Higgins and Means, 1915; Bornstein
and Holm, 1926; Herxheimer and Kost, 1932; Starr et al. 1937; Orkin, Egge
and Rovenstine, 1955).
In a majority of the above quoted studies the doses used were not
standardised and it is not possible to infer whether the variation in the results
reported is to be attributed to dose effects or to other factors. The small
numbers of measurements and replications usually reported, also make
interpretation difficult. As an illustration of the difficulty of interpreting these
results, it may be noted that in the two experiments reported by Bornstein and
Holm (1926), the smaller dose - on the basis of body weight - caused a fairly
marked fall in oxygen uptake, while the larger dose caused a small increase. In
both subjects, ventilation fell markedly, the depression being somewhat greater
after the larger dose.
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There iB little definite information in the literature on the relationship
in the human between the dose of drug and the change in oxygen consumption.
David (1934) compared two groups of 10 subjects each given 0.14 and 0. 22 mg/kg
(10 and 15 mg/70 kg) morphine respectively. Four post drug measurements of
oxygen consumption were made during each experiment. The depression in
metabolic rate was only very slightly greater after the larger dose though the
authors do not mention whether they considered this small difference to be
significant.
Huggins* Spencer* Geddes* Deavers and Moyer (1957) administered
morphine intravenously in successive increments of 15 mg to convalescent
surgical patients. Measurements of ventilation and oxygen consumption*
among others* were made 15 - 20 minutes subsequent to each injection. The
authors state that 90 mg produced very little change in oxygen uptake* although
this dose caused a marked depression in minute ventilation and tidal volume.
The published charts* however* indicate a slight decline in oxygen uptake which
was apparently broken by a slight increase after 45 mg had been administered.
Unfortunately* the primary data on which the chart is based were not published.
The authors mention that the oxygen uptake per ml of ventilation ("ventilatory
equivalent") while little affected by doses up to 30 mg showed a variable though
marked increase following the larger cumulative doses. This would be consistent
with a virtual increase in metabolism though the authors do not mention this
possible interpretation of their results.
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The available evidence tb.ua indicates that the depression in oxygen
uptake following the administration of morphine to human subjects may,
occasionally, be marked. Frequently, however, the fall in oxygen consumption
is very slight, or, an actual increase may occur. The significance of the
changes reported and the existence or otherwise of any definite relationship
to the dose administered cannot be inferred by examination of the published data.
On the available evidence, the most that can be said is that after doses such as
are ordinarily used in clinical practice, morphine causes, more often than not,
a rather variable and usually slight fall in oxygen uptake. However, occasionally
an increase in oxygen consumption will occur, even in association with a modest
or markeu fall in ventilation,
V. EFFECT OF MORPHINE UPON THE VENTILATORY RESPONSE TO
CARBON DIOXIDE
It haB long been recognised that morphine diminishes the respiratory
response to increased concentrations of carbon dioxide in inspired air. Eoewy
(1890) and Eindhard (1911) were the earliest workers to study this phenomenon in
man. The latter author, relating alveolar ventilation to alveolar carbon dioxide
tension, found that this curve was markedly displaced by morphine. Eater
workers have added little to these earlier conclusions. It has been generally
agreed that, following administration of morphine, the ventilatory response to
increased concentrations of carbon dioxide in inspired air is reduced, whether
these concentrations are achieved by adding carbon dioxide in known amounts to
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the Inspired gases (Prescott* Ranson, Thorp and Wilson* 1949; Keats and
Beecher* 1952; Berkowitz. 1961)* by increasing the inspiratory dead space
Herxheimer and Kost* 1932)* or by the use of a rebreathing circuit (Eckenhoff*
Helrich, Hege and Jones* 1955).
Similar results have been reported from experiments on laboratory
species (Cuahny* 1913; Macht* 1915; Wright and Barbour* 1935; Dripps and
Dumke# 1943).
Many modern studies in man have used the displacement of the alveolar
ventilation/alveolar carbon dioxide response curve as a measure of drug effect*-""
chiefly in relation to the evaluation of the respiratory depressant properties
of the newer analgesics and of the effects of the opiate antagonists. Dripps and
Comroe (1947)* Nielsen and Smith (1952) and Bambertsen* Kough* Cooper*
Emmei* JLoeschke and Schmidt (1953) have studied* in normal subjects* the
relationship between ventilation and the carbon dioxide concentration of the
Inspired air or alveolar carbon dioxide tension. Eoeschke* Sweel* Kough and
Eambertsen (1953) first used the displacement of this curve* after administration
of narcotics* as a measure of drug effects. In untreated subjects the slope of
the respiratory response increases very markedly when concentrations of carbon
dioxide in excess of approximately 2% are inhaled* or when the alveolar carbon
dioxide tension exceeds about 40 mm.Hg. At that point ventilation increases
very sharply with increasing inspired or alveolar carbon dioxide tension.
Because of this change of slope* the displacement caused by drugs has been
measured in relation to the steepest portion of the curve. Eoeschke et al. (1953)
using as an arbitrary reference point an alveolar tension of 46 mm.Hg report
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that 10 mg morphine depressed the ventilatory response to carbon dioxide at
that point by approximately 30%• The slope of the response curve was not
affected by morphine, in this study.
Seed, Wallenstein, Houde and BdLville (1958) have used the rebreathing
method of increasing carbon dioxide concentration in the inspired air, with
similar results. The concentration of CO gradually built up to 7 - 8%.
w
These workers, also, measured the displacement caused by morphine at an
arbitrarily chosen level of alveolar ventilation on the steeper portion of the
response curve. Morphine in doses of 5 and 10 mg caused a displacement
- to the right, that i/, towards higher values of P CO , the displacement being/ -A. Ct
greater after the larger dose. They also report a marked tendency for the
magnitude of the drug effect to be proportional to the pre-injection level of
alveolar CO?. In this study, a significant diminution of slope was produced
by 10 mg morphine. Both displacement of the curve and change in slope were
thought by these authors to indicate respiratory depression. However, it
is to be noted that the carbon dioxide output was less depressed by the larger
dose, in nearly all subjects - in fact, the excretion of carbon dioxide either did
not change or actually increased in 3 subjects. This is not entirely consistent
with the claim that both doses depressed respiration, though the authors do not
comment on this point.
Other reports from the same laboratory have confirmed this displacement
by morphine and related narcotics of the alveolar ventilation/P CO responseA c
curve towards higher values of P CO . (Steinberg, Bellvifle and Seed, 1957;A. /£
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Bellville et al. I960; 1962; Houde et al. 1964; Forrest and Bellville, 1964).
A similar displacement of the ventilation/alveolar carbon dioxide tension
curve after administration of morphine has been reported by Wilbrand and
Matthaes (1958).
An increase in arterial or alveolar PCO^ following administration
of morphine to human subjects breathing room air, in association with a fall
in minute ventilation has been recorded by many groups of workers. This
situation presumably indicates a decreased sensitivity of the respiratory
apparatus to carbon dioxide. An increase in alveolar or arterial carbon
dioxide tension, rather exceptionally fails to occur.
Keats and Beecher (1952) report no consistent changes in arterial
carbon dioxide tension 1.5 hours after injection of morphine even though
ventilation was depressed. Taylor, Scott and Donald (1964) record a non¬
significant increase in arterial carbon dioxide tension of approximately 1 mm.Hg
30 and 60 minutes after anaesthetic pre-medication. In the former study,
arterial puncture was apparently performed at the time of sampling, a proceduxe
which might, as the authors point out, cause overbreathing. In the observations
of Taylor, Scott and Daxald (1964) - which did not include measurements of
ventilation - the premedication contained atropine, which may have inhibited
the expected rise (Wangeman and Hawk, 1942).
Other reports available record a rise in alveolar or arterial carbon
dioxide tension, usually, though not invariably, a marked one, after administra¬
tion of morphine to human subjects. In the experiments of Higgins and Means
(1915), alveolar carbon dioxide tension rose slightly following administration of
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16 mg morphine sub-cutaneously to human subjects in 4 instances. A maximum
increase of approximately 2 mm was noted in some individual observations.
The rather small mean increase of slightly less than 1 mm.Hg appears to
have been significant. The mean fall in total ventilation was of the order of
8%. Eoeschke, Sweel, Kough and JLambertsen (1953) reported a significant
increase of 2.6 mm.Hg following 10 mg morphine intra-muscularly which was
associated with a non-significant fall in ventilation. Berkowitz (1961) reports
a mean increase in arterial carbon dioxide tension of 4 mm.Hg after 15 mg
morphine in 5 sulj ects who experienced, at the same time, a 7% decline in
ventilation. Eckenhoff, Helrich, Hege and Jones (1955) studied 4 subjects who
received 10 or 15 mg morphine intra-muscularly. All showed an increase in
alveolar carbon dioxide tension in association with a reduction in minute
ventilation. In one of these subjects the ventilatory response to carbon dioxide
was increased. Wilbrand and Matthaes (1958) using doses of 20 and 10 mg
intravenously, also found that an increase in alveolar carbon dioxide tension
usually occurred. Huggins, Spencer, Geddes, Deavers and Moyer (1957), who
used cumulative doses of morphine in successive increments of 15 mg, report
similarly that, despite the marked fall in ventilation, alveolar and arterial
carbon dioxide tensions increased.
The observations of Thomas et al. (1965) indicate that 5-10 minutes
after intravenous morphine in doses of 3 - 10 mg in 15 experiments the arterial
carbon dioxide tension increased 3-5 mm.Hg in all but one subject in whom
there was a rather marked fall (from 44.5 to 39.0 mm.Hg), presumably due to
overbreathing: among 4 subjects in whom arterial CO tension was measured
20 - 30 minutes after injection* 3 showed an increase and one a decrease as
compared with the control value. In this study ventilation was not measured.
The increased arterial or alveolar carbon dioxide tension which usually
occurs after morphine may be taken* in the formal sense* as indicative of
diminished sensitivity of the respiratory centre to carbon dioxide. However*
these changes have not been studied in relation to the other changes caused by
morphine* namely* changes in oxygen uptake* carbon dioxide output and
minute ventilation achieved by subjects breathing room air.
It has been claimed that the use of ventilation/alveolar carbon dioxide
response curves provides a more sensitive index of drug effects than direct
measurement of ventilation because significant changes in minute ventilation
may not occur despite an increase in alveolar tension (JLoeschke et al.
1953) or because changes in ventilation may represent both respiratory and
metabolic effects (Seed* Wallenstein* Houde and Bellville* 1958). These
arguments appear rather unrealistic and it seems very doubtful that the
results yielded by the use of these curves justify the claims advanced. The
experiments reported appear to have done little more than confirm that
morphine and related narcotic drugs depress respiration* a point on which
general agreement has already been reached. They have not contributed any
fresh data which would support a plausible hypothesis of drug action. One
suspects also that valuable information has been lost in these studies* because
of the failure to undertake orthodox respiratory measurements. For example*
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the interesting observation by Seed et al. (1958) that 10 mg morphine apparently
caused a smaller decline in CO^ output but a greater fall in ventilation than
5 mg is surely worth pursuing.
It may be pointed out* further* that neither these experiments nor any
other available observations have proven that morphine influences respiration
through a change in the sensitivity of the centre to arterial tension.
That human beings and laboratory animals become more tolerant of pain and
other forms of discomfort including increased levels of carbon dioxide in
inspired air after administration of morphine is a well established fact. There
is no proof that respiratory depression is occasioned by this diminished
sensitivity and consequently no evidence that the diminished ventilatory
response to carbon dioxide is an authentic measure of drug induced respiratory
depression. By the same token, it is not justifiable to assume that other
non-narcotic drugs which may depress or stimulate respiration will necessarily
cause a displacement in the response curves measured as above described
(v. Keats and Beecher, 1952). Some workers would appear to have subscribed
to this fallacy (Steinberg, Bellville and Seed, 1957; Bellville, Escarraga,
Wallenstein, Wang, Howland and Houde, 1962). So far as is known the narcotic
family are the only group of drugs with this property of attenuating the effects
of afferent stimuli of noxious or unpleasant character (and acute hypercapnia
and dyspnoea are stimuli of essentially this character), in sub-anaesthetic dose.
That this property and that of causing respiratory depression are in some way
linked, is a reasonable supposition. That the one property bears some causal
relationship to the other is, in present state of knowledge, an entirely
linarppntahlp nrnnnnitinn .
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VI. STUDIES AND THEORIES BEARING ON THE MECHANISM OF ACTION
OF MORPHINE
According to Krueger et al. (1941),Gscheidlen (1869) was probably the
first to suggest that morphine altered respiration by depressing the respiratory
centre. The ideas of the earliest workers have been well reviewed by Cushny
(1913). These early workers, were aware of the increased carbon dioxide
content of the blood, the diminished ventilatory response to increased
concentrations of inspired COand the prolongation of apnoea from forced
breathing in morphinised animals. The general consensus appeared to be
that the drug depressed respiration by depressing the excitability of the
respiratory centre.
Higgins and Means (1915) considered the possibility that a peripheral
mechanism was operative when they reported that in 3 of 4 experiments on
human subjects physiological dead space decreased after administration of
morphine, a change which they interpreted as evidence of broncho-constriction.
These workers concluded that morphine could affect respiration both by causing
broncho-constriction and by depressing the respiratory centre. Although
morphine has long been known to cause broncho-constriction in laboratory
species (Shemano and Wendel, 1965) it seems doubtful that this effect is
important in man.
Cushny (1913), reporting experiments on rabbits, drew attention to the
similarity between the effects of morphine and those of vagotomy in depressing
the respiratory rate while leaving the tidal volume unchanged or even increased.
He was thus led to investigate the possibility that morphine acted by blocking
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the delivery of afferent vagal stimuli to the respiratory centre. It was
demonstrated that augmentor vagal impulses were depressed by morphine while
inhibitory vagal impulses were facilitated. He concluded* however* that the
centre itself rather than the afferent pathway* was depressed by the drug.
Cohen and McGuigan (1924) disputed the proposition that morphine
depressed the respiratory Centre directly and suggested instead that respiration
was depressed because sensory impulses from the periphery which normally
stimulated the centre and maintained its tone were blocked.
Maloney and Tatum (1930) working with anaesthetised rabbits also
studied the effect of the drug on the respiratory response to afferent nerve
stimulation. In the morphinised animal* they found that the respiratory
responses to stimulation of the sciatic nerve and of the intact skin were reduced
They found also that the apnoeic response to increased intra-pulmonary pressure
was enhanced and the acceleratory response to negative intra-pulmonary
pressure depressed. It was concluded that morphine acts as a central
respiratory depressant* reducing the responsiveness of the centre to accelera¬
tory impulses including the stimulus of carbon dioxide and increasing the
effectiveness of inhibitory vagal impulses.
Henderson and Rice (1939) working with anaesthetised rabbits reported
that all vagal reflexes were made more effective by morphine. Its effect on
the respiratory reflexes was such as to cause a slower respiratory rate and
frequently to reduce the tidal volume. However, the response to cutaneous
nerve stimulation was increased by morphine.
Dripps and Dumke (1943) reported that decerebrate doge and cats
given i.m. morphine, while showing the expected depression in the respiratory
response to carbon dioxide stimulation* exhibited an enhanced chemoreceptor
sensitivity to stimulation by Na CN. It was felt that this increased sensitivity
was apparent rather than real.
Ngai (1961) studied the effect of morphine upon the response to vagal
stimulation and to electrical stimulation of the pontile pneumotaxic centre*
the medullary inspiratory and expiratory centres in vagotomised mid-collicular
decerebrate cats. The effect of morphine in the unstimulated preparation
was to cause respiratory slowing of various degrees* the respiratory amplitude
as recorded on a kymograph remaining unchanged or* at times* increasing.
Repeated doses of 1 - 2 mg/kg were administered. The acceleration induced
by stimulation of the pontile pneumotaxic centre was reduced by morphine as
was the hyperpnoea which follows stimulation of the medullary expiratory
centre. The threshold for eliciting inspiratory spasm following medullary
inspiratory centre stimulation was progressively raised with successive doses
of morphine. The drug also reduced or abolished the acceleratory response
to central vagal stimulation with low frequency currents; and lowered the
stimulus threshold for expiratory apnoea induced by high frequency vagal
stimulation. It was concluded that the neural mechanism for respiratory
rhythmicity was depressed by morphine and that the apparently exaggerated
susceptibility to inhibitory vagal reflexes is the result of central depression.
The persistence of inspiratory response to pneumotaxic centre stimulation
and the observation that respiratory amplitude either increased or remained
unchanged, suggest that the mechanism controlling respiratory rhythm is
mainly affected by morphine.
May and Widdicombe (1954) in experiments on anaesthetised cats also
demonstrated that morphine greatly enhanced the Hering - Breuer inflation
reflex. These workers, however, suggested that this enhancement is
secondary to broncho-constriction with consequent increased activity of the
pulmonary stretch receptors.
Breckenridge and Hoff (1952) administered morphine intravenously,
in repeated doses, to intact and mid-collicular decerebrate dogs. Conscious
intact animals, given 10 - lbO mg intravenously, developed a short initial
period of polypnoea followed by a regular sighing rhythm associated with a
slight reduction in the rate and amplitude of eupnoea. This pattern of breathing
is very similar to that produced by decerebration. The results suggested a
release of pontine centres facilitating this type of breathing, which are
normally held in check by cortical and other suppressor activity. At
mid-collicular level morphine reproduces almost exactly the effect of vagotomy,
which further intensifies the deep sighing type of respiration of decerebration
and causes eupnoea to disappear completely. The authors suggest that
morphine operates generally by inhibiting the adtion of suppressor mechanisms.
By contrast, Egbert and Bendixen (1964) report that morphine in doses
of 2.5 or 5.0 mg administered intravenously post-operatively to surgical
patients abolished sighing for approximately one hour, appeared to cause the
volume of individual breaths to become constant, and did not significantly
affect respiratory frequency or tidal volume.
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It is generally agreed that morphine depresses the response to certain
stimuli* such as increased inspired carbon dioxide and pain which ordinarily
increase respiration. The drug also modifies the effects of vagal stimulation
so that vagal impulses which ordinarily cause respiratory slowing are
facilitated and those vhich ordinarily cause respiratory slowing are facilitated
and those uhich ordinarily cause acceleration are depressed. There is no
evidence that the depression in ventilation following administration of morphine
is caused by this attenuation of effect of afferent stimuli. It would be a truism
to point out also that morphine does not cause any paresis of motor respiratory
function since following appropriate stimulation or* in the human* encouragement*
normal or even excessive ventilatory volumes can be attained.
The conclusions of Ngai (1961) that the primary effect of the drug is to
depress the neural mechanism for respiratory rhythmicity is seriously to be
questioned. This opinion is based mainly on the observation that* in unstimulated
animals* the drug caused respiratory slowing without changes in the breath
volume. This could well have been related to the comparatively large doses
employed in most animal experiments. Human subjects given much smaller
doses frequently show no change in respiratory frequency and no obvious
disturbance of respiratory rhythm.
The experiments of Ngai (1961) and of Breckenridge and Hoff (1952)
make it clear that* in achieving respiratory depression, morphine acts at
many sites* including medullary, pontine and more rostral regions. That a
similar situation exists in respect to the analgesic effects is suggested by
the work of McKenzie and Beechey (1962). The superficial resemblances
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between the effects of the drug and those of vagotomy in the rabbit and the cat
(Cushny, 1913; Ngai, 1961) or those of decerebration in the dog (Breckenridge
and Hoff, 1952)) suggests, not that these drug effects have some facile
explanation, but, rather, that these must have very complex origins.
The broncho-constrictor effects of morphine would appear not to be a
significant cause of respiratory depression in man. It is, possibly, of some
marginal importance in some laboratory species (May and Widdicombe, 1954;
Shemano and Wendel, 1965), but it cannot play an important role in the
respiratory depression seen in such animals following drug administration.
VII. EFFECTS OF MORPHINE IN PATIENTS WITH LEFT VENTRICULAR
FAILURE
At this point it is convenient to run aside from the main stream of
the present review in order to consider one of the most important clinical
applications of morphine*
Morphine has been used by generations of physicians in the treatment
of cardiac asthma. By general agreement the drug is of great benefit and
can be life saving in this condition (Fraser, 1923; Bedford, 1939; Luisada,
1940; Hamilton, 1955; Vugrincic, 1955 Daly, I960). Despite occasional
statements to this effect (Hayward, 1955) it seems doubtful that other sedative
drugs, for example, barbiturates, are similarly effective in the treatment of
acute left ventricular failure. Curiously, morphine appears not to be effective in
acute pulmonary oedema induced experimentally in laboratory animals by
chemical agents such as epinephrine (Kohler and Barbe, 1955).
33
The clinical consensus in regard to the use of morphine in acute
left ventricular failure is, naturally, deserving of respect, even though
derived exclusively from an oral tradition based on the bedside observations
of experienced physicians in many countries. Nevertheless it is only fair
to point out that the use of morphine in cardiac asthma and left ventricular
failure has never been rigorously evaluated, that the rationale of its use is uncertain,
and that measurement of the effects of the drug on circulatory and respiratory
function in patients with left ventricular failure, has only very uncommonly
been performed.
None of the circulatory effects known to be produced by this drug in
normal humans or experimental animals would explain the favourable clinical
effects believed to be experienced by patients with acute left ventricular
failure. Acute pulmonary oedema caused by mitral valve disease or left
ventricular failure is immediately related to a rise in pulmonary capillary
pressure(Hayward, 1955). Morphine alone in many cases of acute left
ventricular failure is said to cause clearing of the clinical signs of lung
oedema, in addition to relieving the intense dyspnoea (Fraser, 1923). Yet,
the drug appears to exert no very definite effect upon the pulmonary circulation
which would explain this.
That morphine produced systemic circulatory effects in experimental
animals was known to the earliest workers (Schmidt and Livingston, 1933).
The effects noted were bradycardia, dilatation of the blood vessels of the skin and
mucous membranes and a fall in systemic blood pressure. Schmidt and
Livington, (1933), state that the first intravenous injection of morphine in a
dog or cat regularly causes a primary fall in blood pressure, but, that
repeated injections caused, not a continued or progressive fall, but, rather,
a steady recovery of pressure. This phenomenon of tachyphylaxis has
been shown to occur, also, in the rat (Evans, Nasmyth and Stewart, 1952).
An intravenous injection of morphine, in a dose of 0.5 mg/kg or
over, in a conscious dog, induces marked restlessness, hyperpnoea and
tachycardia followed, immediately afterwards, by clinical signs of circulatory
collapse, lasting for a variable period which depends upon the dose
administered. The stage of excitement and collapse is associated with a
fall in the arterial blood pressure which gradually recovers, as the clinical
signs of collapse regress. The blood pressure recovers completely though
the animal remains sedated. Subcutaneous injection has the same effect
though larger doses are required (Schmidt and Livingston, 1933), Morphine
also reduces the rise in blood pressure produced by asphyxia or carbon
dioxide inhalation and* also, the vasomotor response to afferent nerve
stimulation. Schmidt and Livingston (1933) believed that the dilator action
of morphine was peripheral while bradycardia was due to a central action of
the drug.
Huggins, Glass and Bryan (1951) in experiments on anaesthetised
dogs also confirmed the marked vasodepressor effects of morphine. After
doses of 0.1 - 5.0 mg/kg there was a decrease in peripheral vasomotor
resistance, a fall in blood pressure, an increase in cardiac output and an
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increase in blood flow to the head. The extent and duration of the fall in blood
pressure increased as the dose of drug was increased and, all doses used
caused an increase in the cardiac output. Intra-arterial injection into the
carotid artery was more effective in producing all these changes. These
authors interpret their results as indicating that the depressor effects of
morphine are exerted both peripherally and centrally. The experiments
of Breckenridge and Hoff (1952) emphasised the very marked vaso-depressor
properties of morphine in the dog. They found that doses of morphine which are
administered with safety to decerebrate animals caused so marked a fall
in the blood pressure of animals subjected to mid-collicular and medullary
section, that the respiratory effects were completely overshadowed.
In the anaesthetised cat. morphine administered intravenously, also
causes a prolonged fall in blood pressure (Feldberg and Paton. 1951; Evans.
Nasmyth and Stewart. 1952). An immediate fall is also seen in the anaes¬
thetised rat but this, however* is transient and lasts 20 - 30 seconds only
(Evans. Nasmyth and Stewart* 1952). In spinal and decerebrate cats the
vasodepressor effect is of shorter duration than that seen in anaesthetised
animals. The possibility that endogenous histamine, which is known to be
released by morphine (Feldberg and Paton, 1950; Nasmyth and Stewart, 1950)
might be responsible for the circulatory effects of morphine was investigated
by Feldberg and Paton (1951) and Evans, Nasmyth and Stewart (1952). Both
groups of workers concluded that released histamine did account for some
but by no means all of the observed depressor effects. The last named
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authors showed* further* that* in the cat* the effect of morphine on the
circulation is mediated partly through the vaso-motor centre and partly
through the release of histamine peripherally. In the rat* sensory impulses
in the vagus nerve were shown to mediate the whole of the response -
since the vaso-depressor effect was blocked by bilateral vagotomy but
not by atropine.
Kayaalp and Kaymakcalan (1966) measured the circulatory effects
of intravenous morphine in vagotomised conscious cats rendered immobile
by gallamine triethiodide. The chief effect of the drug was to induce the
occurrence of marked irregularity in the blood pressure record which, in
some studies, appeared to have a regular rhythm. Blood pressure fell
transiently after the larger doses - 5 to 10 mg/kg. In some animals,
the hypertensive response to carotid artery occlusion was considerably
reduced by morphine. Anaesthetised cats, given gallamine triethiodide
and artificially ventilated, showed a precipitous fdLl in blood pressure following
doses in excess of 2 mg/kg. This initial fall was succeeded by a slowly
developing sustained fall. These workers made the interesting observation
that the initial fall only* appeared in animals treated with nalorphine, and
that this could be blocked with the antihistamine mepyramine. The blood
pressure disturbances seen in the conscious animals were corrected by
nalorphine.
Few studies have been published of the circulatory effects of morphine
in normal human subjects.
Starr* Gamble* Margolies, Donal, Joseph and Eagle (1937)* using
the ethyl iodide method report a small, non-significant mean fall of 1%
in cardiac output of seven healthy subjects. Systolic blood pressure
measured with a sphygmomanometer also fell very slightly (2.7%). The
dose usually administered was 13 mg.
Papper and Bradley (1942)* using the ballistocardiqg raphic method*
measured cardiac output in six healthy subjects followig morphine 10 mg.
Cardiac output measured within 1.5 minutes of drug administration rose in
three subjects (by 4, 11 and 20%) and fell in 2 (by 9 and 7%) and was unchanged
in 1* Later measurements remained elevated in 2 subjects (7 and 20%)
and showed a fall ranging between 4 - 8% in the remainder. The peripheral
resistance rose in two subjects (17 and 27%) and fell in two (10 and 18%).
Himmelsbach (1944) reported that morphine* in doses larger than 5 mg
significantly increased the fate of blood flow in the hands and forearm of
addicts* post-addicts and normal control subjects.
Drew* Dripps and Comroe (1946)* also u£ing the ballistocardiographic
method, measured the cardiac output in 7 healthy subjects during and after
the injection of 15 mg morphine intravenously. During the injection, cardiac
output increased in 6 subjects and was unchanged in 1. Measurement of
cardiac output 40 minutes after injection showed near normal values in all
except one subject in whom the initial elevation had persisted. During
injection of the drug, the pulse rate usually increased. The blood pressure*
measured with the sphygmomanometer* usually did not change. Of 25
subjects submitted to tilting into the 75 degree head up position, after intra-
muscular injection of morphine, 11 (44%), either fainted or showed signs and
symptoms indicative of imminent circulatory collapse. These authors
concluded that, while the circulatory effects of morphine are unimportant
in the normal supine individual, they assume much more significance when
the circulation is put under strain. A similar reaction to tilting has been
reported by Helrich and Gold (1964).
Johnson (1951) measured the respiratory and circulatory changes in
9 healthy subjects, 7 male and Z female, before and 20 * 50 minutes after
intravenous administration of anaesthetic premedication consisting of 6 - 18
mg morphine combined with scopolamine. Mean respiratory minute volume
and oxygen consumption fell 15% and 6% respectively. There was a mean
fall of 9% in cardiac output, though two individuals did show a slight
increase. The mean systolic and diastolic blood pressures fell by 9 and 7
mm respectively. There was a mean increase in the peripheral resistance
of 5%. In one case there was a rise of 6 mm.Hg in the pulmonary mean
arterial pressure, but, in the others, this hardly changed. However, there
was a significant increase of 21% in the mean value for the pulmonary vascular
resistance.
Prime and Gray (195Z) measured cardiac output before and 1 hour
after premedication - presumably with morphine and atropine - in 15 healthy
patients. One hour after premedication mean cardiac output increased
from 4.fc _+ 0. 9 to 6.7 1.4 1. /min. Tne authors did not regard this increase
39
as due to the drugs administered but* rather* to apprehension* Since the
oxygen consumption fell* this explanation is possibly inadequate.
It is* unfortunately* not possible to evaluate the contribution made
by scopolamine and atropine to the results recorded in the last two studies
cited. This contribution could well have been significant* since both drugs
stimulate ventilation and scopolamine itself has a slight sg dative effect
(Wangeman and Hawk, 1942).
Thomas, Malmcrona* Fillmore and Shillingford (1965) measured the
circulatory changes in 15 experiments on subjects with recent acute
myocardial infarct, before and after 3-10 mg morphine administered
intra-venously. In 7 instances* there was no change in cardiac output after
i.
,
injection; in 8 studies cardiac output was increased for part or the whole
period of observation. In none did a convincing fall occur. Arterial mean
blood pressure decreased transiently in 7 patients and in 1 case* there was a
persistent fell. One subject showed a very marked and progressive fall in
blood pressure following 3 mg which recovered when the legs were elevated.
Peripheral resistance did not change in 6 instances and, in 8 studies there was
either a consistent or a transient fall. Central venous pressure was unchanged.
The known circulatory effects of morphine may, therefore, be summarised
as follows. The immediate effect of the drug* particularly when administered
intravenously* is, frequently, to cause a fall in the systemic blood pressure
which may be quite sharp. In the cat and in the dog, and, apparently, also
in some human studies a sustained fall in the blood pressure may follow this
transient depressor phase. During the initial vaso-depressor phase, cardiac
output increases in the dog. In human studies* a transient increase in
cardiac output also frequently occurs* and a sustained rise also has been
noted in some studies. In many cases* the cardiac output is little changed.
The fall in blood pressure is associated with a fall in the systemic vascular
resistance and the animal studies referred to previously make it clear that
there is both a peripheral and a central cause for this. It seems definite
that released endogenous histamine is responsible in part for the initial
phase of hypotension. More sustained hypotension* when present* has been
reversed or inhibited by nalorphine as* also* have the curious irregularities*
at times rhythmic* in the blood pressure tracing reported by Kayaalp and
Kaymak^alan (1966) in cats. This reversal by nalorphine presumably indicates
the existence of a central vaso-motor effect and other data also are consistent
with this supposition.
Only uncommonly have respiratory or circulatory measurements been
made before and after administering morphine to patients suffering from left
ventricular failure. For obvious reasons* studies performed on patients during
acute pulmonary oedema have been rare.
Herxheimer and Kost (1932) measured ventilation and oxygen consumption
before and 20 minutes after administration in the course of 10 experiments on
patients with cardiac failure* and in 6 normal subjects. Normal subjects
received 20 mg and cardiac patients 5-20 mg sub-cutaneously. The clanges
in both groups were very similar. Ventilation fell in all subjects and mean
oxygen consumption declined. A slight increase in oxygen consumption
occurred in 2 normal and in 2 cardiac studies. When inspiratory dead
space was increased, usually by 1 litre, the carbon dioxide retention
occurring after morphine was greater in the cardiac group. The subjective
effects in the two groups were somewhat different. In normal subjects,
unpleasant sensations predominated, as was also noted by the authors in
themselves following self-administration, whereas to the cardiac patients,
the effects of the drug were very pleasant. Presumably this was related
to relief from the burden of dyspnoea and, objectively, the authors state
they appeared to be improved.
Resnik, Friedman and Harrison (1935) measured ventilation and
oxygen consumption in two patients suffering from congestive failure due to
syphilitic aortic insufficiency. Ventilation and oxygen consumption and
cardiac output measured by the three sample acetylene test, fell in each case.
The moderately severe dyspnoea present before treatment in each case was
relieved. It was noted that very similar changes occurred after venesection
and bed rest respectively.
Starr, Gamble, Margolies, Donal, Joseph and Ragle (1937) measured
the effect of 15 or 30 mg morphine administered to 8 patients with cardiac
disease of various types, all seriously ill, though none in congestive failure.
Cardiac output was measured by the ethyl iodide method of Starr and Gamble.
Mean oxygen consumption, cardiac output and left ventricular work diminished
somewhat more than in the healthy coxtrol group studied in the same way.
None of the changes were* however* statistically significant. It is worthy
of note that the oxygen consumption, while declining in 5 individuals, rose
in 3. The authors draw attention to the greater fall in left ventricular work
after morphine in the cardiac than in the non-cardiac group.
Scebat and Lenegre (1949) measured the effect of morphine on right
heart pressures in 30 patients, all except one (a well compensated mitral),
seriously ill. Ten patients suffered from mitral disease and the majority
of the remainder from aortic or hypertensive disease. Morphine 10 mg
was given to all patients by intra-auricular or intra-ventricular catheter.
Right atrial pressure, measured in 19 patients, showed a marked fall in
14 which appeared after 2-3 minutes, and attained a maximum in 5-20
minutes: this fall was most often transitory and often followed by recovery
to higher than control pressures. It rarely lasted as long as 25 - 70
minutes. However, in 5 individuals a variable increase in right atrial
pressure occurred which lasted throughout the period on observation.
mean ,
Right ventricular/pressure was measured in 15 patients, in 9 of
whom a fall occurred. This appeared after 2-5 minutes, was often
transient and followed by recovery, though the fall persisted, at times, for
the entire period of observation. In 3 cases a significant increase in right
ventricular pressure occurred which persisted for the entire study period
of more than an hour.
The authors point out that the fall in right auricular and right
ventricular pressure observed in a majority of subjects is a desirable effect.
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Nevertheless, this effect is often transitory or hardly apparent and* in an
appreciable number of studies - 8 out of 34 - the pressure in the right heart
chambers was increased by morphine* an undesirable effect in a cardiac
patient. Thus while morphine usually has a favourable haemodynamic
effect in cardiac failure* this effect is unreliable* and the drug may* theoretically*
be harmful in one quarter of Such patients.
Fejfar, Bergmann, Fejfarova and Valach (1957) studied the effects
of 10 mg . morphine administered intravenously to 21 patients with mitral
stenosis* Ventilation, measured 10 minutes after injection, fell in 19 and
increased slightly in 2 patients. Cardiac output* in 20 patients* measured
10 - 15 minutes (direct Fick method) after drug administration*increased
significantly (10 - 43%) in 9 patients* decreased in 6 and did not change in 5.
Oxygen consumption increased in 3 studies, decreased in 5 and did not change
significantly in 12 individuals. The authors do not state how the significance
of the observed changes was assessed. The majority of patients showed a
consistent rise in pulmonary artery pressure and in only two was there a
significant decrease. The authors state, though they do not provide supporting
data, that patients with initially low cardiac output showed an increase after
administration of the drug, and that those with normal output showed no change
or a fall. Changes in total peripheral and pulmonary resistance were inversely
related to changes in cardiac output. Right and left ventricular work increased
with*ncreasing cardiac output. One patient who developed acute pulmonary
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oedema before injection of morphine showed the following changes. The pulmonary
mean arterial pressure* which rose markedly when acute pulmonary oedema
developed* fell only very slightly after injection of the drug. Following
injection of morphine* cardiac output rose sharply (24%), apparently a
transient increase, pulmonary resistance fell (31%)* pulmonary ventilation
fell by 35% and oxygen saturation decreased to 68%,
Finlayson, Luria* Stanfield and Yu (1961) studied the effect of hexa*
methonium and morphine in 5 patients suffering from mitral or aortic
valvular disease who developed pulmonary oedema during cardiac catheterisation.
The principal findings during pulmonary oedema included a marked rise in
pulmonary artery and pulmonary wedge pressure* low cardiac output* and*
in the two instances where this was measured* a rise in systemic arterial
pressure. Four patients treated with hexamethonium showed a rapid and
dramatic response, the fifth patient treated with intravenous morphine*
oxygen and venous tourniquets improved much more slowly.
Other workers have reported similar pressure changes in patients*
almost invariably suffering from mitral valve disease* who developed acute
pulmonary oedema during cardiac catheterisation. The effect of
morphine was not investigated in these studies (Lenegre, Scebat* Besson*
Benchemoul and Damien, 1953, Gorlin, .Lewis* Haynes* Spiegl and Dexter* 1951).
Roy* Singh* Bhatia and Khanna (1965) measured the effects of morphine
on the pulmonary and systemic circulation in 4 male subjects who had
recovered from high altitude pulmonary oedema and were asymptomatic at
the time of the study. These authors had used morphine to good effect in
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patients with high altitude pulmonary oedema who did not respond completely
to oxygen therapy. The control pulmonary blood volume was significantly
increased in two subjects and within the norm! range in the other two.
Morphine 10 mg injected into the pulmonary artery* in each case caused the
pulmonary blood volume to fall * the mean fall was 26% and the range 15 - 40%.
A s light (2 subjects) or a moderate (2 subjects) fall in heart rate, cardiac
index and stroke index occurred. Femoral arterial, pulmonary arterial
and left ventricular filling pressures fell slightly, but these changes were
not significant. The systemic vascular resistance increased somewhat,
while the pulmonary vascular resistance was not altered. The authors appear
to consider that the decrease in pulmonary blood volume, the fall in cardiac
output and the reduction in ventricular filling pressures are related to the
beneficial effects of the drug in pulmonary oedema.
Sharp, Bunnell, Griffith and Greene (1961) considered the possibility
that morphine might favourably influence the physical properties of lung tissue
since these are known to be altered in pulmonary congestion and acute pulmonary
oedema. They found that 10 mg morphine given intravenously to 3 patients
with acute pulmonary oedema due to arteriosclerotic, rheumatic valvular or
hypertensive heart disease exerted no significant effect on lung compliance or
pulmonary resistances.
The aforementioned reports do not explain completely how morphine
might benefit patients suffering from acute left ventricular failure. There is
general agreement that the drug, both in healthy subjects, and in those suffering
from cardiac failure, causes ventilation to fall. Dyspnoea, when present, is
relieved. In a majority of experiments morphine has caused oxygen
consumption to decline, though not necessarily to any marked degree. A
few subjects, however, both normals and those in congestive failure, experience
an increase, at times a marked increase, in oxygen consumption. Whether
or not morphine can reverse the circulatory changes in acute pulmonary
oedema has not been settled by the rare observations recorded on the effects
of the drug in this disorder. The results of such studies have not been
consistent, and, as the great majority have been performed on patients
suffering from mitral valve disease, the findings may not necessarily apply
to patients with pulmonary oedema due to other varieties of heart disease.
It is evident that more complete respiratory and circulatory studies, both
in normal subjects aid in patients with congestive cardiac failure, are needed
before a satisfactory evaluation of the effects of the drug in left heart failure
can be made.
Even on the basis of these rather limited observations, it is useful
to consider how the respiratory, metabolic and circulatory effects reviewed
earlier might be relevant to the benefits derived by individuals suffering from
left ventricular failure. The hypotensive effects noted in animal experiments
have not been prominent in human studies, but do occur, very rarely in marked
degree. Peripheral dilator effects, however, are the rule and, if hypotension
is not severe, would presumably contribute to drainage of the lung by relieving
the load on the left ventricle, with consequent relief of symptoms. The
effectiveness of ganglion blocking agents in relieving dyspnoea and in reducing
elevated systemic venous and right heart pressures in patients with congestive
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cardiac failure and acute pulmonary oedema suggests that these peripheral
dilator effects of morphine may be of equal value (Sarnoff, Goodale and
(1958).
Sarnofft 1952; Kelley, Freis and Higgins, 1953; Ellestad and Olson, 1956), Yu et al. I
Not infrequently the cardiac output rises, at times considerably, and, no
doubt, this is one cause of the absence of significant hypotensive effects in
most recumbent human subjects given morphine. An increase in the cardiac
output, even a transient one, might also contribute to relief of the pulmonary
congestion. Nevertheless, a marked rise may well be tolerated poorly by
some individuals with coronary artery insufficiency or myocardial infarction*
These arguments are largely speculative since, a rise in cardiac output does
not invariably, nor even perhaps in the majority of cases, occur. When
such an increase has been recorded in patients with heart filure, a fall in
the right heart or pulmonary artery pressure has not necessarily followed.
The fall in ventilation which nearly always occurs after therapeutic
doses of morphine may well, in itself, be of benefit to patients in severe left
ventricular failure. There can be no question of the subjective benefits to
the patient occasioned by the relief of dyspnoea. Does this improvement involve
more than the relief from the severe discomfort of dyspnoea analogous to the
role of the drug in jelieving pain, or, does cardio-pulmonary function improve
measurably after morphine? While the literature can supply no certain answer
to this question, it would be helpful to set out certain considerations which seem
to have some bearing on the matter.
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Patients with heart disease have reduced vital capacity and pulmonary
compliance and patients with pulmonary oedema* in addition* show increased
resistances - both inspiratory and expiratory - to air flow (Brown, Fry and
Ebert* 1954; Sharp* Griffith, Bunnell and Greene* 1958). For these reasons
among others* the oxygen cost of increased ventilation and the work of breathing
are higher than normal in patients with congestive cardiac failure (Hoeschen*
Gold* Cuddy and Cherniack, 1952; Cherniack* Cuddy and Armstrong, 1957).
Further, many reports indicate that when high levels of ventilation are achieved
actively or passively in normal subjects* changes in ventilation are responsible
for the major portion of changes in oxygen uptake: and that as the upper limit
of ventilation is approached the oxygen cost rises very rapidly with little
increase in ventilation (CournandJ Richards, Bader* Bader and Fishman, 1954;
McKerrow, and Otis* 1956; Murray, 1959). Presumably this wo uld be true
also of patients with severe cardiac failure and acute pulmonary oedema with
marked tachypnoea.
Also there is some evidence from the work of Yamamoto and Mclver
(I960) in rats that a sustained very high level of pulmonary ventilation may*
in itself* be a cause of pulmonary oedema and cardiac failure even though it
may be doubted that levels of ventilation comparable to those induced by these
workers occur in clinical practice.
It is possible* therefore, that the reduction in ventilation itself which
results from the administration of morphine might achieve a useful saving in
energy expenditure with little, if any, increase in hypoxia. It is not known
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whether this in fact occurs since the blood gas changes in patients with
cardiac failure given morphine have not been studied. It is known, however,
that oxygen uptake does not necessarily decline after morphine despite the
marked fall in ventilation which usually occurs, and may even increase.
When oxygen uptake declines, the change is not necessarily a marked one, and,
in fact, it is seldom that the fall in oxygen uptake is of the same order as the
decline in ventilation. Some correspondence would, of course, be expected,
if the relationship between these two parameters at resting ventilation is as
close as that observed during voluntary or passive hyperventilation. These
considerations apply both to normal subjects and to patients with congestive
cardiac failure. There is in the literature no answer to this conundrum.
The changes in blood gas tensions in patients with congestive cardiac
failure following administration of morphine have not been fully studied.
Presumably, as in normal subjects, hypercapnia an d hypoxaemia will occur.
Since many patients with severe left ventricular failure and pulmonary
engorgement have a low or low normal arterial carbon dioxide tension, such
hypercapnia may not be in every case an important consideration. Thus
whether morphine-induced depression in ventilation and its accompaniments,
hypercapnia and hypoxaemia, are physiologically useful, whether they represent an a
acceptable compromise or whether they are in some instances harmful, cannot
be inferred from published evidence.
Finally, some inevitable uncertainty enters into a discussion of tie
benefits of morphine in left heart failure because the effects of the drug in
such patients have never been fully evaluated. Although formal evaluation
is not likely to disprove the central tenets of traditional teaching, it is
certainly important to find out whether the different categories of heart
disease which cause acute pulmonary oedema respond in differing manner
to the drug. It would be desirable also to determe the dose / effect
relationships and thus improve precision and discrimination in the routine
use of morphine.
VIH. OTHER PHARMACOLOGICAL. EFFECTS OF MORPHINE
Morphine produces certain other effects, in addition to those on
respiration and circulation, which are of less chrect importance to the
present investigation. These effects will be briefly mentioned only as it is
impracticable fully to review the literature on these points.
IX. HISTAMINE RELEASE
Morphine is a potent liberator of endogenous histamine (Feldberg and
Paton, 1950; Nasmyth and Stewart, 1950). This has been discussed, in a
previous section of this report, as one, though not the sole, factor in the
vasodepressor effects of morphine. Such released endogenous histamine is,
no doubt, also responsible for some of the clinically less important effects
of morphine, namely, local wheal formation, corgunctival and palpebral
erythema, pruritus, abdominal cramps, and, possibly also the broncho-
constriction observed in some laboratory species.
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X. HYPERGLiYGAEMIA
Morphine causes hyperglycaemia in man and in all laboratory species
studied. Tolerance to this effect develops with repeated administration.
It is worthy of note that hyperglycaemia has occurred irrespective of whether
or not overt excitement or depression or respiratory stimulation or depression
develops following drug administration. The cause of this hyperglycaemia is
not completely understood. The available evidence suggests that hyperglycaemia
results primarily from an action on the hypothalamic autonomic centres with
consequent rdease of epinephrine from the adrenal medulla. The reaction
is diminished by adrenalectomy and adrenergic blockade.
The literature on morphine hyperglycaemia has been reviewed by
Reynolds and Randall (1957).
XX. EFFECTS ON ADRENAL GLANDS AND ON HYPOTHALAMUS
After administration to cats* morphine causes the appearance of
increased quantities of pressor substances in adrenal venous blood* an
indication of adrenal medullary stimulation (Evans* Nasmyth and Stewart*
1952). In the rat* the ascorbic acid content of the adrenal glands diminishes
after morphine* evidence that adrenal cortical activity has been stimulated*
presumably through release of ACTH. The ACTH releasing effect appears
to be mediated partly through release of histamine and partly through adrenalin
released from the adrenal medulla, but there is an important residual effect
due to unidentified factors, possibly related to a central effect of the drug on
the hypothalamus (Nasmyth, 1954). These observations no doubt partly
explain the old observation that morphine is considerably more toxic to
adrenalectomised than to intact rats (Lewis, 1923).
Morphine also appears to influence other hypothalamic functions.
It markedly inhibits water diuresis and the evidence indicates that this is
achieved by an effect upon the hypothalamo-hypophyseal system (de Bodo,
1944).
Summary of Respiratory and Circulatory Effects by Morphine
The literature on the effects of morphine, with particular reference
to man, on behaviour, respiration, oxygen consumption and circulation has
been reviewed. The literature on the effects of the drug on patients suffering
from left ventricular failure has also been reviewed.
In laboratory species and in man the drug is primarily a central
nervous system depressant. In some animals, namely* the cat, mouse and
dog, morphine, in certain circumstances, causes restlessness, an effect
which appears to be related to the dose. In most laboratory species, very
large doses cause convulsions* an effect interpreted by many workers as
evidence of stimulation. The evidence that morphine ever overtly stimulates
or causes excitement in non-addicted human subjects is not good and, mainly,
heresay. Nevertheless, there is good evidence that, in certain circumstances,
morphine produces hyperpnoea and increases oxygen uptake and cardiac output,
both in human subjects and in laboratory animals.
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In human subjects and in all laboratory species morphine causes
respiratory depression* even though in some species* namely the cat and
the dog such depression may not, under all conditions, be apparent. In
the rabbit and in the rat - species ior which data are most complete - the
depression in minute ventilation is proportional to the logarithm of the dose
used. The relationship between dose and effect is not known in the human.
The doses reported in experiments on laboratory animals are* on a weight
basis, considerably larger than those ordinarily used therapeutically in man..
Both in human and in animal studies, the change in minute ventilation has
been the most reliable index of respiratory depression after morphine.
Changes in respiratory rate and tidal volume have been very variable,
particularly in man,
The effects of morphine upon oxygen consumption are not definitely
known. Experiments with laboratory species have suggested that small
doses depress and larger doses either cause no significant change or may
increase oxygen uptake. In the majority of studies in man, oxygen consumption
was depressed by morphine but what relationship these changes bear to the dose
administered cannot be inferred from the published data. In some studies,
the drug apparently caused oxygen uptake to increase even though ventilation fell.
Morphine diminishes the respiratory response to increased concentrations
of carbon dioxide in inspired air. The drug also causes an increase in alveolar
or arterial carbon dioxide tension in association with a fall in ventilation. The
displacement of the ventilation/alveolar carbon dioxide response curve towards
higher values of P CO has been used by many workers as a measure of drug
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effects. The use of such curves has been criticised in the review. There
seems to be no good reason for thinking that the drug depresses respiration
because of this diminished sensitivity to carbon dioxide.
Morphine also attenuates the effects upon ventilation of other varieties
of afferent stimulation. The increased respiration normally seen after
painful stimulation is diminished and afferent vagal impulses are altered so that
inhibitory impulses are enhanced and acceleratory reflexes inhibited or
depressed.
Because of these effects upon nociceptive and other afferent stimulation
some workers have suggested that respiration is depressed because of inter¬
ference with afferent impulses while others have postulated that it is the
responsiveness of the centre itself, rather than the strength of afferent
stimulation which is depressed. The peripheral effect of the drug as a broncho-
constrictor has occasionally been assigned some importance in the respiratory
depressant properties of the drug. It is doubtful that this last named effect
of morphine is an important cause of respiratory depression in man. Studies
on decerebrate and brain stem preparations suggest* by contrast* that the
drug acts at many sites* including medullary* pontine and more rostral regions.
Morphine produces systemic circulatory effects in laboratory animals
and in man. The drug causes a fall in the systemic blood pressure, peripheral
vasodilatation and, frequently, a rise in cardiac output. The fall in blood
pressure may be transient* but* in the cat and in the dog, is often prolonged.
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In human subjects, the vasodepressor effects have not been marked though
occasional subjects have shown a steep and prolonged fall in systemic blood
pressure* However, circulatory studies on man using modern techniques
have been few.
Circulatory and respiratory measurements in patients suffering from
heart failure after administration of morphine have, only uncommonly, been
reported. In the majority of such studies, ventilation and oxygen uptake fell.
In some studies, however, oxygen uptake rose. The circulatory changes
reported nave been very variable. Many patients suffering from left heart
failure have shown an increase in pulmonary artery or xi ght atrial pressure,
and others, a decrease after administration of morphine. An increase in
cardiac output has been reported, in one report, to have occurred in several
subjects. One group of workers report a decrease in pulmonary blood volume,
in cardiac index and in left ventricular filling pressure following administration
of morphine to patients convalescing from high altitude pulmonary oedema*
The literature on the circulatory and respiratory changes after administration
of morphine to individuals suffering from left heart failure is not extensive.
Also, the majority of patients reported in the post-war studies have suffered from
mitral valve disease.
The mechanism whereby morphine might cause clinical improvement
in patients suffering from left ventricular failure lm« been discussed. It is
possible that the peripheral vaso-dilator effects of morphine - like those of
ganglion alockiagagents - and, the increase in cardiac output, when this occurs,
might each contribute to relief of pulmonary congestion. It is possible that
the fall in ventilation which regularly occurs aifer administration of morphine
might itself be of benefit to patients in left ventricular failure. It is not
known whether this decrease in the greater than normal work of breathing
would be achieved without an undesirable increase in the degree of hypoxia.
EXPERIMENTAL DESIGN, METHODS, MATERIALS
AND STATISTICAL TREATMENT OF RESULTS
Experimental Design
After some preliminary studies, which will not be reported in the
present Thesis, the following experimental design was laid down.
Treatment Groups
Three categories of subjects were studied X«
1. Fit subjects not suffering from pulmonary disease or cardiac failure
treated with morphine ("normal subjects"). These subjects were divided
into four treatment groups to whom doses of 5, 10, 15 and 20 mg/70 kg
body weight morphine respectively were administered. These treatment
groups confained respectively 6, 9» 9 and 4 subjects.
2. Moderate to severely ill patients suffering from left ventricular
failure at the time of the study. These subjects were complaining of
exertional dyspnoea, were orthopnoeic and exhibited clinical evidences of
pulmonary congestion. To this group, morphine 15 mg/70 kg was administer
There were 6 subjects in this group.
3. A group of 4 fit subjects not suffering from pulmonary disease or
heart failure ("normal subjects") treated with soluble phenobarbitone in doses
of 3.14 - 3.64mg/kg.
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The normal subjects were in-patients at the time of study and volunteered
on request. The purpose of the experiment and the procedures to be adopted
were fully explained to them. Each subject was studied once only. The
patients in left ventricular failure were invited to co-operate in studying the
effects of a drug which, it was explained, would in any case be used in
treatment. There was no definite plan of allocation of subjects except that
no normal subject was ever selected as being suitable for the administration
of any particular dose. The majority of studies in the 10 and 15 mg/70 kg
groups were performed earlier in the series than those in the other two groups.
It was intended, at the start, that the treatment groups should contain equal
numbers of subjects, but, in the event, this proved not to be practicable because
of the great pressure on the facilities of the laboratory. It would have been
helpful if the 20 mg/70kg group were larger. However, the small size of
this group has proved, in practice, to be not a serious inconvenience. The
numbers in the other treatment groups, though unequal, are entirely satisfactory
for statistical treatment.
Experimental Procedures
A standard experimental procedure was laid down in advance and
closely adhered to in each subject. All experiments were performed in one
of two rooms in the Department of Medicine, Royal Infirmary. Entry into
this room by other persons was not permitted after commencement of recording.
All experiments were performed in the forenoon. Subjects were
permitted a light breakfast at the same time as other patients in the ward
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at about 7 a.m. and reported to the laboratory between 9 - 9.15 a.m.
After weighing* normal subjects lay supine with one pillow on a comfortable
trolley covered with a soft mattress of Dunlopillo for 30 - 40 minutes before
any procedures were attempted. After this period of rest* a brief outline
of the procedures to be used was given. Patients suffering from left
ventricular failure were studied sitting up in their beds supported by a back
rest. They were wheeled from the ward to the laboratory on the morning
of the experiment. Otherwise the procedure for studying these patients was
identical with that described for normal subjects.
Venous and, when required, arterial catheters were then inserted
under strict asepsis. A 12 inch polythene catheter, of outside diameter 1.34
mm, was introduced percutaneously (Berneus, Carlsten, Holmgren and
Seldinger* 1954) into an antecubital vein, usually the left. The catheter
was tested for free reflux* filled with heparinised normal saline and protected
with a light plastic two-way tap. In two subjects* in whom venous catheterisation
proved unsatisfactory, a Gordh needle was inserted into a vein on the dorsum
of the left hand.
In 13 normal subjects treated with morphine, in 3 patients in the group
with left ventricular failure, and in 3 subjects in the group treated with
soluble phenobarbitone, a similar catheter was inserted into the Brachial
artery of the same side using an identical technique. Thus arterial gas
tensions could be measured only in approximately one half c£ the normal
subjects treated with morphine * These facilities were not available for
many of the earlier studies and* when this service became more regularly
available* arterial puncture occasionally failed.
After insertion of the venous and arterial catheters* subjects breathing
room air were made to expire into a Tissot spirometer by way of a low
resistance valve whose measured dead space was 60 mis* A light nose clip
prevented leakage through the nostrils* During the ensuing practice period
of not less than 20 minutes* the spirometer bell was washed out with expired
air four or five times. During this period* the subjects became familiar,
with the circuit and none showed evidence of discomfort or complained of
difficulty with breathing into the valve.'
Experimental Protocol
All experiments were performed according to an identical protocol
which* for convenience* has been outlined on the attached diagram (figure 1)*
Each study is* in effect* divided into consecutive four minute recording
periods* during which ventilation was continuously recorded on the spirometer
drum. These recording periods are separated by intervals of one minute*
during which a sample of expired air is removed from the spirometer which
is then emptied* Arterial blood samples* when taken* were withdrawn at the
start of the second minute of each recording period*
Five control periods* extending over a total of 24 minutes, and 12
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studies, 1-3 minutes were lost during the post drug period because of
delays in emptying the spirometer or in replacing the recording paper.
These minor departures from the protocol are, for the present purposes^ of
no importance.
Blood samples were withdrawn during the last 3 control periods.
Because of the pressure on the laboratory facilities, sampling was not
always performed during the entire post drug period.
The experimental protocol, in consequence, yielded the following data
1. Minute by minute records of ventilation, respiratory frequency and
tidal volume over a continuous period of approximately 85 minutes, except
for the regular interruptions noted previously.
2. Mean measurements derived from the recorded minute ventilation
and the analysis of expired air, of oxygen uptake and carbon dioxide excretion
per minute over the same period. Occasional samples of expired air were
lost.
3. In 13 cases, arterial blood gas tensions at intervals of 5 minutes,
consisting of 3 control and 9-12 post drug samples.
Morphine sulphate, in the dose selected, was made up to a volume
of 10 ml with sterile saline before recordings were started. The drug was
administered as a single rapid injection through the venous catheter, exactly
at the commencement of the first period immediately following the last
control period. Soluble phenobarbitone was made up and administered in
exactly the same manner.
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Throughout the experiment, the apparent state of alertness of the
subject was recorded as frequently as appeared to be necessary throughout
the period of the study.
.Laboratory Techniques
Spirometry
One of the two Tissot spirometers was used dun ng each study.
The calibration factors were respectively 1.01b and 1.416 litre/cm, the
respective volumes being 80 and 105 litres. They were calibrated by the
standard method of filling the bell of the instrument with a measured quantity
of air displaced by a known volume of water. The smaller instrument was
calibrated by myself and cross-checked against that of the larger instrument,
which had, some time previously, been calibrated. Close agreement wa3
found between the two calibrations.
Minute by minute measurements of ventilation and respiratory
frequency were rriade. The volume displacement of the spirometer was
measured from the inscribed record to the nearest 0.1 cm by means of an
engine divided rule. The number of breaths during each minute were
enumerated direct from the tracing. The mean volume per breath (tidal
volume) was calculated from the measured volume related to the number
of completed breaths enumerated in that minute.
Where arterial carbon dioxide tensions were availably alveolar
ventilation was calculated, in the usual manner, by subtracting Dead Space
from Total Ventilation. Physiological Dead Space was calculated in the
standard manner by the use of the equation
P CO - P CO
v - —-— L y
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Oxygen uptake and carbon dioxide output were calculated from the
measured volume of ventilation and the results of the analysis of the expired
air samples. For calculation of the oxygen uptake in subjects breathing
room air, the standard formula was used, namely
F F .
I x EXT
V = V ( 2 2 - F )
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Samples of expired air were taken into paraffin lined syringes of 50
ml capacity. Gas analysis was performed by myself on the same day on a
Haldane gas analysis apparatus as modified by Lloyd (1958). The results
of duplicate analyses, which were done on all specimens, agreed within 1%
or less. The reliability of the paraffin lined syringes used in this laboratory
has been personally evaluated. It has been found that, provided these
syringes are kept well greased, they hold the contained gases extremely
well over a period of 48 hours at least and probably longer. For each
experiment, a set of duplicate specimens was analysed at the end of the
day's run and significant differences from the initial result were rarely found.
Arterial blood samples were taken into heparinised syringes which
were immediately capped and handed over for analysis. Arterial carbon
dioxide tensions were measured by means of the Severinghaus electrode
(Severinghaus» 1959). oxygen tensions by means of the Clark cell (Bishop
and Pincock, 1959) and pH by means of an E.I.D. glass electrode system.
In accordance with standard practice (Fed Proc 1950) measurements
were expressed, unless otherwise stated, in the following units
Ventilation (V) L/min/sq.m. BSA, BTPS
Respiratory frequency (f) Breaths/min.
Tidal Volume (volume per breath) L. BTPS
♦
Oxygen uptake (Vq?) E/min/sq.m. BSA, STPD
CO2 output (Vj^qq ) D/min/sq.m. BSA, STPD
Body surface area was read off from a nomogram calculated from the
subjects' height and weight according to DuBois and DuBois (1915).
Statistical Analysis of Data
A standard method of statistical treatment was employed.
For each subject, in respect to each function measured, the control
and post drug means were compared, in the usual manner, by the use of
Student's :,t" test. The level of significance chosen was 0.05. Where
highly significant differences between variances were present, the procedure
recommended by Bailey (1959) has been used for testing the statistical signi¬
ficance of differences between means.
In each treatment group the individual changes were treated as
normally distributed variables, and the significance of the difference
from zero of the mean change observed was tested by the use of the
standard formula
t = —y—s v n
Differences among the treatment groups were tested, in the first
instance, by analysis of variance, before more detailed testing using
Student's "t" values was used. Where justified, the relationship of
observed changes to dose administered has been studied by the calculation
of appropriate regression slopes. The significance of the slopes was
tested in the usual way by the use of the attached estimate of its standard error.
The control data relating to the normal subjects in the four treatment
groups have been tested for homogeneity as to age, minute ventilation and
oxygen uptake by analysis of variance.
Since oxygen uptake, carbon dioxide output and arterial carbon
dioxide tensions are each linked to ventilation, the changes in these measure¬
ments have been further explored by the methods of regression analysis.
By the use of these methods, it is possible to *ir;d out, provided that suitable
regressions can be calculated, whether changes in these parameters have
occurred independent of changes in ventilation. The method used has been
as follows. In each treatment group a common regression slope has been
estimated separately for control and post drug periods by the method of
covariance analysis (Snedecor, 1962). In calculating the common control
regressions, all 5 available control periods have been used* The common
regression lines so estimated have then been compared in respect to slope
and elevation. Differences in elevation have been tested by calculating
the adjusted means and testing for significant differences between these.
In the use of regression analysis in the present study, the most
difficult problem has been the presence, in some treatment groups, of
evidences of significant slope differences among the individual subjects.
Where such differences exist, a common estimate of slope derived in the
manner indicated may not be valid. There can be no stereotyped method
for dealing with this difficulty and the following measures have been
employed, as indicated later. It is sometimes possible to locate the source
of heterogeneity, for example, an individual subject or a set of observations
which can be removed from the calculations if the experimental protocol
will permit this, and, if removal does not distort the observations or
introduce bias into their interpretation. At times, a common slope is
acceptable as the best available estimate, even though there is evidence of
heterogeneity, if there are good grounds for assuming that the slope differences
are not marked, especially if there is evidence from other data, that the derived
slope must be very close to the true value. Occasionally, however, it has had
to be accepted that, owing to heterogeneity of slope,avalid estimate of common
regression could not be derived.
Finally, for the purpose of evaluating the significance of differences
between the control and post drug means, a decision had to be made on the
length of the control period to which the post drug changes should be related.
Although 5 control periods, representing observations over 24 minutes,
were available it was decided to refer the changes following drug adminis¬
tration to the final 3 control periods only. This decision, which was taken
before the analyses were undertaken, may be justified as follows. It seems
reasonable to suppose - and experience supports this - that such changes
must be related most genuinely to the period immediately preceding drug
administration. Consequently, the use of 5 control periods for these
comparisons could well result in the loss of valuable information. The
three periods chosen provide 12 individual measurements of ventilation,
respiratory frequency and tidal volume, a convenient number for statistical
comparison with the more extended post drug period comprising 48 individual
observations. Logically, the use of the last control period only should
provide a convenient basis for the measurement of changes. This argument
has substance, but the procedure is, notwithstanding a less satisfactory one
because a valuable measure of statistical control would thereby be sacrificed.
Particularly, sources of error and variation which cannot be eliminated from
any experiment would be less well allowed for in the statistical analysis if only
4 individual observations were available.
Unfortunately, the control period so selected, yields only 3 individual
observations of oxygen uptake, carbon dioxide output and gas tensions.
Happily, this has been less of an inconvenience than might be thought, mainly
because of the very stable metabolic state achieved in the majority of subjects.
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Note on Equipment used in this Project
The sources of the apparatus used in the present study are given below.
The venous and arterial catheters used were "Portrex" catheters
supplied by Portland Plastics Ltd., Hythe, Kent.
The Tisaat spirometers were manufactured and supplied by:-
Siebe Gorman Ltd.,
Neptune Works, Davis Road, (105 litre instrument)
Chessington, Surrey.
G. Plant and Son Ltd.,
Bull Street, Harborne, (80 litre instrument)
Birmingham, 17.
The Severinghaus pCO electrode was manufactured by National
u
Welding EquipmentCo., 219 Fremont Street, San Francisco, California.
The Clark electrode was made in the Engineering Workshop,
Department of Medicine, Queen Elizabeth Hospital, Birmingham.
The E.I.L. replaceable capillary glass electrode system was supplied
by Electronic Instruments Ltd., Richmond, Surrey.
The respiratory valve used was the low resistance instrument
described by Theron, Zwi and McGregor (1958).
RESULTS IN NORMAL SUBJECTS TREATED WITH MORPHINE
Personal Particulars and Control Observations
The personal particulars relating to all subjects studied are given in
Table 1. The control measurements for minute ventilation, oxygen consumption
and carbon dioxide excretion are set out in Table 2.
The control data relating to the normal subjects in the four groups
treated with morphine, have been tested for homogeneity by analysis of variance.
There is evidence of significant heterogeneity among the treatment groups in
respect to age (.025 > P > .02) and detailed testing shows that this is due to
the 15 mg/70 kg group in which the mean age is greatest.
The control minute ventilation also shows some slight evidence of
heterogeneity among the treatment groups (P - . 05, nearly) and further tests
show that the control minute ventilation in the 20 mg/70 kg group is significantly
greater than that of the 5 mg/70 kg group. The other two groups show no
significant differences between themselves and are neither significantly different
from the 5 or 20 mg/70 kg group.
In respect to oxygen uptake and carbon dioxide output, the normal
treatment groups show no evidence of significant heterogeneity.
Variability, expressed as the ratio of the estimated standard deviation
to the mean (S. D. /mean), in respect to control minute ventilation and oxygen
uptake has also been tested for homogeneity. The variability in control
70
oxygen consumption is remarkably small and there are only small and
non-significant differences among the four treatment groups in this respect.
Variability in minute ventilation is rather greater but the differences between
the treatment groups are far from significant (Table 2).
To summarise* the main source of heterogeneity among the four
groups of normal subjects treated with morphine, is the age distribution, and,
this is due to the rather greater mean age in the 15 mg/70 kg group. There
is just detectable heterogeneity in respect to the control minute ventilation
attributable to a significant difference between the 5 mg and 20 mg/70 kg
groups. There is no evidence of significant heterogeneity in respect to
oxygen consumption and carbon dioxide output or variability in ventilation
and oxygen consumption. The mean value for oxygen consumption is very
close to published figures for adults in the basal state (Boothby, Berkson
and Dunn, 1936; Baldwin, Cournand and Richards* 1948).
The possible influence of age on the respiratory effects of morphine
will be considered later. The control values show that in every other
respect these four treatment groups are very suitable for comparative study
of possible drug effects.
Presentation of Data
The results have been assembled and summarised in tabular form
and, also, in the form of diagrams which indicate graphically the most
important changes attributable to the drug. The present section of the report
will deal with the effects of morphine in normal subjects but, as far as
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possible, the results relating to other categories of subjects will be presented
in the same manner.
In respect to the normal subjects treated with morphine the following
tables are presented
Measurements of respiration, oxygen uptake, and carbon dioxide
output, for each subject during successive 4 minute control and
post drug periods (Tables 3, 4. 5. 6)
Mean control and post drug values of the same for each subject
in each treatment group with estimates of statistical parameters
attached. (Tables 7. 8. 9. 10)
Mean fractional changes in respect to each variable in each
treatment group with estimates of statistical parameters (Table 11)
Mean values are presented with the estimate of standard error (S.E.)
and standard deviation (S.D.) indicated thus Mean jh S.E.
(S.D.)
Estimates of slope are presented in the text and in the tables with the
standard error attached.
The units employed are those indicated previously, except that in
these tables, the carbon dioxide output is expressed as actual output
(litres/min STPD) and not related to body surface area.
The level of significance of the observed changes is indicated in
the tables by asterisks as follows
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* significant at or beyond. 05 level
** >> ii ii n ,02 "
*** " " "• " ,oi "
**** '» If II I' .001 "
The diagrams illustrate these changes and will be referred to in
the appropriate portions of the text. In addition* the movements of
respiration* oxygen uptake and carbon dioxide output have been plotted
in relation to time on diagrams (figures 2, 9* 11J2.20). In constructing
these diagrams the mean values at each period of the experimental protocol
have been computed from the individual measurements together with an
estimate of the standard error^. The latter is indicated in relation to
each plotted point on the diagrams. Thus changes in ventilation, respiratory
frequency, tidal volume, oxygen uptake and carbon dioxide output could be
referred to the time of drug administration.
(l) One subject (R.M.) in the 10 mg/70 kg group has been excluded from
these calculations. In this study, continuous measurements of ventilation
etc. were made using two spirometers connected in series.
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Effect on Respiration of Morphine (5, 10, 15 and 20 mg/70 kg) in normal subjects
Minute Ventilation
Minute ventilation is significantly depressed by each dose adminis¬
tered (Table 11* Figures 21, 3 ). After 5 or 10 mg/70 kg the mean ventilation
increases before depression supervenes (Figure 2). Following administration
of 15 or 20 mg/70 kg, an initial increase is not apparent in the pooled
observations. However, some individuals in the former group do experience
such an increase (figure 7).
Over the entire post drug period of 60 minutes, the fall in minute
ventilation in the 5 mg/70 kg group is just short of the .05 level of
significance (l > P > .05). After exclusion from the calculations of the
initial period during which an increase in minute ventilation occurs, this
post drug depression is statistically significant (.02 > P > .01). The
depression in minute ventilation, measured over the 60 minute post drug
period in the 10, 15 and 20 mg/70 kg groups is highly significant.
Analysis of variance shows a significant dose effect in respect to
the depression in minute ventilation (P < .001). Comparison between
the individual treatment groups show no significant difference between the
effects of 15 and 20 mg/70 kg (P > .7), and significant differences between
the 5 and 10 mg/70 kg (. 05 > P > .02) and between the 10 and 15 mg/70 kg
(.01 > P > .001) groups. The mean depression in ventilation after 20 mg/
70 kg is actually slightly smaller than that caused by 15 mg/70 kg and this
may mean that a levelling off of effect occurs after doses in excess of



























Minute Ventilation before and after
Administration of 5.10,15, and 20mg/70kg Morphine I.V.
• Mean Values *SE. Control: Mean Values during 3 successive 4min. periods immediately prior
to injection.
Post Drug: Mean Values during 12successive 4min periods following injection.
Figure 2
Changes in Respiratory Minute Volume (pooled observations) in
relation to time* after 5, 10. 15 and 20 mg/Kg. morphine
administered to normal subjects* Each plotted point is the mean
value for all subjects + S.E. (One subject - R.M. - excluded
from the IO mg/70 Kg. group for reasons given in text).
Dene of Mtfohinc 5 10 15 20 5 10 15 20 5 10 IS 20
mg/TOkg f I f I t I t I •! 1 I I f I I I I I ' I t * *
FRACTIONAL
CHANGES
Fractional Change Fractional Change Fractional Changes
in Ventilation in Respiratory Rate in Tidal Vbiumes
Fractional Changes in Minute Ventilation, Respiratory Rate and Tidal Volume
in Normal Subjects measured over 60 minutes following • Individual Changes at Doeei Speotfed
5k 10,15 and 20 mg/70kg Morphine IV £ Mean Change * SE.
Figure 3
Fractional changes in minute ventilation* respiratory frequency and
tidal volume after 5* 10* 15 and 20 mg/70 Kg. morphine in normal
subjects. Individual values and mean values ± S.E. for each group
are shown. Measurements are over the 60 minute post-drug >r
period.
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in deciding this question.
The depression in ventilation is linearly related to the size of dose
administered (figure 4). The slope of the straight line vhich gives the
best fit to the observations is highly significant (P < .001). The fitted
regression has the equation
Fractional depression in ventilation = .0050 + (.0089 + -0019)^ x Dose
(mg/70 kg)
Because, as previously discussed, experiments with laboratory
species have indicated a logarithmic relationship to the size of dose, the
best fitting line to express this has, as a matter of interest, been fitted
(figure 3). It will be clear from inspection, that this line is not a good fit
to the observations.
These results indicate that, for doses between 5 and 15 mg/70 kg,
the depression in minute ventilation, as measured in the present experiment,
is proportional to the size of the dose. The results indicate that this linear
relationship may break down for doses larger than 15 mg/70 kg. However,
because of the rather small size of the Z0 mg/70 kg group, and the significantly
higher mean age of the subjects in the 15 mg/70 kg group, this question must
remain open.
(l) Regression equations will be presented throughout in the form



















20 Dose of Morphine
mg./70kg.
1-0 148 1-30 log Dose
loglO log 15 log20
Observed Mean Fall in Ventilation±SE.
Fitted Curve to Equation
y= -00498+•00893X
Fitted Curve to Equation
y-Q577+-0212 log X
Relationship between fall in Minute Ventilation( expressed as a
fraction of the Control Ventilation and the dose of Morphine
Curves fitted to Data from 28 Normal Subjects.
Fi8^P 4
Fitted regression line (least squares method) relating fall in minute
ventilation to dose of drug:-
Fractional change
e
VE = .0050 + (.0089 + .0019) x Dose (mg/70 Kg.)
The fitted line has been extrapolated to include the 2.5 mg/70 Kg. point.
The changes in ventilation observed in the individual subjects are
consistent with the group changes noted above (Tables 7 - 10). Each
individual in the groups given 10, 15 and 20 mg/70 kg experienced a fall
in minute ventilation which was nearly always statistically significant.
In 2 subjects, however, both in the 10 mg/70 kg group, this depression
was not significant. In the 5 mg/70 kg group, two subjects showed a
slight increase in minute ventilation - in both subjects the tidal volume
fell significantly. The other 4aibjects in this group all experienced a
fall in minute ventilation; in two subjects this was significant, and, in the
other two was just short of the .05 level of significance.
The results indicate that all doses of morphine used have a
definite depressant effect upon minute ventilation which is proportional
to the dose with an apparent levelling off of effect after doses greater than
15 mg/70 kg. In a few subjects, particularly among those given the smaller
doses, the depression in ventilation will be slight, or may even not occur.
Hyperpnoea after Morphine
It has been our experience that morphine frequently causes an
immediate increase in minute ventilation before depression supervenes
(figures 2, 5,-8). Inspection of the data shows that this increase is most
frequently present in the treatment groups given 5 and 10 mg/70 kg, is less
common in the 15 mg/70 kg group and has occurred in none of the subjects













Fractional Changes in Minute Ventilation during first 4 minutes following I.V.
Administration of 5mg/70kg Morphine
(6 Normal Subjects)
• Individual Subjects. £ Mean Changes ±S.E.
Figure 5
Fractional changes in ventilation at 1 - 4 minutes after administration
of 5 mg/70 Kg. morphine (normal subjects). Individual values and


















TIME MINS 1-2 1-3 1-4
Fractional Changes in Minute Ventilation • Individual Changes
during first 4 minutes following I.V. £ Mean Changes ± S.E.
Administration of I0mg/70kg Morphine
(8 Normal Subjects)
Fi&Vr*
Fractional changes in ventilation at 1 • 4 minute* alter administration
of 10 mg/70 Kg. morphine (normal subjects). Individual values and














Fractional Changes in Minute Ventilation • Individual Changes
during first 4 minutes following I.V. ^ Mean Changes ± 5.E.
Administration of I5mg./70kg. Morphine
(9 Normal Subjects)
Figure 7
Fractional changes in ventilation at 1 - 4 minutes after administration
of 15 mg/70 Kg. morphine (normal subjects). Individual values and






TIME MINS 1-2 1-3 1-4
Fractional Changes in Minute Ventilation • Individual Changes
during first 4 minutes following I.V. (£> Mean Values ± S.E.
Administration of 20mg/70kg Morphine
(4 Normal Subjects)
Figure 8
Fractional changes in ventilation at 1 - 4 minutes after administration
of 20 mg/70 Kg. morphine (normal subjects). Individual values and
mean value + S.E. shown for each treatment group.
76
Hiis phenomenon has been analysed in the following manner. The
change in ventilation (with the appropriate sign attached) shown by each
subject has been calculated at each of the initial four minutes following drug
administration. These changes have been treated in the usual manner as
normally distributed variables, and the significance of the difference from
zero of the mean change so computed has been tested by the use of the
standard formula
=tV
A two tailed test has been considered appropriate in this case even though
in the 5 and 10 mg/70 kg groups, there is only slight evidence that the
drug causes any immediate depression of ventilation.
The changes so calculated are set out in Table 12 and illustrated in
the diagrams (figures 5,-8'). Inspection of the plotted values indicates that
after 5 and 10 mg/70 kg,a large increase in ventilation was not uncommon
during the first minute following drug administration and, further, that an
immediate fall in ventilation was distinctly uncommon in these treatment groups.
This initial overbreathing, where present, regresses very quickly and has
largely disappeared by the third minute. In the 15 mg/70 kg group, ventilation
increased during the first minute in 4 subjects, and fell in 5 subjects. None
of the 4 subjects given 20 mg/70 kg experienced an initial increase in
ventilation. The depression in ventilation at the first minute after injection,
even in this small group of 4 subjects, is significant (.05 > P > .02).
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Thus, in all the treatment groups* there is a gradual decline in
ventilation during the first four minutes after injection* either from initially
high levels (as in the 5 and 10 mg/70 kg groups) or following an immediate
decline (figures h,-8).
Although the majority of subjects given 5 or 10 mg/70 kg morphine
experience an initial increase in ventilation - in some cases a very large
increase - in neither group is the rather large mean increase statistically
significant (P > . 3 and >4 respectively). Since there is no significant
difference between these two treatment groups in this respect* the data
have been pooled* but* even after pooling* the mean increase of 21% is
still short of the .05 level of significance (P = .05* nearly). This failure*
to attain an acceptable level of statistical significance* is no doubt to be
attributed to the rather large variance.
Subjects treated with 15 mg/70 kg less commonly show an initial
increase in ventilation* though increases of 9 and 15% occurred in two
subjects. There was a mean fall in ventilation at the first minute in this
group of approximately 2%* a non-significant change. As previously noted*
subjects in the 20 mg/70 kg group experienced an immediate and significant
depression in ventilation, the mean change being approximately 10%.
This change in ventilation (with appropriate sign attached) at the
first minute after injection is linearly related to the dose administered
(figure 10). The slope of the regression line fitted to the observations by
Straight Line fitted to Data -r
Change in Ventilation = *4502- *0302" Dose (mg/70kq)
10 15
Dose of Morphine (mg/70kg)
20
• Individual Values
£ Mean Value*SE. at each dose
Fractional Changes in Minute Ventilation during first Minute
following I.V. Administration of 5, 10,15, 20mg /70kg Morphine
to Normal Subjects.
Figure 10
Fitted regression line (least squares method) - changes in ventilation
at 1 minute post-drug related to dose of morphine (normal subjects).
Fractional change
e
Vj_. = .4502 (.0302 £ .0106) + dose (mg/70 Kg.)
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the method of least squares is significant (.01 > P > .001). The fitted
regression has the equation
Fractional change in ventilation = .4502 - (.0302 + .0106) x Dose
(mg/70 kg)
Because of the marked variability of these iritial changes after
administration of morphine an attempt was made to locate some of the
factors which might contribute to post drug hyperpnoea. This initial
change in ventilation does not correlate vi th the levels of control ventilation
(r =.093, n = 14), or with the level of oxygen uptake (r = - .033* n = 14).
There is a suggestion that this post drug increase might be related to the
variability of the control ventilation as measured by the individual standard
deviations (r = .312, n = 14 P > .1). A larger number of observations would
be needed to decide this point.
It may, however, be taken as established that morphine frequently
causes, ia man, an initial increase in ventilation lasting 1-2 minutes at
most before sustained depression supervenes. This, presumably, may occur
after any dose, although no subject in the 20 mg/70 kg group showed such
an increase in ventilation. This tendency shows a highly significant inverse
relationship to the size of the dose so that the initial increase is most
marked after 5 mg/70 kg and decreases steadily thereafter. It cannot,
therefore, be doubted that this hyperpnoea is an authentic drug effect.
Nevertheless, the great variability, quantitatively, in this response, suggests
that the phenomenon is influenced by factors, other than the dose of drug itself,
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which are unpredictable in appearance and, consequently, not yet amenable
to control. The possible relationship to the variability of the control
ventilation suggests that these factors might relate to the internal
environment - physiological or psychological.
Effect of Age on Respiratory Depressant Effects of Morphine
It is desirable to consider whether the fall in ventilation after
administration of morphine is dependent upon the age of the subject.
It has been pointed out in a previous section of this report that the treatment
groups show evidence of significant heterogeneity in respect to age which
was attributable to the high mean age of the 15 mg/70 kg group. This
relationship has been studied in the following manner.
The regression slopes relating change in ventilation (expressed as
a fraction of the control value) to age of sutject have been calculated for
each treatment group, and, these slopes have been compared in the usual
manner by covariance analysis (Table 13). The estimate of slope is
significantly different from zero only in the 15 mg/70 kg group (.01 > P > .001).
This slope is negative, apparently indicating in this group a tendency for the
older subjects to experience a greater depression in minute ventilation
after morphine. The sJqpe estimates in the other treatment groups are not
significantly different from zero.
Covariance analysis brings out significant slope differences among
the treatment groups (.05 > P > .025) and further analysis shows that this is
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due to the 15 mg/70 kg slope. If despite the presence of significant slope
differences, the sums of squares are pooled, the common slope estimate so
derived is far from significant. The estimate of common slope derived,
following exclusion of the 15 mg/70 kg group, is also, not significantly
different from zero, and is, numerically rather close to the former. It
seems likely, therefore, that the significant negative slope and the high correlation
between age and respiratory depression, in the 15 mg/70 kg group are spurious.
The failure to demonstrate a relationship between changes in ventilation
and age in the other treatment groups and the loss of significance when the
sums of squares are pooled make this conclusion almost certain. The
alternative explanation that this relationship holds only with doses of
15 mg/70 kg is rather improbable.
Consequently, it seems likely either that the relationship between
age and depression of minute ventilation is a purely chance finding or, that
some other factor which is correlated with age is present in the 15 mg/70 kg
group, in greater degree than in other groups. The clinical histories were
therefore scrutinised in an attempt to locate such a factor (Table l). These
show that the 10 and 15 mg/70 kg groups contain an excess of subjects with
hypertension or cardiovascular disease. In the 10 mg/70 kg group, there
were no symptoms referable to vascular disease except in one subject who
had recovered from a recent myocardial infarct. In the 15 mg/70 kg group,
2. subjects had recent myocardial infarcts and 2 had recent transient cerebro¬
vascular accidents. All subjects were, of course, fit and free from
symptoms at the time of study. It seems difficult to understand how the
response to morphine might have been influenced by the above factors.
It appears advisable therefore to investigate more fully the possible
influence of age and clinical status on the respiratory depressant properties
of morphine. Meanwhile* it would be wise* for the present, to keep an
open mind on the matter.
Effect on Respiratory Frequency {figures 3, 9
tables 7 - 11)
The changes in respiratory frequency in relation to time are
illustrated in figure 9. The pooled values show a slight initial increase in
respiratory frequency after 5 or 10 mg/70 kg and an immediate decline after
15 or 20 mg/70 kg. Sustained depression thereafter is apparent in the 10,
15 and 20 mg/70 kg groups. The net effect in the 5 mg/70 kg group would
appear to be slight.
The mean changes, as measured over the 60 minute post drug period,
are significant in the 10 and 15 mg/70 kg groups (.01 > P > .001) and not quite
significant (.1 > P > .05) in the 20 mg/70 kg group, probably because of the
small size of the last named. In the 5 mg/70 kg group, there is a slight
and non-significant mean increase (P > .5). One subject only in this last~
named group showed a significant depression in respiratory rate. In another,
there was a significant increase and in the remainder, the changes were not
significant. A majority of subjects who were given 10, 15 or 20 mg/70 kg
experienced a significant decline in respiratory frequency. Only 2 subjects
in the 10 mg/70 kg group and 1 each in the 15 and 20 mg/70 kg groups failed















Respiratory Rote before and after 5.10. 15 and 20mg/70 kg Morphine
• Mean Values iSE.
Control : Mean Values Ajring 3 Successive 4 minute
periods immediately prior to Injection
Post Drug • Mean Values during 12 Successive 4 minute
periods following Injection
Changes in respiratory frequency (pooled observations) in relation
to time after 6, 10, 15 and 20 mg/70 Kg. morphine. Explanations *
as for Figure 2.
Analysis of variance confirms the existence of a dose effect
(.01 > P > .001). However, this dose effect disappears when the 5 mg
group is eliminated (P > . 2). The apparently greater effect of 15 mg
as compared with 10 mg/70 kg is not significant (. Z > P > .1). The
effect of 20 mg/70 kg upon the respiratory frequency is apparently less
than that of 15 mg although this difference is not significant (P > .4).
If the changes caused by 10, 15 and 20 mg/70 kg are pooled, the mean
depression is significant (P < .001).
Thus, doses of morphine in excess of 5 mg/70 kg significantly
depress respiratory frequency, but, this effects is not related significantly
to the size of dose. By contrast, a dose of 5 mg/70 kg has no significant
effect upon respiratory frequency even though it causes significant depression
of ventilation.
Changes in Tidal Volume
The changes in tidal volume in relation to time are shown in figure 11.
In the 5 mg/70 kg group, there is an initial, though non-significant (P > .3)
increase which lasts rather longer than the analogous increase in ventilation
and respiratory frequency. In the other treatment groups, tidal volume
falls immediately after drug administration, appears to recover later in the
lo and 15 mg/70 kg groups, but remains depressed throughout the post drug
period in the 20 mg/70 kg group.
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Tidal Volume before and after 5,10,15,and 20mg/70kg Morphine
• Mean Values S.E. Control: Mean Values during 3 successive 4min. periods
immediately prior to injection.
Post Drug: Mean Values during 12 successive 4min. periods
following injection.
Figure 11
Changes in tidal volume (pooled observations) in relation to time
after 5, 10, 15 and 20 mg/70 Kg. (normal subjects). Explanation
as in Figure 2.
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Over the 60 minute period following drug injection, changes in
tidal volume are most clear cut in the 5 and 20 mg/70 kg treatment groups
(Tables, 7, 10 and 11).
All four subjects in the 20 mg/70 kg treatment group experienced
a significant fall in tidal volume. Of the subjects in the 5 mg/70 kg group,
tidal volume rose significantly in 1 and fell in the remaining 5. Among
these latter, the depression was significant in 2, just short of significance at .05
level in 1 and non-significant in 1.
The mean fractional depression in the 20 mg/70 kg group was
.0667 and, even in so small a group was highly significant (.01 > P > .001).
The mean fractional depression of .0595 in the 5 mg/70 kg group was
not significant (P = .1). This is clearly to be attributed to an increase
in the mean tidal volume which occurred in the first 9 minutes following
injection. When this initial period is excluded from consideration the mean
fall in tidal volume in this group is significant (.05 > P > .02).
In the 10 and 15 mg/70 kg groups the changes were more variable.
In each group the net effect, over the 60 minute post drug period, was a
slight mean depression in tidal volume which was* in neither case,
significant (P > . 3 and > .4). A significant fall occurred in 2 of 9 subjects
in the 10 mg/70 kg group, and in 3 of 9 subjects in the 15 mg/70kg group
(Tables 8, 9 and 11). It will be observed that the tidal volume fell in
approximately one half of the subjects in these two groups.
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The variability of the response in the four treatment groups
is considerable* the standard deviation in each group being appreciably
larger than the mean value. The effects of 5 and 20 mg/70 kg
in depressing tidal volume are nearly equal and considerably greater
than the small mean fractional depression of under 2% attributable to the
10 and 15 mg/70 kg doses.
These results would appear to indicate that doses of 5 and
20 mg/70 kg have a very significant tendency to depress the breath volume
while this is hardly affected by the intermediate doses* However* analysis
of variance and tests between the individual treatment groups show that these
apparently differences are not statistically significant (Table 11). This is
clearly attributable to the rather large variances. Inspection of the data diows
that larger treatment groups would not materially improve the chances of
demonstrating statistically Significant differences among the treatment
groups. Thus, the smallest group numerically, 20 mg/70 kg, exhibits
the least variability and the mean depression attains a comfortable level
of significance. Further* doses of 10 and 15 mg/70 kg cause* in some
subjects, a net increase in tidal volume* thus obscuring* in the pooled
calculations* the fall which occurred in other subjects. This source of
variability would, presumably* not be removed by any practicable increase
in the size of the treatment groups.
If the data in the 4 treatment groups are pooled (Table 11) - a
procedure justified by the absence of significant differences - the resulting
mean depression in tidal volume of approximately 3% is highly significant
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(.01 > P > .001). This indicates that* despite the aforementioned
differences* the predominant effect of morphine in all doses used was to
depress the volume per breath.
Nevertheless* it seems definite that* in addition to the clearly
demonstrable depressant effects* there is a fairly marked tendency for
tidal volume to increase after morphine - an effect which is related in a
rather complex manner* to the size of the dose. This tendency is apparent
after 5 mg/70 kg, only during the initial 9 minutes of the post drug period;
is very marked throughout the greater part of the 10 and 15 mg/70 kg groups;
and is at no time apparent in the 20 mg/70 kg group. This mingling of effects
could be responsible for the large variances, and, for the failure to
demonstrate statistically significant differences among the four treatment
groups, despite the apparent existence of such differences. These dose
differences appear to be real, even though there is no simple way, such as
the use of larger groups* of demonstrating statistically significant differences.
However, more detailed dissection of the present data* has, in some measure,
surmounted these difficulties.
Inspection of the plotted changes in tidal volume (Figure 11) shows
that, immediately after drug administration, the mean tidal volume rises
in the 5 mg/70 kg group and falls in the other groups. In the 10 and 15 mg/70 kg
treatment groups, this depression in tidal volume lasts for some 19 minutes
following which a gradual recovery supervenes. In the 20 mg/70 kg group,
the tidal volume, though showing some tendency to fluctuate, remains
depressed throughout the post drug period. It therefore appears that the
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initial effect of doses larger than 5 mg/70 kg is to depress the tidal volume*
at any rate for some 19 minutes following drug administration. Consequently,
the changes in each treatment group occurring during the first 4, 9» 14
and 19 minutes after drug administration have been separately analysed,
in the usual manner, by treating the individual differences as normally
distributed variables, with the following results (Table 14).
The depression in tidal volume occurring during the initial 4 minute
period is significant in the 20 mg/70 kg group (.05 > P > .02), is short of
the .05 level of significance in the 15 mg/70 kg group (.1 > P > ,05) and not
significant in the 10 mg/70 kg group (p > . 2). The increase noted, at the same
time, in the 5 mg/70 kg group is not significant (P > .3). Analysis of
variance shows a just significant dose effect (P = .05) which disappears after
removal of the 5 mg/70 kg group (. 2 > P > .1), although the result suggests
that a rather weak dose effect might be present.
Further analysis of the changes at 9> 14 and 19 minutes post drug
yields very similar results. The depression in tidal volume at these times,
in the 15 and 20 mg/70 kg groups is significant, while the changes in the 5 and
10 mg/70 kg groups are not. Again, the depression in tidal volume appears
with the dose administered, but, this apparent dose effect is not significant
(. 2 > P > .1). The variability in the 5 and 10 mg/70 kg groups particularly
is considerable, mainly, because of the increase in tidal volume which occurs
in some subjects.
These results may, therefore, be interpreted as follows. The
predominant effect of the drug on tidal volume, in the doses administered,
is depressant, and, this effect increases with the size of the dose. In
addition, the opposite effect, that is, a tendency to increase the breath
volume, is also present. Both effects occur in each of the treatment
groups. In the 5 mg/70 kg group the stimulatory effects are most prominent
during the initial 9 minutes of the post drug period. In the remaining groups,
the depressant effects can be shown to be predominant during the initial 19
minutes of the post drug period. Presumably, both effects are present
in all the treatment groups throughout the post drug period. Although this
could not be rigorously demonstrated, both effects are almost certainly
related to dose. Thus may be explained the paradox that 5 and 20 mg/70 kg
are equally effective in depressing the volume per breath.
.Later, it will be shown that the effects of the drug in oxygen consumption
are rather similar to those on tidal volume, encompassing a mixture of
depressant and stimulatory effects. It is very probable that changes in
tidal volume and changes in oxygen consumption are indeed linked.
Effect on Oxygen Consumption
The movements of oxygen consumption in relation to time are shown
in figure 12. An immediate increase in oxygen consumption followed by a
fall to values somewhat below control levels, occurs in the 5 and 10 mg/70 kg
groups. To a considerable extent, the changes in these two groups mirror
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Changes in O uptake (pooled observations) in relation to time
after 5, 10* 15 and 20 mg/70 Kg. (Normal subjects). Explanation
as in Figure 2.
15 and 20 mg/70 kg groups is a sharp fall in the mean value for oxygen
uptake followed by a rather rapid recovery to values rtiich are somewhat
below the control levels.
A significant depression in oxygen uptake* in individual subjects*
was rather uncommon. No individual in the 20 mg/70 kg group experienced
such a fell; two subjects in each of the remaining groups did so. A significant
increase in oxygen uptake occurred in one subject in the 10 mg/70 kg group*
and non-significant increases occurred in 2 and 4 subjects in the 10 and 15
mg/70 kg groups respectively* and in 2 subjects in the 20 mg/70 kg group
(Tables 7 — 10* figure 13).
In each treatment group there was a very modest mean decl ine in
oxygen uptake varying from less than 1% in the 20 mg/70 kg group to 2.5%
in the 5 mg/70 kg group (Table 11). This change is significant only in the
5 mg/70 kg group (.05 > P > .02). Among 21 subjects in the 10* 15 and 20 mg/
70 kg groups, 9 experienced a net increase in oxygen consumption over the 60
minute post drug period * a feature which contributes to the very marked
variability of response such that the standard deviations are appreciably
larger than the means.
Analysis of variance on these data shows no evidence of a dose effect*
the mean square within being greater than the mean Square between the
treatment groups though not significantly so (.1 > P > .05). This finding
would appear to point to the existence of some important influence operating
within the treatment groups. These observations do not, of course, prove
that the size of dose is unrelated to the effect of the drug on oxygen consumption
Dose of Morphine
mg /70 kg
5 10 15 20






Fractional Changes in 0* Uptake and CO* Excretion • Individual Changes at Doses Specified
in Normal Subjects measured over 60 minutes following [
6 Mean Changes - SE.
5, 10, 15 and 20mg/70Kg Morphine I.V. I
Figure 13
Fractional changes in uptake and CO2 output after 5, 10, 15 and
20 mg/70 Kg (normal subjects), measured over the 60 minute post-
drug period. Individual values and mean values + S.E. for each
group are shown.
but rather suggest that there are factors operating within the treatment groups
to submerge any such dose effect which may exist.
If the data relating to the four treatment groups are pooled - a valid
procedure since the differences are not significant - the resuitingsmall mean
depression of approximately 2% is significant (.02 > P > .01) (Table 11).
This shows that the predominant effect of the drug upon oxygen uptake is
depressant at any level of dose used in the present study.
A linear relationship exists between oxygen consumption and minute
ventilation both during the control period and that following drigadministration
(figures HA 14). Rather surprisingly, however, changes in oxygen uptake
do not correlate significantly with changes in ventilation (r = . 224, n = 26,
figure 15). The common regression line derived by covariance analysis
has a non-significant slope, (.1 > P > .05), the equation being :
The standard deviation around the regression line is .0382.
While it is likely that a larger number of observations would have
yielded a significant slope, the results do suggest that the drug may have
caused changes in oxygen uptake entirely independent of its effects on
ventilation.
Since oxygen uptake and ventilation are linked, the changes in the
former have been further studied by comparing the control and post drug
regression lines relating these two variables. Mean values for oxygen
uptake and ventilation during the control period have been plotted for 31




.0133 + (. 2898 _+ .1619) X Fractional changes
in ventilation
r- 0 621 p<-OOI
Y- *0557 * (-0170 4-0040) X
MINUTE VENTILATION I /min B.T.PS./sq.m.
0, Uptoke related to Minute Ventilation during Control Period (31 Normal Subjects)
Figure 14a
Fitted regression line - uptake related to ventilation (mean
control values in 31 normal subjects).
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30 3-5 4 0 4-5 5-0
MINUTE VENTILATION L./sq.m. BTPS.
Fitted Regression Line - Mean value for 0, uptake and minute ventilation during
60 minute period following 5,10,15, 4 20m^/70Kg
morphine I.V. (26 subjects)
(Control regression line drawn in for comparison)
5-5
Post Drug Regression Line:—
Y—0-0541 +(0-0193 ± 0-0038)X
Control Regression Line
Y=0 0557+(0 0170 ±00040)X
• 5mg./70Kg.
O l0mg./70Kg.
A 15mg./ 70 Kg.
X 20mg. / 70 Kg.
Figure 14
Fitted regression line - uptake related to ventilation (mean values
over 60 minute period following 5, 10* 15 and 20 mg/70 Kg. morphine
in 26 normal subjects).
•
Vq2 = .0541 + (.0193 + .0038) V,£







































Fractional Changes in 0» Uptake related to Changes in Ventilation after 5.10,15 and 20mg./70kg. Morphine I.V.
(26 Normal Subjects)
Figure IS
Fitted rtgmiiiw Um • (total regression). Fractional changes in
Oj uptake related to changes in ventilation*
Fractional changes
• s
VQ * . 005b + (.US3 * .2025) x fractional change in2
The regression derived by covariance analysis (see text) is probably
a better estimate than the above and somewhat closer to significance*
normal subjects. These include the subjects in the four groups treated
with morphine, 4 subjects in the phenobarbitone group and one subject in
whom the study was abandoned after the control data had been collected.
The mean paired values for oxygen uptake and ventilation over the entire
post drug period have been similarly plotted for the 26 subjects given ,,
morphine (figures 14A.14). Both slopes are positive and significant (P < .001).
They are not.significantly different from one another* It is to be noted,
however, (figure 14) that the regression line fitted to the post drug obser vations
lies above the control line. Formal testing of the difference between the
'■-'6 • •' . »'»i . <• ' < .« ' ... s' "k " • , f • - »
adjusted means (.0086 +. .0035) confirms that the elevation of the post drug
regression line is significantly greater than that of the control line (.05 > P >
.02). Thus, after administration of morphine, a given level of ventilation is
apparently associated with a larger oxygen uptake than during the control period.
■ .; >';' ' •1 . ' ■' ■
These observations mean, that* independent of its depressant effects upon
■ • •
.... ■ ■
ventilation, the drug simultaneously increases oxygen uptake. . The difference
■ 1
between the adjust/means suggests that this effect upon metabolism is an
k IV'-i- ' ■■■■
appreciable one.
*(1) The estimates of correlation co-efficient (r = .364) and slope derived
by this method are rather closer to significance than the statistics used
in figure 15.
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Y a + (b + S.E.) X
Control .621 29 .0128 .1358 .0556 + (.0170
+ .0040)
4.723
Post drug .721 24 .0105 .1347 .0541 + (.0193
+.0038)
4.184
The relationship between the dose of morphine and the apparent
increase in oxygen uptake which the drug causes will now be considered, and,
for this purpose also, the methods of regression analysis are very suitable.
The above mentioned regression lines are not, however, efficient instruments
for this purpose. Consequently, the following method has been used* In
each treatment group# common regression lines have been derived by co-
variance analysis in respect to the control and post drug pei ods separately.
This technique makes it possible to consider, in each group separately, any
differences which arise between the control and post drug regression lines
relating oxygen consumption and ventilation and thus to separate the presumed
effects of each dose of morphine upon oxygen uptake from those upon ventilation.
For the derivation of the common control regression the 5 paired
observations of oxygen uptake and minute ventilation for each subject have
been used. In estimating the common post drug regression the initial 3 paired
observations have been excluded from the calculations because of the marked
instability in ventilation and oxygen uptake which is, at that time, present in
many subjects. The removal of these initial observations has been found
by trial and error, to lead to more satisfactory treatment of the data
because of the disappearance, after such removal, of much of the
variability between individual subjects. This procedure, however,
involves the disadvantage that the conclusion of this analysis are applicable
only to the latter 45 minutes of the post drug period - a limitation found
in practice not to be significant.
The results of this analysis will now be considered in detail (Table 12,
figures 16 - 19). In respect to the control regressions, there are evidences
of significant slope differences between subjects, only in the 15 mg/70 kg
group (.025 > P > .01). There is no satisfactory method of removing this
heterogeneity and, in consequence, the derived common estimate of slope
has been accepted as the best available and as suitable for present
purposes. The treatment groups show significant differences in slope
among themselves (.025 > P > .01) - a finding which emphasises the
importance of estimating a separate control slope for each treatment group.
As a matter of interest and as an illustration of the linear relationship
which exists between oxygen uptake and ventilation under the very stable
conditions of the control period, the common regression derived by
pooling all treatment groups is given (Table 15).
The post drug regressions show no evidence of significant slope
differences between subjects in any of the four treatment groups.




40 4 5 50 55
MINUTE VENTILATION (l/sqm B.TPS)
O2 uptake related to Minute Ventilation before
and alter 5mg/70 Kq. Morphine IV (5 subjects)
(Initial 3 Post Drug observations omitted)
Fitted Common Regression Lines
I Control
II Post Drug
Y- 00998 + (0 0088 ±00030)X
Y= 00868 + (00109 ±0002I)X
Figure 16
Fitted regression lines (common lines derived by covariance analysis) -
uptake related to ventilation before and after 5 mg/70 Kg. morphine
(initial three post-drug observations excluded from computations) -
normal subjects.
• #
I Control V0 = .0998 + (.0088 + .0030) V£















3 5 4 0 4-5 50 5-5
MINUTE VENTILATION (1/sg.m BTPS.)
60
O2 uptake related to Minute Ventilation before
and after IOmg./70Kg. Morphine IV (8 subjects)
(Initial 3 post drug observations omitted)
Fitted Common Regression Lines —
I Control Y± 0 0566 + (00175 ± 0 0030)X
H Post Drug Y=D0729 + (00151 ±00030 )X
Figure 17
Fitted regression lines (common lines derived by covariance analysis)
- O2 uptake related to ventilation before and after 10 mg/70 Kg. morphine
(initial three post*drug observations excluded from computation) * normal
subjects.
• •
I Control Vq2 = .0566 + (.0175 + .0030) VE




o2 uptake related to Minute Ventilation before
and after l5mp./70Kp. Morphine I.v. (9 subjects)
(Initial 3 post drup observations omitted)
35 +0 45 50 55
MINUTE VENTILATION (t/spm BTPS)
Fitted Common Repression Lines
I Control Y = 0 0073 + (00264 i 00044)X
n Post Drup Y — 00500 + (00196 * 00023)X
Figure 18
Fitted regression lines (common lines derived by covariance analysis)
• O2 uptake related to ventilation before and after 15 mg/70 Kg.
morphine (initial three post-drug observations excluded from
computation) - normal subjects.
I Control VQ = .0073 + (.0264 + .0044) V£
2 .
















604 0 4 5 5 0 5-5
MINUTE VENTILATION (l./sq.m B.T.P.S.)
O2 uptake related to Minute Ventilation belore and Fitted Common Regression Lines -
after 20mq /70Kq Morphine IV (4 subjects) I Control Y - 00539 +(00178 t 00050)X
(Initial 3 Post Drug periods omitted) II Post Drug Y =01176 + (00063±0 0052)X
Figure J?
Fitted regression lines (common lines derived by covariance analysis)
- C>2 uptake related to ventilation before and after 20 mg/70 Kg.
morphine (initial three post-drug observations excluded from
computation) - normal subjects.
• •
I Control VQ = . 0539 +(. 0178 + .0050) V£
2 •
II Post-drug VQ = .1176 + (.0063 + .0052) V£2
The four control slopes and the post drug slopes with the exception
of that of the 20 mg/70 kg group (. 3 > P > ; 2), are significant.
When each post drug regression line is compared with its control
■Hf'
the findings are as follows (Table 15, figures 16 - 19). There is no
significant slope difference between the control and post drug regressions
in any of the four treatment groups. The post drug slope of the 20 mg/
70 kg group is, however, not significant. In the 5, 10 and 15 mg/70. kg
groups, the elevations of the two regression lines are significantly
different. The 5 mg/70 kg post drug line is significantly depressed,
the 10 and 15 mg/70,kg post drug lines are significantly elevated, as shown
by the significant differences between the adyusted means. Because of
the non-significant slope of the 20 mg/70 kg regression, it is doubtful
whether it is justifiable to test for a significant difference between the
a trusted means. Nevertheless, inspection of the curves shows that, not
only is this slope flattened, but the line itself is displaced upwards, so
ionally
that the effect of this dose is direct^ / similar to that of 10 and 15 mg/70 kg
and perhaps more marked. The difference between the adjusted means,
however, is not significant (P > .5).
The results of this andysis show conclusively that, independent of any
effect on ventilation, a dose of 5 mg/70 kg depresses^ and doses of 10, 15
and 20 mg/70 kg increase oxygen uptake. Thus morphine is clearly shown
to be a metabolic stimulant in man when administered in doses within the
ordinary therapeutic range: that this effect increases vith increasing dose:
that it is quite marked and lasts throughout the post drug period of
observation in the 10» 15 and 20 mg/70 kg groups. After a dose of
5 mg/70 kg, the stimulant effects upon oxygen uptake are apparently
restricted to the early post drug period.
This stimulant effect upon oxygen uptake must therefore be regarded
as an independent effect occurring pari passu with the depressant effect
which, the regression relationship indicates, must necessarily accompany
the decline in minute ventilation recorded in all treatment groups. It is,
further, interesting that an independent depressant effect upon oxygen
consumption can be shown to have occurred during the later post drug
period in the 5 mg/70 kg group. In this last named group, the stimulant
effect upon oxygen uptake is restricted to the early post drug period, when
it is associated, even though for a very brief period, vd th a fairly marked
increase in ventilation. Presumably these independent depressant effects
are due to "sedative" or other central depressant action of the drug and
may well exist also in other treatment groups. Unfortunately, there is
no available method of analysis which will uncover this effect. However,
it is rather attractive to speculate that the sharp initial decline in oxygen
uptake which regularly occurs after doses of 15 and 20 mg/70 kg (figure 12)
at a time when ventilation is changing less dramatically, represents a
central depressant effect upon metabolism which is later obscured by the
more potent stimulant effects.
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The effects of morphine* as administered in the present study,
upon oxygen uptake* may be summarised as follows. Over the 60 minute
period following intravenoua administration, the net effect of the drug* in
the series considered as a whole is to cause a small but significant
fall in oxygen uptake. There are no significant differences between the
four treatment groups in respect to this depression in oxygen uptake,
although paradoxically the fall is significant only in the group treated with
5 mg/70 kg. More detailed analysis shows that morphine affects oxygen uptake
in three ways.
First, the drug causes a fairly marked increase in oxygen uptake,
independent of any effects on ventilation, in the 10, 15 and 20 mg/70 kg
groups. In the 5 mg/70 kg group, this effect is limited to the early post
drug period, when for a very brief part of this period,there is an associated
marked increase in ventilation. The stimulant effect upon metabolism is
appreciable and has been shown to be directly related to the dose
administered.
Secondly, the drug depresses oxygen uptake because of its depressant
effects upon ventilation. The present study has demonstrated conclusively
that, within the range of ventilation studied, both during control and post
drug periods, a linear relationship exists between oxygen uptake and ventilation.
Consequently, changes in the one,will of necessity, produce changes in the other.
Thirdly, the drug depresses oxygen uptake, independently of its
depressant effects upon ventilation and this is, presumably, related to
its sedative and other central effects. Such a depression can be shown
by direct analysis of the date to have occurred only in the group which
received 5 mg/70 kg after the initial period of metabolic stimulation
had ended. In this group, as judged by the depression of the post drug
regression line, this depressant effect upon oxygen uptake appears to
be fairly marked. Presumably, this effect occurred also in the treatment
groups which received larger doses, although this could not be shown
directly to have occurred, on the available data. It is possible that
the initial sharp and very transient fall in oxygen uptake which regularly
occurs in the 15 and 20 mg/70 kg groups may represent an independent
metabolic depressant effect.
This mingling of effects, each with its own relationship to the size
of dose, no doubt explains why direct comparisons of changes in oxygen
uptake do not show significant dose effects, and, also, the paradox that
a dose of 5 mg/70 kg is more regularly effective in depressing oxygen
uptake that larger doses.
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Changes in Carbon Dioxide Excretion
The effects of morphine on carbon dioxide excretion will be presented
and analysed in a manner similar to that used in the preceding section.
The charts (figure 20) indicate that in the 5 and 10 mg/70 kg groups
the mean carbon dioxide output rose shaply immediately following drug
administration before a sustained fall to values well below control levels
occurs. This initial increase was slightly more marked in the 5 mg/70 kg
group. In the 15 and 20 mg/70 kg groups, the carbon dioxide output fell
sharply immediately after injection and though recovering slightly, remained
depressed below control values for the remainder of the experiment.
Individual subjects nearly always experienced a fall in carbon
dioxide output after morphine. One subject each in the 5 and 10 mg/70 kg
groups showed a small, non-significant increase in carbon dioxide output.
Of the remaining sutgects. 13 showed a significant and 11 a non-signficant
decline in carbon dioxide output (Tables 7 - 10). The highest proportion of
subjects showing a significant fall occurred in the 15 mg/70 kg group - 6 of
9 subjects in this treatment group experienced such a fall. In the remaining
groups, there was a significant decline in carbon dioxide output in approximately
50% of subjects.
The mean fall in carbon dioxide output was, in each treatment group,
statistically significant (Table 11). The decline in carbon dioxide output
shows an apparent slight relationship to the dose administered. However,
analysis of variance fails to demonstrate any significant differences among
the treatment groups, and the slope of the regression line relating changes


























CO, Excretion before and after 5,10,15 and 20mg /70kg Morphine
• Mean Values ±S.E. Control: Mean Values during 3 successive 4min periods immediately prior
to injection.
Post Drug: Mean Values during I2successive 4min periods following injection.
fligwrtiSfl'.
Changes in C02 output (pooled observations) in relation to time after
5, 10. 15 and 20 mg/70 Kg. morphine - normal subjects. Explanations
as in Figure 2.
in carbon dioxide output to dose of drug is not significant (-.0023 + .0019
n = 26, P > .2). It is -tobe noted that variation within the treatment groups
is rather marked, the standard deviation being approximately equal to the
mean in the 5 and 10 mg/70 kg groups and over 50% of the mean in the 15 and
20 mg/70 kg groups.
The causes of these changes in carbon dioxide output will now be
considered*
The fractional changes in carbon dioxide output have been considered,
by the use of regression analysis* in relation to changes in ventilation and
oxygen uptake. Fractional changes in carbon dioxide output are linearly
related to charges in ventilation, and, also, to changes in oxygen uptake.
Common slopes derived, in the usual way by covariance analysis, are
significant (P< >001 for both slopes) and the tests show that there are no
significant slope differences among the four treatment groups. Thus, the
relationship between changes in carbon dioxide output and changes in
ventilation and oxygen uptake is not affected by the dose administered. The
regression equations derived in this manner are as follows:
Fractional changes in output - .0037 + (.6323 + .1609) x change in
ventilation
" " " " " 0500 + (.9412 ± .1640) x change in
oxygen
uptake
The standard deviation about the regression lines are .0380 and .0308
respectively.
It seemed desirable to calculate partial regression constants for
linking these threevariables in one equation. The partial regression
constants so calculated (using the pooled sums of squares) are, in each
case, highly significant (P < *01 and < .001 respectively). The fitted
regression line has the equation :
Change in CO^ output =-.0063 r (.4143 j; .1188) x change in ventilation
+ (.7519 +, .1491) x change in O uptake
M
The standard deviation about the regression line is . o26l.
Thus, following administration of morphine, changes in carbon
dioxide output are related to changes in ventilation and, independently, to
changes in oxygen uptake. It will be apparent from the above regression
constants that the dependence upon changes in oxygen uptake is considerably
the more marked. Since, as demonstrated in the previous section, changes
in oxygen uptake are only slightly and, non-sigiificantly in the statistical sense
related to changes in ventilation, it is not surprising that the changes in carbon
dioxide output following drug administration are not significantly related to
the size of dose. It seems reasonable to presume that the relationship to the
size of dose has been attenuated by the above multilateral relationships.
Carbon dioxide output and ventilation are linearly related (figure 21).
This relationship is rather closer than that vhich exists between oxygen
uptake and ventilation, so that about 70% of the variation in carbon dioxide
CONTROL REGRESSIONS
CO? OUTPUT RELATED TO MINUTE VENTILATION (NORMAL SUBJECTS)
• 5mg./70Kg. group
o IOmg/70Kg. group
x I5mg /70Kg. group
■ 20mg/70Kg group
Common Regress km Linos
I 5mg /70Kg. group Y=00l46 + (00?35 tO<X)l8)x
H lOmg./TOKg group Y=00I68+(008II iOOO») X
IHI5mg/70Kg group Yr- 0088+{0(»5J±000?6)X
nz: ?0mg/70Kg.group Y; 0008l+(00?IB±0005l)x
Fitted regression lines (common lines derived by covariance analysis)
• CO, output related to ventilation during control period - all normal
morphine treatment groups*
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output during the control peri od is to be attributed to variation in ventilation.
The changes in carbon dioxide will be further considered, as were changes
in oxygen uptake, by regression analysis, The regression considered will
be that of carbon dioxide output on ventilation, mainly because the movement
of oxygen consumption has also been considered previously in relation to
ventilation. No doubt CO output /O uptake regression would be equally
4is C*
efficient and, probably would lead to the same conclusions.
In each treatment group, CO output/ventilation regressions have been
£*
derived separately for control and post drug periods by covariance analysis
in the usual way. The changes in regression, if any, caused by each dose
used and, thus, any effects upon carbon dioxide independent of effects on
ventilation, could then be considered.
The control slopes derived in this way have usually shown significant
slope differences among the individual subjects (Table 16). Only the
15 mg/70 kg treatment group is homogenous in this respect. No acceptable
method of removing this heterogeneity of slope could be found and the
derived common slopes have been accepted as the best estimate available.
The treatment groups show no evidence of significant differences among them¬
selves in the slopes so derived. These slopes, are numerically very close to
each other, ana are believed to be satisfactory estimates of slope for the
purposes of this analysis.
The post drug regressions, similarly derived, and omitting the
initial 3 paired observations, for reasons previously given, also usually show
significant slope differences among the individual subjects. Only the
5 mg/70 kg group is homogenous in this respect. There are no significant
differences among the treatment groups in respect to the slopes so derived.
These slopes also are considered satisfactory for the purposes of the present
study. It will be noted that the pooled estimate of post drug slope is
numerically very close to that of the control slope.
All slopes* control and post drug, are significant.
In each treatment group, the control and post drug slopes are not
significantly different and, except in the 20 mg/70 kg group, numerically
are very close. However, in each treatment group, the test of adjusted
means show/that the control and post drug elevations differ significantly.
These changes are directionally identical with those previously noted when
oxygen consumption was similarly studied. Thus, the 5 mg/70 kg post
drug regression line is significantly depressed and the 10, 15 and 20 mg/
70 kg regression lines are significantly elevated, as compared with the
control line (Table 16, figdres 22 - 25).
These results would appear to indicate quite conclusively that
morphine affects carbon dioxide output, as it does oxygen consumption,
independent of ventilation. Thus, 5 mg/70 kg depresses, and the other
doses increase carbon dioxide output independent of any changes in
ventilation during the latter43minutes of the post drug period of observation.
Consequently, morphine depending on the dose used, is both a depressor
and a stimulant to endogenous carbon dioxide formation. The stimulant















CO2 output and ventilation before and after
5mg/70Kg. Morphine IV (5 subjects)
(Initial 3 post drug observations excluded)
_l_ _l_
35 40 45 50
MINUTE VENTILATION (l/sgm. B.T.PS.)
Fitted Common Regression Lines
derived by Covariance Analysis -
I Control Regression
II Post Drug Regression
55
Y~ 00146+ (0 0235 ±O OOI8)X
Y=0 0175+ (00223 ±0 0018) X
Figure IZ
Fitted regression lines (common lines derived by covariance analysis)
« CO- output related to ventilation before and after 5 mg/70 Kg.
morphine (initial three post-drug periods excluded from computations)
• s
I Control Vco =. 0146 +(. 0235 + .0018) V£2»
e




CO2 Output and Ventilation before and
after IOmq./70Kq. Morphine IV (8 subjects)
(Initial 3 post druq observations excluded)
40 45 SO
MWUTE VENTLATION (l./sqm B.T.PS.)
Fitted Common Reqrcssion Lines
Derived by Co-variance Analysis:-
I Control Regression Y= 0 0168 ■♦■(002111 OOQ26)X
D Post DruqReyessbnY=00309H>OW ±0*0024) X
Figure 23
Fitted regression lines (common lines derived by covariance analysis)
• CC>2 output related to ventilation before and after 10 mg/70 Kg.
morphine (initial three post-drug periods excluded from computations)
• s
I Control Vco = . 0168 +(. 0211 + .0026) V£2
• •




COa Output and Ventilation before and
alter l5mq /70Kq- Morphine I.V. (9subjecls)
(Initial 3 post drug observations excluded)
3-5 4 0 4 5
MINUTE VENTILATION (l./sqm BT.PS)
Fitted Common Regression Lines
Derived by Co-variance Analysis
I Control Regression Yr-0 0088+(00235 + 0 0026) X
n Post Drug Regression Y- 0007 + (0 0232 ± 0 0017) X
■ftflarf. *4
fitted regre»»ion line* (common line* derived by covarlance analysis)
• CO. output related to ventilation before end after 15 mg/70 Kg.
morphine (initial three poet-drug period* excluded from computation*)
• •
I Control Vco • .0058 +(.0235 + .0026)




4 0 4 5 5-0
MINUTE VENTILATION l./sq.m. B.T.PS.
COa Output and Ventilation before and
after 20mq./70Kq Morphine IV. (4 subjects)
(initial 3 post druq observations excluded)
Fitted Common Reqression Lines
Derived by Co-variance Analysis -
I Control Reqression
Y=0008I«<X)2I8±0005I)X
H Post Druq Reqression
Y=0 0435+(0 0(5610 0029)x
Figure 25
Fitted regres|ion lines (common lines derived by covariance analysis)
- CO2 output delated to ventilation before and after 20 mg/70 Kg.
morphine (initial three post-drug periods excluded from computations)
e •
I Control VCQ = .0081 + (.0218 + .0051) V£
• 2
II Post-drug VC02 = .0435 + (.0156 + .0029) V£
The elevation of the 20 mg/70 kg regression line above its own
control line is less than the similar elevation of the 15 mg/70 kg post
drug line, and only very slightly greater than that relating to the 10 mg/
70 kg regression. Hov/ever, the slope of the post drug line in the 20 mg/
70 kg group is appreciably less than that of its control, though not
significantly so in the statistical sense. It is likely, therefore, that the
20 mg/70 kg dose has both flattened the curve and displaced it upwards -
that is, that its effect in increasing carbon dioxide formation was more
marked than that of any of the lesser doses. It will be recalled that a
similar effect upon oxygen uptake was suggested.
The effect of morphine upon carbon dioxide output may be summarised
as follows. In each treatment group, a significant depression in carbon
dioxide output occurred. This change is significantly related to changes
in ventilation and, independently to a greater extent numerically, to cnanges
in oxygen uptake. The changes in carbon dioxide output are not significantly
related to the dose administered, no doubt, because of this closer dependence
upon the changes in measured oxygen uptake - these latter being not
significantly related either to the dose administered or to changes in
ventilation. Regression analysis shows, further, that the drug affects
carbon dioxide output independently of ventilation, presumably by altering
the amount of endogenous carbon dioxide formation - an effect which is
related to the size of dose administered. During the period covered by
these analyses, a dose of 5 mg/70 kg depresses carbon dioxide formation
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independent of ventilation and 10, 15 and 20 mg/70 kg, in that order, increase
the amount of endogenous carbon dioxide formation.
These effects are, in every respect, analogous with the previously
demonstrated effects upon oxygen uptake. They may, therefore, be
briefly outlined as follows:
1. A depressant effect upon carbon dioxide output due to a fall
in ventilation.
2. A depressant effect upon carbon dioxide output, independent
of the effect on ventilation, due to increased carbon dioxide formation,
demonstrable only in the 5 mg/70 kg group.
3. A stimulant effect upon carbon dioxide output, independent of
an effect on ventilation due to increased carbon dioxide formation, and
demonstrable after doses of 10, 15 and 20 mg/70 kg .
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Changes in Arterial Carbon Dioxide Tensions and pH after Morphine^
Arterial carbon dioxide tensions and pH were measured in 13
normal subjects only. Three control and, usually, 12 post drug samples
drawn at consecutive 5 minute intervals were examined. In 2 subjects
(G.F. and J.R. in the 10 and 20 mg/70 kg groups respectively) only 7 and
9 post drug samples were examined (Table 17, Figure 26).
Arterial blood samples were examined in 5 of the 6 subjects in
the 5 mg/70 kg treatment group, in all 4 subjects in the 20 mg/70 kg
group and in only 2 subjects in each of the groups receiving 10 and 15 mg/
70 kg morphine. Consequently, for ease of statistical treatment, the four
subjects in these two last-named groups have, for some purposes, been
considered together as one pooled 10 and 15 mg/7Gkg group.
An increase in arterial carbon dioxide tension during the post drug
period almost invariably occurred (Figure 26, Table 17). One subject
only in the 5 mg/70 kg group failed to show such an increase. This increase
in P CO ranged from less than 1 mm.Hg to 5. 3 mm.Hg. The mean
increase in all 13 subjects considered together was 2.76 .4866 with a
standard deviation of 1.755 and was highly significant (P < .001).
In the 5 mg/70 kg treatment group, 2 subjects showed a significant
increase in P CO , 2 a non-significant increase and, 1 a small non-
significant fall. In the remaining subjects the rise in arterial carbon
dioxide tension was significant, except for one subject (J.R.) in the
(l) Owing to laboratory mishap some control PQ^ samples were lost and consequently










Change in Pa CO, and pH after 5, 10, 15 and20mg/70kg Morphine I.V. (Normal Subjects)
Figure, 26
Changes in PaCO^ and arterial pH (13 normal subjects) after 5, 10,
15 and 20 mg/70 Kg. morphine (normal subjects).
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20 mg/70 kg group, in whom the increase in P CO was short of the .05
Ct
level of significance.
The mean increase in the 10 and 15 mg/.70 kg combined group and
in the 20 mg/70 kg group was, in each case, significant (.01 > P > .001 and
.05 > P > .02 respectively). The mean increase in P CO in the 5 rag/
d. m
70 kg group was not significant (. 2 > P > .1).
Analysis of variance shows that there is a significant dose effect
(.05 > P > .025). Detailed testing shows thattiisis due entirely to the
significantly smaller increase in P CO in the 5 mg/70 kg group. There
2L u
is no significant difference between the 10 and 15 mg/70 kg combined
gx>up and the 20 mg/70 kg group in regard to the post drug increase in
arterial carbon dioxide tension. The mean increase caused by the larger
dose is, in fact, slightly less.
The measured values of P CO., have been used to calculate
a 2
physiological dead space and alveolar ventilation (Table 18).
Arterial pH almost invariably fell during the post drug period,
particularly after the larger doses in excess of 5 mg/70 kg when a
significant degree of acidosis developed (Table 17, Fig. 26).
The reasons for the increase in arterial carbon dioxide tension
after administration of morphine will now be considered. Intuitively,
it might be thought that the depression in ventilation which was induced
by all doses used would explain this increase. However, the fractional
106
changes in P CO do not correlate significantly either with changes in
total ventilation (r = - .317, n = 13, P > .1 Figure 27) or, with changes
in alveolar ventilation (r = -.350 P > .1). The estimated slopes of the
fitted regression lines, while negative, are, neither significant (P > .2)
Fractional changes in P CO^ = .0451 - (.2073 _+ .1872) x change in
total ventilation
= .0457 - (.2203 _+ .1776) x change in
alveolar ventilation
The treatment group* do not show significant slope differences among
themselves and the common regression line derived by covariance
analysis also has a non-significant slope (P - .4)
Fractional change in = *0877 + (.1838 + .2070) x fractional
change in total ventilation
The standard deviation from regression is .0360
Although these statistics suggest that a larger number of observations
might have demonstrated a significant relationship, clearly, the fall in
ventilation cannot be the principal cause of the recorded increase in
arterial carbon dioxide tension.
By contrast, for all observations considered together, fractional
changes in P CO correlate significantly with fractional changes in oxygen
3l w
uptake (r = .596 .05 > P > .02). The fitted regression line (figure 28)
has the equation
Fractional change in P^CO^ = .0826 + (.9400 _+ .3820) x fractional
change in oxygen uptake
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Figure 27
Fitted regression line - Fractional changes in Pa related to
fractional changes in ventilation after morphine (normal subjects).
FRACTIONAL CHANGES
PaCOa
and Fractional Chanpes in Oa Uptake with Fitted Repression Lines - I Common (derived) Line Y= 00788+ (0 698910 523-4) X
II Repression Line calculated from raw data
Y=00626+ (09400103820) X
28
Fitted regression line - Fractional changes in PaCO^ related to
fractional changes in uptake after morphine (normal subjects).
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The common regression derived by covariance analysis probably yields
a more valid estimate of slope than the foregoing even though the loss of
2 degrees of freedom makes this not quite significant at .05 level
Fractional change in PaCO^ - .0718 + (.6989 + .3234) x fractional
changes in oxygen uptake
with a standard deviation from regression of .0305*
Presumably this estimate incorporates a negative effect attributable
to compensatory influences upon minute ventilation, produced by changes
in oxygen uptake. This latter effect would explain, in part, why changes
in ventilation do not correlate significantly with changes in P CO .
ct b
These results indicate that, after morphine, the rise in arterial
carbon dioxide tension is caused, not mainly by the fall in ventilation, but
to a greater extent, by the changes in oxygen uptake.
The changes in arterial carbon dioxide tension have been further
examined by the use of regression analysis, in a manner similar to that
used for oxygen uptake and carbon dioxide output. The regression
relationship chosen has been that of arterial P„ on alveolar ventilation.
Z
It is generally accepted that P CO is more closely related to alveolar than
ct ^
to total ventilation, and the observations in the present study confirm this.
The respective regressions derived by covariance analysis and relating to
the control period are as follows
PaCG^ = 48.656 - (1.485 + .809) VE (l)
PaCO = 47.89 - (1.938 + .719) V. (2)
& A
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with standard deviations from regression of .9913 and .8731 respectively
and 21 degrees of freedom. Three paired control observations from
each subject have been used for computing these statistics. Equation (l)
has a non-significant slope (.1 > P > .05) and has been derived from data
contributed by all four treatment groups. Equation (2) has a significant
slope (JjZ > P > .01) but, in computing the statistics the 2 subjects of the
10 mg/70 kg group have been excluded because of significant slope
differences from the rest of the population (.05 > P > .025). From the
statistics in Table 19, it is evident that only about 25% of variation in
PaCO is to be attributed to alveolar ventilation.
u
Control and post drug regressions have been compared, in the
usual way, for differences in slope and elevation. , Owing to the limited
number of observations it was not possible to make a useful estimate of
control slope for each treatment group separately. Consequently, the.
slope of equation (2) has been assumed for eachof the treatment groups
individually, except the 10 mg/70 kg group which, for the reason given
above, could not be incorporated in this estimate. For computing the
adjusted means, the actual observed mean in each treatment group has
been used. The actual computed control regression of the 10 mg/70 kg
has been used even though this is not a very satisfactory estimate and is
based on a very limited number of observations. In calculating the post
drug regressions, extreme values during the initial period of hyperpnoea
have, where present, been excluded because experience has shown that this
results in more satisfactory estimates.
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The results of these analyses are a* out in Table 19 and the fitted
regression lines in Fig. 29* The 5 mg/70 kg post drug elope is
significant (.01 > P > .001). The 10, 15 and 20 mg/70 kg post drug
slopes are not (P > .1, > .05 and > .1 respectively). Comparison of
these slopes by covariance analysis shows no evidence of significant
differences among them. The common post drug slope derived by pooling
the data from all treatment groups is highly significant (P < . 001). Thus,
it would appear that both before and after drug administration P^CO^ is
significantly related to alveolar ventilation. However, the non-significant
slopes in the 10, 15 and 20 mg/70 kg groups cannot be due to any limitation
in the available degrees of freedom and require explanation. The likely
explanation is that doses of morphine greater than 5 mg/70 kg have
affected ventilation and P CO , to some extent , independently even though2L Ca
the linear relationship between the two is readily apparent from the fitted
regression lines in Figure 29.
That this is the probable explanation is suggested by a consideration
of the differences in elevation of the control and post drug regression lines.
Although the post drug slopes are slightly larger than the common
control slope, these differences are not significant, and, in consequence,
the adjusted means may usefully be compared (Table 19). The 5, 15 and 20 mg/
70 kg adjusted means are significantly larger than the control: the a^jvded
mean of the 10 mg/70 kg post drug regression line is also larger than its
control, but not significantly so, probably because of the rather inadequate
estimate of control regression available. From Table 19, it would appear
ALVEOLAR VENTILATION l-Anin,/sq.m.
I CONTROL REGRESSION (IIsubjects) Y = 47809-(l 938 ±07I9)X E POST DRUG REGRESSION ISrrKj/70Kq.sub]ects)Y=5206l-(2958± 1599)X
H POST DRUG REGRESSION 5m)/70Ki) (5subjectt) Y-50044-C259+0739) X I POST DRUG REGRESSION 20mg./70KR.(4subj«ts) Y=K700-(J772± 1-852) X
IT POST DRUG REGRESSION IOm»/70Kq. (2 subjects) Y=50-433-(2-537± 1-685) X
Figure 2?
Fitted regression lines - PaCO^ related to alveolar ventilation (V^)
- Control and post-drug periods for normal subjects computed as
described in the text.
that the elevation of post drug regression is* to some extent* related to
dose* increasing from 5 to 15 mg/70 kg and* then* levelling off* The
elevation of the 5 mg/70 kg post drug regression line is quite small - a
little less than 1 mm.Hg - but is nevertheless very significant.
These findings indicate clearly that morphine prodices independent
effects also upon alveolar ventilation and arterial carbon dioxide tension*
and therefore* confirm that the increase in P CO cannot be due entirely
3. M
to the decline in alveolar ventilation. That this decline in ventilation plays
a significant role is suggested by intuition and indicated by the significant
slopes of the regression lines: that this decline is not the principal cause
of the increase in P^CO^ after administration of morphine* particularly
after doses in excess of 5 mg/70 kg* is shown by the non-significant slope
in these treatment groups post drug and the dose related inc rease in elevation
of the post drug regression line in all treatment groups. The demonstration
earlier that fractional changes in P CO are significantly correlated not
■~vv <t C*
with changes in ventilation but with changes in oxygen uptake: and that
morphine causes an increase in oxygen consumption and endogenous carbon
dioxide formation independent of its effect on ventilation: - these indicate
very strongly and almost conclusively that the increase in arterial carbon
dioxide tension is caused mainly by these stimulant effects of the drug
upon metabolism and the consequent increase in endogenous carbon dioxide
formation which this entails.
These regressions emphasise further what a relatively slight effect
upon metabolism is produced by a dose of 5 mg/70 kg.
It is to be noted that the drug apparently caused an increase in
slope which, although not statistically significant, might well represent
a real drug effect.
The effects of morphine on arterial carbon dioxide tension may,
therefore, be summarised as follows. Each dose administered caused
an increase in P CO which was non-significant in the 5 mg/70 kg group
a Cm
and significant in the other groups. By the rather more sensitive method
of regression analysis it was shown that even the very small increase in
the 5 mg/70 kg group was statistically significant. Although the decline
in alveolar ventilation does contribute to the increase in arterial carbon
dioxide tension, a more important cause of the latter is the stimulant




Effect of Morphine on the Sensitivity of the Respiratory Centre to Arterial
Levels of PCO^
The increase in arterial or alveolar carbon dioxide tension which
has long been known to occur after morphine in the presence of depression
of ventilation has been generally regarded as an indication that the
sensitivity of the respiratory centre is depressed by the drug. This is
no doubt correct in the above sense. However, sensitivity defined as the
variation in ventilation as a function of the variation in PaCO - AV/APaCO - |2
has never been shown to be affected by morphine.
The observation that carbon dioxide formation and ventilation are,
in significant degree, independently influenced by the drug, provides an
opportunity for studying V^/PaCO^ relationships over a range of values
never before studied. An attempt has, therefore, been made to find out
whether any evidence can be obtained from these relationships of any change
in sensitivity to carbon dbxide as above defined.
Alveolar ventilation/PaGO regressions were computed in the usual
u
way by covariance analysis for the control period. As in the previous section,
the slope contributed by the 2 subjects in the 10 mg/70 kg group is a serious
source of heterogeneity and has been excluded from the estimate of common
control slope. The derived common slope is significant (.02 > P > .01)
and negative:-
VA = 8.6807 - (.1325 + .0492) x PaCO?A ^
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The assumption is made that this reciprocal relationship between and
P CO incorporates a component, which cannot be measured directly,
2- dt
attributable to the sensitivity of the respiratory centre to changes in P CO .
cL u
Past drug regressions have been computed in the same way (Table 20)
The post drug slopes are, in each treatment group, flatter than the control
slope and all are, of course, negative. However, the difference from the
control slope is significant only in the case of the 20 mg/70 kg slope (.05 > P >
.02). The 5 and 15 mg/70 kg post drug slopes, although appreciably smaller
than the common control slope are neither significantly different in the
statistical sense from this. The 10 mg/70 kg post drug slope is, also,
significantly less than its own rather inadequate estimate of control slope
(.05 > P > .025). The tests of adjusted means shows that the elevations
of the 5 and 15 mg/70 kg regression lines are significantly depressed - this
merely confirms what is already known, namely, that after morphine larger
P^CO^, levels are found for a given level of ventilation than would be recorded
prior to administration of the drug. In that sense, the CO sensitivity has
been diminished.
The quotient AV /aP CO cannot be measured directly but certainA St u
assumptions are permissible. First, it is to be assumed that, under all
conditions, the respiratory centre is sensitive to changes in P CO_. Second,
a 2
it may validly be assumed thatthis sensitivity, as expressed by the quotient
AVA/APaC02 is incorporated in the above estimate of slope.
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It is apparent also that this negative slope, invariably present over the range
of values studied would become steeper as the dependence of P CO upon
st Ct
ventilation becomes more marked, for example, when ventilation is, for
any eason, varying over wide limits. In such a situation the V. /P CO„A a 4
regression is hardly if at all influenced by the sensitivity of the respiratory
centre to carbon dioxide. Under more stable conditions this reciprocal
relationship between ventilation and P CO as embodied in the negative
3.
regression slope still holds, but, it may be assumed that the ideal quotient
AV /aP CO then represents a significant part of the slope estimate and is
3. u
responsible for the tendency of the slope to flatten under resting quiet
conditions.
It follows, therefore, that if no factor other than the quotient AV, /AP CO_A a 2
had altered, then, an "increased CO sensitivity" should result in flattening
or reversal of slope while a "decreased CO^ sensitivity" should increase
the negative slope.
It will be observed from the statistics in Table 20 that all doses used
decreased the estimated slope of the V /P CO regression, that is, there
was an apparent increase in sensitivity to P CO ; or put in another form,
S> L*
morphine appears to improve efficiency of homeostasis at the selected
alteredrange of V and P CO . This is, however, probably not true.J\- 3, L.
It has been shown earlier that ventilation and carbon dioxide formation,
and consequently P CO? levels are independently influenced by morphine -
is
the former being depressed and the latter increased. This circumstance
would itself tend to flatten the slope of V^/P^CO^ regression. It seems
likely that this is the cause of the major part of the slope decrease which
occurred. This interpretation is entirely consistent with the finding that
the decrease in slope appears to some extent to be dose related.
These results do not therefore provide any support for the view
that morphine depresses respiration by depressing the sensitivity of the
respiratory centre to carbon dioxide. Can it be stated, however, tiat
carbon dioxide sensitivity is unaltered by morphine ? It is conceivable
that the metabolic effects are so marked that slope effects which might
otherwise have appeared have been submerged. This, however, seems
*
unlikely. If P CO increased because of increased CO formation and V
3. L» L»
fell because of respiratory depression (through whatever mechanism),
then, the negative slope ofV^/^ regression would clearly have become
steeper in the presence of coincidental depression of sensitivity.
It seems most likely, therefore, that sensitivity as defined by the
quotient AV^/aP^CO^ is neither depressed nor enhanced by the doses of
morphine administered. On the contrary, the regression statistics indicate
that normal homeostasis is achieved, in all treatment groups studied, in
relation to the selected new levelsof alveolar ventilation and arterial
CO tension.
Ct
These conclusions, while fully supported by the data presented, are
offered with certain reservations. It is manifestly desirable that an
acceptable control slope should be separately computed for each treatment
group before it can be accepted as proven that the changes in slope are
due to the drug* It seems likely from the estimates of statistical parameters
presented in Table 20 that the conclusions are not likely to be materially
challenged when such control slopes are available*
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EFFECTS OF MORPHINE IN PATIENTS SUFFERING FROM LEFT
VENTRICULAR FAILURE
Six patients suffering from left ventricular failure were studied by
means of a protocol identical with that used in the normal subjects (Table 1,
Figure 1). Because of their clinical state they were studied sitting
propped up in their beds. Morphine 15 mg/70 kg was administered to these
patients because this is a dose very commonly used therapeutically in this
condition.
Personal Particulars and Control Observations
Clinical Details
Case summaries in respect to the six patients studied are given
at the end of this section.
When studied, these patients showed signs and symptoms of
congestive heart failure, which was believed to be of the left ventricular
type, namely, raised jugular venous pressure, orthopnoea and basal
crepitations. In one subject (R.McI.) symptoms were rather slight,
another was only moderately distressed and, in the remaining subjects,
symptoms were severe or very severe. All patients were fully assessed
clinically as to their fitness for the study and all consented to the
invitation to participate.
Left ventricular failure was due to hypertensive disease in 3
subjects (L. McA., R.McI., and A. G. ) and was secondary to is chaemic
heart disease in 3 (A. O., A.M., and E.S.).
Age
Apart from one subject»aged 30 years, with hypertension, patients
were aged 60 years or over. The mean age in the group of 57.33 is, of
course, greater than that of the normal subjects. This age difference
is significant whether or not this young patient is excluded from
consideration (.05 > P > .02). The mean age of the group is also greater
though not significantly so than the group of normal subjects in the 15 mg/
70 kg group (Table 22).
Control Observations
Mean minute ventilation and respiratory rate during the control
period in patients with left ventricular failure were significantly larger
than in normal subjects (Table 22). The variance far ventilation in this
group is also significantly larger (P < .001), an indication mainly of the
important differences among the patients in clinical severity of signs and
symptoms.
Variability of the control minute ventilation, expressed as the ratiu
Standard Deviation
Mean ' *S rat^er larger though not signiiicantly so at the .05
level, in the patients with left ventricular failure than in the normal group
treated with the same dose of morphine (.1 > P > .05). There is no
significant difference in variability of control ventilation between this
and any other group of normal subjects. The mean variability in the
control oxygen uptake of approximately 3% suggests a relatively stable
metabolic state and is not significantly different from that of any group of
normal subjects.
Thus* despite their dyspnoea* patients with left ventricular failure
were metabolically stable at the time of the study* while some degree of
respiratory instability was present*
Mean tidal volume was somewhat lower in the patients with left
ventricular failure but this difference is not signficant (P > *3).
The mean control oxygen consumption is slightly larger in the
group of patients with left ventricular failure than the normal subjects*
\ ■
_ i i
a non-significant difference (P > .6). Having regard to the significantly
larger minute ventilation in the former group*the observed difference in
oxygen uptake of 3*3 ml/min is rather unimpressive.
Despite the larger minute ventilation and oxygen uptake* the carbon
dioxide output per minute in the group was somewhat less than that of the
normal subjects* a non-significant difference.
Arterial gas tensions were estimated in three patients only. One
subject was moderately hypoxaemic (Po^ = ^9. 33 mm.Hg)* another was
slightly so (Po^ = 82.33)* and in the third Pq^ was normal (96.67 mm.Hg).
■
. v: ; . V , ' 1 r ■' < ' - . t . '
P CO was low in 2 patients (33 and 30.83 mm.Hg) and vithin normal limits
in the third (43*17). pH values were on the alkaline side of normal. Thus
the two severely dyspnoeic patients had normal or low normal Po^» *ow
P CO and alkaline pH. (Table 23, figure 30).
3. «
Changes in PaCOt and pH in 3 Subjects in Left Ventricular Failure
after 15mg/70kg Morphine I.V
Wtvm,30
Changes la PaC02 and arterial pH after IS mg/?0 Kg. morphine,
(patient# with left ventricular failure).
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Effects on Respiration
(Tables 24, 25, Figure 31)
Of the 6 patients studied,5 experienced a significant fall in minute
ventilation. In the sixth (A.O.) depression is just short of significance at
.05 level, no doubt, because of the fairly marked initial post drug hyperpnoea
which occurred. If this period of hyperpnoea is excluded from consideration,
the subsequent depression is significant (.05 > P > .02). The mean
depression in minute ventilation in the group is significant (.01 > P > .001).
The respiratory frequency fell significantly in 5 patients. In the
sixth (A.G.) there was a very small and non-significant increase. The
mean depression in respiratory frequency in the group is significant, (.05 >
P > .02).
The fractional depression in minute ventilation in the group is
appreciably larger than that vhich occurred in normal subjects treated
with the same dose of morphine (Table 25), but this difference is only just
significant (P = .05, nearly). The fractional depression in respiratory
frequency is also larger than in the normal group given 15 mg/70 kg but
not significantly so (P > .3).
The changes in tidal volume are more variable. In 4 patients, there
was a significant change - in 2 this increased and in 2 there was a decline.
In the remaining 2 subjects, there was non-significant fall in tidal volume.
The mean depression in tidal volume of approximately 5% is not significant
(P > .5). This also is larger than the depression recorded in the normal
group, but the difference is not significant (P = .7).
Ventilation RespRate Tidal Vol 0,Uptake CO,Excnetion











Patients in Left Ventricular Failure
Change in Minute Ventilation, Respiratory Rate, Tidal Volume,
0, Uptake and CO, Excretion after I.V. Administration of
Morphine I5mg/70kg
• Individual Changes O Mean Values ± S.E.
Figure 31
Changes in minute ventilation, respiratory frequency, tidal volume,
C>2 uptake and CO output after 15 mg/70 Kg. morphine (patients with
left ventricular failure).
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The changes in respiration, in relation to time, are shown in
Figure 32. Mean ventilation, respiratory frequency and tidal volume
fell during the first post drug period and tended to remain depressed for
the remainder of the post drug period. The plotted changes ase remarkably
similar to those recorded in the normal group treated with 15 mg/70 kg
morphine (figures 2, 9» 11). It is to be noted that, although the minute
ventilation fell very considerably, the post drug values are still
appreciably larger than those of the normal group.
Post Drug Hyperpnoea in Patients with Left Ventricular Failure (Table 12,
figure 33)
In all patients, an increase in minute ventilation which, in 3 subjects,
was very marked, occurred furing the first minute following drug adminis-
(1)
tration (Fig. 33). The mean fractional increase of approximately 25% is,
however, marginally short of the .05 level of significance, no doubt because
of the marked variability of the response (Table 12). The normal treatment
groups in which post drug hyperpnoea was marked also showed,it will be
remembered, similarly marked variability of response.
During the subsequent 3 minutes, two patients continued to show some
increase in ventilation as compared with the control period, albeit in
diminishing degree. In the remaining patients overbreathing ended during
the second minute following drug administration.
(1) One subject (D.McA.) excluded from the calculations because of a very
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Minute Ventilation, Respiratory Rate, Tidal Volume, 0, Uptake and CO. Excretion before ond after
15 mg /70kg Morphine IV to patients in Left Ventriculor Failure
• Mean Values ±S.E. Control: Mean Values during 3 successive 4min periods immediately prior
to injection.
Post Drug: Mean Values during 12successive 4min periods following injection.
rfoqy 32
Changes in minute ventilation, respiratory frequency, tidal volume,
uptake and CO^ output in relation to time, after 15 mg/70
















TIME MINS 1-2 1-3 1-4
• Individual Values Fractional Changes in Minute Ventilation
Mecn Values t SE. during f,rst 4 minutes following I.V.
Administration of I5mg/70kg Morphine
to patients in Left Ventricular Failure
(5 Subjects)
Figure 33
Fractional changes in ventilation during first 4 minutes after
injection of 15 mg/70 Kg. (patients with left ventricular failure)
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This immediate increase in ventilation in the group of patients
suffering from left ventricular failure is to be contrasted with the behaviour
of normal subjects given the same dose of morphine. In this group, as
(2)
pointed out the previous section * an initial hyperpnoea, though sometimes
recorded* was very uncommon and never as marked.
In two subjects (A.O. and D.McA.)* oxygen uptake increased during
the first post drug period. '
Changes in Oxygen Uptake
(Tables 21, 24 and 25)
' : •
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Although the control ventilation is considerably greater in patients
with left ventricular failure than in the normal group (Table 22), the difference
in oxygen uptake is very slight and* in the statistical sense* non-significant.
It will be noted from Figure 34 that the plotted mean values for ventilation
and oxygen uptake in the group nearly all lie below the normal control,r-: ' • ' 1 '-- • ; . . •• •••
W\ regression line. That this difference in oxygen uptake is highly
significant can be shown, in the usual way* by regression analysis. In
Figure 35 are shown the fitted Vq^'/V^, regression lines derived by covariance
analysis. The slopes do not differ significantly but comparison of the adjusted
means shows that the elevation of the control regression of the left ventricular
group is significantly less than that of the normal control regression (P < .001).
Thus* patients suffering from left ventricular failure had a significantly
lower oxygen uptake than normal sub j ects for the level of ventilation achieved.
(2) Page 75
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Over the 60 minute period following drug administration, oxygen
consumption fell in all 6 patients, but this was significant only in 2 patients
(Table 24, figure 33). The depression in oxygen uptake varied from 4 -
16 mis per minute. The mean fractional change in the group of approximately
8% was very significant (.01 > P > .001). This depression in oxygen uptake
is appreciably and significantly greater than that which occurred in the
group of normal subjects to whom the same dose of morphine was
administered (.02 > P > .01). Even so, the change in oxygen uptake is
proportionally considerably less than the change in ventilation - a discordance
which, as previously noted, exists also in the normal treatment groups
(Table 25, figure 31).
The mean changes in oxygen uptake in the group in relation to
time illustrated in Figure 32 show that oxygen uptake fell early in the post
drug period and remained depressed throughout. The sharp initial fall in
oxygen uptake noted in the normal group (figure 12) is not apparent, presumably
because of the initial increase in ventilation which occurred in all subjects
with left ventricular failure.
The changes in oxygen uptake have been further considered, as in
the normal subjects, by the methods of regression analysis. The regression
chosen is, as in the normal groups, that of oxygen uptake on ventilation.
The common control regression computed by covariance analysis showed evidence
of significant slope heterogeneity which could be attributed to the data
contributed by one subject (A.G.). After exclusion of this subject from
124
thegroup an entirely satisfactory estimate of control regression was obtained.
In estimating the post drug regression, the initial 3 periods have, for the
reasons previously given, been excluded. The estimate of post drug
regression so obtained shows no evidence of significant slope differences
among patients. It was considered preferable not to exclude from the
computation of post drug regression the patient dropped from the control
estimate.
The results are shown in Table 26 and the fitted regression lines
in Figure 35. Both slopes are significant, the post drug slope being slightly
greater than the control but not significantly so. It is evident from
Figure 35 that the elevation c£ the post drug regression line is considerably
greater than that of the control and the test of adjusted means confirms that
this difference in elevation is highly significant (P < .001). Thus in patients
suffering from left ventricular failure, also, morphine increases oxygen
uptake independent of its effect on ventilation. In the group of patients with
left ventricular failure, the increased elevation of the post drug regression
line (. 0212 _+ .0024), as compared with its control, is greater than the
corresponding change in the 15 mg/70 kg normal group (.&30jf .0017), a
difference which is without doubt significant. It will be noted also that
the elevation of the post drug regression line is still appreciably less
than that of the control normal line and also of the post drug regression
line of the normal group treated with 15 mg/70 kg morphine.
Thus, patients in left ventricular failure after treatment with morphine
continued to show a rather large respiratory minute volume and an
appreciably lower oxygen uptake than vo uld be expected from the level of
ventilation.
x PRE DRUG VALUES Mean values for Control and Post Drug 0, Uptake Straight line is the fitted Regression Line derived from
• POST DRUG VALUES related to corresponding values of Minute \fentilation 31 normal non morphinised subjects and projected be>ond
in 6 subjects with Left Ventricular Failure given the limits of the supporting data
I5mg./70kg. CL Uptcke = -0557 + (*0170*•0040) Ventilation
(l / m in/sam STPD) (1/min/sqm.BT.PS)
Figure 34
Patients with left ventricular failure - control paired values for




SO 60 70 »0
MINUTE VENTILATION (l./sq.m. B.T.PS)
Fitted Regression Lines
I Common Control Regression Line ~l (5 subjects) Y =0 0550+ (OOI24± 0 0036)X
rLYF.
II Common Post Druq Regression LineJ (6 subjects) Y=00553+ (00!54± 00022)X
m Common Control Regression Line Normals (26 subjects) Y =00618 + (0OI60± 00018) X
12Common Post Drug Regression Line Normals (9subjects) Y=00500+ (00196 ♦ OOQ23)X
I5mg./T0 Kg
Figure 35
Patiente with left ventricular failure: Fitted regression lines -
uptake related to ventilation - control and post-drug regressions
compared with regression lines for normal subjects (all regressions
derived by covariance analysis).
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Changes in Carbon Dioxide Output
(Tables 21, 24)
Carbon dioxide output fell in all subjects except one (A.O.) in
whom the mean post drug value was almost identical with the control.
The depression in carbon dioxide output was significant in 4 patients and
non-significant in the fifth. The mean depression in the group was
significant (.02 > P > .01). The fractional depression in carbon dioxide
output is larger than that of oxygen consumption but less than the change
in ventilation. The depression in carbon dioxide output is larger, though
not significantly so, than that which occurred in the normal group treated
with 15 mg/70 kg (P = .1) (Tables 21, 24, 25, figure 31).
The changes in carbon dioxide output in relation to tine are shown
in figure 32. Carbon dioxide excretion fell early in the post drug period
and remained depressed thereafter.
As in the normal group, the changes in carbon dioxide output have
been studbdby the use of regression analysis. Comparison between the
control and post drug Vqq^/V^; regressions makes it possible to separate
the effects upon carbon dioxide output attributable to changes in ventilation





















Both slopes are significant and neither estimate shows evidence of
significant heterogeneity. The post drug slope is slightly larger, but not
significantly so, than the control slope. The post drug adjusted mean is
significantly larger than that of the control. The degree of elevation
observed (.0157 +; ,0019) is somewhat greater than the elevation of the
post drug normal 15 mg/70 kg regression above its own control (.0106 +
.0011), a difference which is without doubt significant.
Thus in patients with left ventricular failure also the fall in
carbon dioxide output after morphine is greater than can be accounted for
by the depression in minute ventilation. In these subjects, it is to be
presumed that increased carbon dioxide formation consequent upon the
increased oxygen uptake is responsible for a significant portion of the
change in CP^ odput.
Effect on Arterial Blood Gas Tensions
It was possible to measure arterial blood gas tensions in 3 patients
only. Two subjects were hypoxaemic before drug administration while
arterial oxygen tension in the third was nornal. P CO was low in 2
ci L*
and normal in 1 patient. pH was normal in 1 and on the alkaline side of
normal in 2 patients (Table 23, figure 30).
After administration of morphine, there was ahnarked and significant
i
decline in arterial oxygen tension in 2 patients, as measured over tine 60
minute post drug period. In the third, mean measured over the same
period was identical with the control value.
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Arterial carbon dioxide tension rose significantly in all 3 subjects.
The increase was particularly maked in the 2 patients -with moderate (A.G.)
and severe (E.S.) dyspnoea associated with low control values of P CO .
ci Lt
In these two patients, P CO entered the normal range after administration
cL &>
of morphine. The third subject became definitely hypercapnic during
the post drug period.
Arterial pH fell significantly in all three patients. In one subject
(A.M.) pH fell to acidotic levels in association, as noted above, with a
degree of hypercapnia: in the other 2 patients arterial pH remained on
the alkaline side of normal after drug administration.
An attempt has been made as in the normal subjects, by the use
of P&CO^/V"a regressions, (v - Table 18), to find out whether the increase
in arterial carbon dioxide tensions after morphine can be explained
entirely by the fall in ventilation. Owing to the limited nurrber of
observations these regressions have been rather difficult to handle.














.811 5 .4778 35.667 42.076 - (1.645
± -531)
3.896 -6. 608 _+
3. 309
Post drug . 296 24 3.450 47.018 58.657 - (4.^2
+ 3.107)
2.518 .1 > P > .05
(1) difference from control slope is not significant (.4 > P > .3)
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Despite the limited degrees of freedom the control slope is significant.
This is probably related to the degree of respiratory instability present -
the consequence of dyspnoea - when a greater part of the variation in P CO
cL C*
is to be attributed to ventilation than under eupnoeic conditions. The post
drug slope, despite the larger number of observations, is not significant
(. 2 > P > .1). It is, difficult to compare these two regressions because of a
highly sigiificant difference between the variances from regression (P < .001).
The post drug slope is numerically steeper than the control, but, by the use
of the method recommended b Bailey (1959) it was all own that this slope
difference is not significant (P > . 3). The calculated difference between
the adjusted means is quite marked. However, in view of the marked
difference in variances from regression, this estimate of elevation and its
attached standard error cannot be accepted without serious reservations.
It would seem legitimate to conclude, however, that the loss of significance
of slope and the apparent increase in elevation would be consistent with the
view that, in patients with left venlricular failure as in normal subjects, the
increase in arterial carbon dioxide tension vh ich occurs after administration
of morphine is not to be attributed mainly to the fall in ventilation. Since
in such patients morphine increases oxygen consumption the observations
are entirely consistent with the view that increased carbon dioxide formation
plays an important role in causing the recorded increase in P CO .
Ci C+
CASE SUMMARIES
Patients suffering from left ventricular failure
A 61 year old male was admitted on 6.11.63 complaining of
breathlessness on exartion. In Augusts 1963, he developed a myocardial
infarct for which he was treated in hospital andhad since complained of
exertional dyspnoea. On the day of admission he developed acute
breathlessness at rest which became rapidly worse. On admission, he
was intensely breathless, orthopnoeic and rather distressed.
Advanced signs of left heart failure were present. Chest x-ray showed
some cardiac enlargement with appearances of pulmonary congestion.
Electrocardiogram showed no evidences of further infarction. He
was studied on 19*11>63. He had been digitalised on the day after
admission with considerable improvement though signs of left ventricular
failure were still present at the time of study. Digoxin was stopped on
the previous day and restarted immediately after the study was completed.
He has remained well.
D. McA.
A 30 year old male labourer was admitted on 14th December 1963
complaining of breathlessness on exertion of 4 weeks duration, occasional
attacks of nocturnal dyspnoea for some months and swelling of the ankles
first noted some weeks prior to admission. At the age of 18, he was
refused entry into the Navy because of high blood pressure. There was
also a history of sweating and palpitations for 2 years associated with
feelings of anxiety. On admission, the blood pressure ranged betweei
190 - ZZO systolic and 120 - 140 diastolic. He was orthopnoeic. The
heart was clinically much enlarged, and triple rhythm was heard. At
times, pulsus alternans was noted at the wrist. Jugular venous pressure
was raised, bilateral basal crepitations were heard and ankle oedema
was present. Chest x-ray confirmed the cardiac enlargement and
showed also appearances of pulmonary congestion. ECG showed left
ventricular hypertrophy and strain. He was studied on 9.1.64 while
still in congestive cardiac failure. Later, he was treated with
Guanethidine, Bendrofluozide and digoxin. The last named was started
on 24.12.63. He has remained reasonably well on this treatment.
R. Mcl.
A 58 year old male shoemaker was admitted on 29th December 1963
complaining of breathlessness on exertion and tiredness for the precedng
8 months. An elevated blood pressure had been found 8 years previously
but treatment with methyl dopa was started only in May 1963. The
present admission was intended to secure better control of his hypertension.
On admission> he was orthopnoeic and signs of early heart failure were
present. Chest x-ray showed cardiac enlargement with pulmonary
congestion. Electrocardiogram showed well marked left ventricular
hypertrophy and strain. The effects of morphine were studied on 14.1.64
when the signs of heart failure were still present. He was later
re-stabilised on Guanethidine but control of hypertension has remained
unsatisfactory.
A.M.
A 62 year old male Polish labourer was admitted on 4. 3. 64
complaining of angina of effort for some months previously. For
about 2 years he had complained of exertional dyspnoea and for
some months past had had a troublesome night cough. Three days
before admission he developed continuous precordial pain. On
admission, he was orthopnoeic and showed signs of left heart failure.
He was treated as for myocardial infarction though serial electrocardiograms
were negative. He was digitalised on admission and studied on 10. 3. 64.
He was then no longer complaining of precordial pain but the signs of
congestive heart failure were still present. He has remained well
though continuing to complain of exertional dyspnoea and nocturnal
dyspnoea.
A 71 year old housewife was admitted on 1.4.64 complaining of
increasingly severe breathlessness for the preceding 10 - 14 days with
ankle swelling. In October, 1962, she developed a myocardial infarct
and since then had been maintained on digoxin. About 2 weeks prior to
admission increasingly severe exertional dyspnoea appeared so that
by the day of admission she was breathless even at rest. She was also
orthopnoeic. On admission, severe breathlessness in bed was
apparent with orthopnoea and advanced signs of left ventricular failure.
Some peripheral oedema was also present. Chest x-ray showed
cardiac enlargement with pulmonary congestion. Electrocardiogram
showed evidences of old antero-septal infarction. She was studied
on 3.4.64. On the following day, her condition deteriorated and she
died rather suddenly. Autopsy showed gross myocardial fibrosis,
severe coronary artery atherosclerosis and bilateral nephrosclerosis.
A 60 year old housewife was admitted on 28.4.64 complaining
of increasing breathlessness on exertion with occasional attacks of
nocturnal dyspnoea during the preceding 8 months. A left nephrectomy
had been performed in 1948 for an "enlarged kidney" . On admission,
she was orthopnoeic with signs of left heart failure. Blood pressure
ranged between 180 - 220 systolic and 105 - 130 diastolic. Chest x-ray
showed cardiac enlargement with pulmonary congestion. Electrocardio¬
gram showed evidence of left ventricular hypertrophy and strain with
associated myocardial ischaemia. Creatinine clearance was reduced
(42 ml/min.). She was studied on 28.4.64 following which she was
digitalised. She was later treated with methyl dopa but control of
hypertension has never been satisfactory.
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CHANGES IN RESPIRATION, OXYGEN CONSUMPTION, CARBON
DIOXIDE OUTPUT AND BLOOD GASES AFTER SOLUBLE
PHENOBARBITONE ~ " ™
The effects of an intravenous injection of soluble phenobarbitone
were studied in 4 normal subjects according to a protocol identical with
that used in the experiments with morphine (figure 1). The purpose of
the study was to compare the respiratory effects of morphine with that
of anotner drug known to produce drowsiness. The doses of pheno¬
barbitone used were respectively 3.46, 3.64, 3.14 and 3.14 mg/kg. The
doses used invariably produced marked drowsiness which was thought to
be similar to that produced by 5 or 10 mg/70 kg morphine. Personal
particulars of the subjects were set out in Table 1.
Control Observations
The average age in tire group, at 51, is somewhat greater than
that of the normal subjects in the morphine treatment groups, a non¬
significant difference.
Minute ventilation and tidal volume are rather lower and respiratory
frequency rather higher than in the morphine series. None of these
differences is significant. However, oxygen consumption and carbon
dioxide output in the phenobarbitone group are significantly lower than in
the normal subjects of the morphine treatment groups (Table 27).
The statistics indicate very stable respiratory and metabolic
conditions during the control period. The differences noted would not,
of course, invalidate comparisons between the effects of these two drugs.
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Effects on Respiration
(Tables 28, 29, figure 36)
Over the 60 minute period following drug administration, ventilation
usually showed little change. Minute ventilation increased slightly (l and 2%
respectively) in 2 subjects, and fell (3 and 10% respectively) in 2. The
fall in ventilation was significant (P < .001) in one subject; the other
changes were non-significant. The mean depression of approximately
2% over the 60 minute post drug period was far from significant. No
evidence of hyperpnoea after administration of this drug was detected
(Tables 28, 29, Figure 3d).
The mean respiratory frequency over the 60 minute post drug period
declined in all subjects, but in 2 the post drug value was nearly identical
with the control. The other 2 subjects experienced a significant depression
in respiratory frequency. The mean depression in the g»up of nearly 5%
is not significant at .05 level (. 2 > P > .1). A larger group would pacbably
have yielded a significant result (Table 28, 29, figure 36).
Tidal volume usually increased. In one subject there was a very
slight non-significant decrease in tidal volume ; the increasein tidal volume
was, in one subject, significant and, in the other 2 non-significant. The mean
increase in tidal volume of approximately 3% was far from significant (. 3 > P
>. 2).
These results suggested that the drug primarily affected the respiratory
frequency and that changes in tidal volume were compensatory in nature.
The combined data plotted in relation to time (figure 37) appears to lend support
to this surmise. It will be noted that both ventilation and respiratory frequency
12 60 12 12
Fractional Changes in Minute Ventilation, Respiratory Rate and Tidal Volume
over Periods of 4, 8, 12, and 60 minutes following Intravenous Administration
of soluble Phenobarbitone
C4 Subjects)
Individual Changes during Period Specified
Mean Changes t SE.
Fractional changes in minute ventilation, respiratory frequency and
tidal volume over periods of 4, 9, 14 and 60 minutes after

















Mean Ventilation. Respiratory Rate, Tidal Volumes,
0, Uptake and C(\ Excretion before and after
Soluble Phenobarbitone (4 Subjects')
Post Drug
Mean Values ±S.E.
Mean Values during 3 Successive
4 min periods immediately prior to
Injection
Mean talues during 12 successive
4miaperiods following injection.
ngw* V
Changes in ventilation, respiratory frequency, tidal volume, O
uptake and CO_ output after soluble phenobarbitone (normal c
subjects) in relation to time.
fell during the early post drug period. The fall in respiratory frequency
is the more marked and persists to 3ome extent throughout the period of
observation. Minute ventilation soon recovers from the initial fall and
thereafter fluctuates somewhat. The tendency for tidal volume to be
increased throughout the post drug period is apparent from the plotted
values.
Consequently, the changes in ventilation, respiratory frequency
and tidal volume have been studied in relation to the initial three post
drug periods. Theindividual differences from the control value at the
end of each of these periods with appropriate sign attached, have been
treated, in the usual way, as normally distributed variables and the
significance of the mean change tested by means of the standard formula
t = —*
s Vn
a two-tailed test being considered appropriate for the present purpose.
The results (Table Z9, Figure 3b) emphasise the almost specific
effect of soluble phenobarbitone on the respiratory frequency. The
mean depression in respiratory frequency at the 4th and 9th minute is,
in each case significant; the depression at the 14th minute does not
attain significance at .05 level. The fall in ventilation at the 4th minute
is not significant at .05 level probably because of the small number of
observations. The depression in ventilation at the 9th and 14th minute
is, in neither case significant. The tidal volume shows an increase over
the same period but this is significant only at the 14th minute.
There seems little doubt, therefore, that soluble phenobarbitone
produced an early depressant effect upon the respiratory frequency which
tended to persist throughout the 60 minute post drug period. This may be
associated, though not necessarily, with a decline in minute ventilation.
The tidal volume tends to increase following drug administration - this is
presumably a compensatory increase.
The drug caused periodic respiration to appear in all subjects.
The rather regular fluctuations evident in the combined data in figure 37
are probably a reflection of this phenomenon.
Effect on Oxygen Consumption
(Tables 28, 29 Figures 37, 38)
Oxygen uptake fell significantly in one subject (J. C.) . In this
subject, a significant decline in minute ventilation and respiratory rate
also occurred. The other 3 subjects showed essentially no change in
oxygen uptake as measured over the 60 minute post drug period. The
changes in oxygen uptake in relation to time (figure 37) show a tendency
to an initial decline followed by recovery and some fluctuation later in
the post drug period. These early changes are slight and non-significant.
The mean change for the group over the whole post drug period is - 2%
approximately, a non-significant change. These observations suggest
that soluble phenobarbitone probably depresses oxygen uptake, but thatthe
depressant effect is slight and would require a larger number of observations
for attainment of statistical significance. It is to be noted that the mean
decline in minute ventilation is of the same order (2%) as the change in
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38
Fractional changes in uptake and C02 output over periods of
4, 9* 14 and 60 minutes after administration of soluble
phenobarbitone(four normal subjects).
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oxygen uptake - a contrast to the situation obtaining with morphine.
Because both ventilation and oxygen uptake appear to be slightly
depressed by soluble phenobarbitone, the changes in oxygen uptake have been
considered further, as in the subjects treated with morphine, by regression
analysis. Regression statistics relating oxygen uptake and minute
ventilation for control and post drug periods separately have been
computed, in the usual way, by covariance analysis. Five paired
observations are available for estimating the control regression. All the
post drug observations - 12 pairs for each subject - have been used. This
drug has not caused hyperpnoea and the regressions so computed have
been entirely satisfactory.
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.0036 .1207 .0302 + (.0201 4.499 _
+ 0064) .00*7*
.0033 .1163 .0481 +(.0155 4.394 10
+ .0030)
Both slopes are significant and neither shows evidence of significant
heterogeneity. The post drug slope is somewhat flatter than control but
this apparent slope difference is far from significant. The fitted regressions
shown in Figure 39 suggest some difference in elevation and the test of
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O2 uptake related to Minute Ventilation before
and after soluble Phenobarbitone IV (4 subjects)
Fitted Common Regression Lines
I Yr 00302+ (0 0201+ 00064)x
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Fitted regression lines (derived by covariance analysis) * 07 uptake
related to ventilation before and after soluble phenobarbitone' (four
normal subjects).
• •
I Control VQ = . 0302 + (. 0201 + .0064) VE
e
II Post-drug = .0481 +(.0155 £ .0029 ) VE
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is nevertheless very significant (P - .01). This analysis therefore proves
that the effect of the drug upon oxygen uptake, though very slight, is
nevertheless a real one.
Effects on Carbon Dioxide Output
(Tables 28, 29, Figures 37, 38)
The changes in carbon dioxide output over the 60 minute post drug
period have usually been insignificant. In one subject (J.C.) there was a
significant depression in carbon dioxide output after drug administration;
in this subject, as previously noted, minute ventilation, respiratory frequency
and oxygen uptake also fell significantly during the post drug period. The
very slight changes in the other 3 subjects (+8, +4.6 and -3.0 ml/min respec¬
tively) were, in each case, non-significant. The mean change in carbon
dioxide output in the group - a depression of less than 1% - is not significant
(P > .8).
The combined data showing the changes in carbon dioxide output in
relation to time show that the post drug values tend to fluctuate round the
control level (figure 37).
Regression analysis has been applied also to the changes in carbon
dioxide output after soluble phenobarbitone, with computation of control and
post drug V /V regressions in the manner described above. The
regression statistics are given below:-
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/ V"k: Regression (soluble Phenobarbitone group)
Control -
r S i a+(b+S.tj.) X ^ f"g
^ yx \ _ / adjustedFreedom .
mean + SR.*
$$$$
Control .781 15 .0022 .1019 .148 +(.0194 + 4.499
regression .0040) .0007
. 0008
Post drug .791 43 .0027 .1005 .0108 +(. 0204 + 4.394
regression .0024)
(1) non-significant (.4 > P > .3)
Both slopes are significant and neither shows evidence of significant
heterogeneity. Numerically, the slopes are nearly identical and not, of
course, significantly different from one another. Both regression lines are,
in the statistical sense, identical, as may be readily appreciated from the
fitted curves in figure 40. Formal testing of the adjusted means show no
evidence whatever of any significant difference (P > .3). These regressions
confirm that in the present group, soluble phenobarbitone has no significant
effect upon carbon dioxide output and, any change which might be present can
be explained entirely by changes in ventilation. Evidently, the depression in
oxygen uptake which the drug, without doubt, causes is too small to be
reflected by any change in carbon dioxide output.
Effects on Arterial Carbon Dioxide Tension and pH
(Table 30)
Arterial carbon dioxide tension and pH were measured in 3 subjects.
P CO fell significantly in 1 subject. There was a small non-significant
3. Ld
increase in each of the other 2 subjects. The arterial pH hardly altered.
The increase in P CO in the sole patient showing a significant de cline in
a 2
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Figure 40
Fitted regression lines (derived by covariance analysis) - CO output
related to ventilation before and after soluble phenobarbitone (four
normal subjects).
SUMMARY OF RESULTS, DISCUSSION AND CONCLUSIONS
General Summary of Experimental Results
Normal Subjects
In normal subjects respiration is significantly depressed by
each of the four doses administered, although this would not necessarily
occur in every subject, particularly in the groups which receivodthe
lower doses. There is a linear relationship between the depression in
minute ventilation and the dose administered with an apparent tendency
for the effect to level off at 15 mg. /70 Kg. This latter could not be
rigorously demonstrated because of the small size of the 20 mg/70 Kg.
group, and the possibility that the greater mean age of the 15 mg/70 Kg.
group may have caused this apparent plateau of effect. The slope of
the fitted line suggests that dosesoof morphine much smaller than
5 mg./70 Kg. would be expected to depress minute ventilation (Fig. 4.).
An increase in minute ventilation which lasts 1 - 2 minutes
not uncommonly occurred after administration of morphine particularly
in the 5 and 10 mg. /70 Kg. groups. There is a significant inverse
relationship between the dose of drug and the initial change in ventilation
so that the smaller doses (5 and 10 mg/70 Kg) are more likely than not
to cause an increase in respiratory minute volume of varying degree, and,
larger doses (15 and 20 mg/Kg.) more frequently cause an immediate
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depression. The initial post drug hyperpnoea is veryvariable in degree
and it is possible that this response is strongly influenced by factors
other than the dose of the drug. These factors* possibly* relate to
the internal environment, physiological and psychological.
During the first four minutes after injection ventilation declines
progressively from these initially elevated or depressed levels.
The respiratory frequency was significantly depressed in the
groups treated with 10 andl5 mg/70 Kg; in the 20 mg/70 Kg. group this
depression did not attain significance at the .05 level* no doubt because
of the small size of this group. In the 5 mg/70 Kg. group there was a
small non-significant increase in the respiratory frequency.
Tidal volume was significantly depressed only in the 5 and 20 mg. /
70 Kg. groups - in the former, this significant depression followed an
initial increase lasting nine minutes. Detailed analysis shows-that the
effect upon tidal volume is a mixture of depression and stimulation and
that depressant effects are predominant in all treatment groups| Stimulant
effects are moot obvious in the 10 and 15 mg/70 Kg. groups. In the 5 mg/
70 Kg. group the stimulant effects are apparently restricted to the first
nine minutes of the post drug period. In the 10, 15 and 20 mg/70 Kg.
groups depressant effects are dominant during the early post drug period
and appear to be dose related although this relationship could not be
rigorously demonstrated. Stimulant effects upon the tidal volume are
not evident at any time in the 20 mg/70 Kg. group although they are
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presumably present albeit submerged by the more dominant depressant
effects.
Because of the significantly greater mean age of the 15 mg /
70 Kg. group* the relationship between depression of minute ventilation
and age of subject has been examined. There is a significant regression
slope only in the 15 mg/70 Kg. group, the result appearing to indicate a
tendency in this group for older subjects to experience a greater depression
in minute ventilation. This relationship disappears when the data is
pooled by covariance analysis* suggesting either that this holds only for
the 15 mg/70 Kg. group - a most improbable situation - or* more
plausibly, that the significant correlation is spurious. In an attempt
to locate the likely origin of this spurious result it was noted that the
15 mg/70 Kg. group contained an excess of subjects suffering from recent
occlusive vascular disease. The question has been left unresolved,
and it must be accepted that a possible, though unlikely, cause of the
apparent peak effect of the 15 mg/70 Kg. dose is that subjects in this
group were, because of age or through unknown clinical factors, more
sensitive to the respiratory depressant effects of the drug.
In individual subjects a significant change in oxygen uptake was
very uncommon. In each treatment group there was a small mean
depression in oxygen uptake which was significant only in the 5 mg/70 Kg.
group, but the small differences present among the four treatment groups
were not statistically significant. The depression in oxygen uptake was
numerically largest in the 5 mg/70 Kg. group and least in the 20 mg/
70 Kg. group. When the changes in all normal subjects are considered
together the small mean depression in oxygen uptake is significant.
The more sensitive technique of regression analysis shows that
oxygen consumption is affected by morphine independently of its effects
upon ventilation. The regression relationship indicates that the drug
causes a depression in oxygen consumption because of the decline in
ventilation which it induces. In addition and independent of this effect
the drug markedly stimulates oxygen uptake and this effect is related
to the dose* being least in evidence after 5 mg/70 Kg. and most marked
after 20 mg/70 Kg. The drug also exerts an apparently slight depressant
effect distinct from that achieved through the depression in ventilation.
This last named effect could be demonstrated directly to have occurred
only after a dose of 5 mg/70 Kg. but there is evidence* principally from
the early changes in oxygen uptake, that it is present also after larger
doses. The observations indicate that these stimulant and depressant
effects are nearly balanced in the 10. 15 and 20 mg/70 Kg. groups, with
the depressant effects predominating slightly. In the 5 mg/70 Kg.
group the stimulant effects appear to be confined to the initial nine
minutes of the post drug period.
The measurements of carbon dioxide output complement the
data on oxygen consumption. The regression relationship indicates a
rather closer dependence of carbon dioxide output, than of oxygen uptake,
upon ventilation so that approximately 70% of the variation in CO^ output
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during the control period is attributable to ventilation. Carbon dioxide
output fell significantly in all the treatment groups but there is no
significant dose effect when the 5 mg/70 Kg. group is excluded from
consideration. Changes in carbon dioxide output are significantly correlated
both with changes in ventilation and changes in oxygen uptake. The partial
regression constants indicate that there is a closer dependence upon
changes in oxygen uptake than upon changes in ventilation. Regression
analysis shows that the drug increases carbon dioxide output independent
of any effect on ventilation. It seems certain that this increase is caused
by increased endogenous CO^ formation consequent upon the previously
demonstrated stimulant effect upon oxygen consumption. This increase
in carbon dioxide output also is dose related. Concurrently, the drug
depresses carbon dioxide output because of the depressant effect upon
ventilation and. in addition, produces an independent depressant effect upon
CO^ formation presumably related to the analogous depression in oxygen
uptake. The measurements of carbon dioxide output thus complement the
data on oxygen consumption and confirm that the drug is a potent metabolic
stimulant.
Arterial carbon dioxide tensions, measured in 13 subjects,
almost invariably increased. The increase in the5 mg/70 Kg. group
was not significant, that in the other groups was. After exclusion of
the 5 mg/70 Kg. group there is no significant relationship between the
increase in P C07 and the dose of drug administered. Changes in
arterial carbon dioxide tension correlate significantly with changes in
oxygen uptake but not with changes in ventilation. The interpretation
of.these results has bden extended by the use of regression analysis.
V, ;■
This shows that* while changesiin alveolar ventilation are responsible in
part for the increase in after morphine* the major part ofithis
increase is independent of the changes in ventilation. By this method also
the very small increase recorded in the 5 mg/70 Kg. group has been
shown to be significant. It would* therefore* appear certain that the
greater part of the increase in P^CC^ is caused by increased carbon
dioxide formation consequent upon the increase in oxygen consumption.
The observations show conclusively that the respiratory effects
of all doses or morphine administered are predominantly depressant,
though some stimulant effects* particularly - but not exclusively •
during the initial post drug period, are probably present in all treatment
groups. The effect upon metabolism of doses greater than 5 mg/70 Kg.
was predominantly stimulant, and, such depressant effects as were
demonstrable were related almost entirely to the depression in
respiratory minute volume causeiby all doses.
An attempt has been made to find out whether the drug causes
any change in the sensitivity of the respiratory centre to changes in
arterial carbon dioxide tensions. It can be shown that after morphine
higher levels of PaCO^ are found for any given level of ventilation, so
that, in that sense, the sensitivity to P CO? has been depressed.Si b
Sensitivity, defined as the quotient A VlAP^CO ^ has also been considered.
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This ratio cannot be measured directly but, with certain assumptions,
s
the computed YA/PaCO^ control and post drug regressions have been
used as an indirect measure of changes in sensitivity. The results
show an apparent increase in sensitivity or homeostatic efficiency after
the drug which has been interpreted as spurious and probably to be
attributed to the fact that the drug produces independent effects upon
respiration and PaCC>2;, depressing the former and increasing the latter.
From the result it appeared most unlikely that sensitivity as above
defined was either depressed or enhanced by the doses used. On the
contrary, the regression statistics indicate that normal homeostasis was
achieved in all treatment groups studied in relation to the selected new >
level of alveolar ventilation and arterial CO^ tensions.
Patients with Left Ventricular Failure
The effects of morphine in six patients suffering from left
ventricular failure have been studied. Control observations indicate a
larger respiratory minute volume in these patients than in normals but
only a slightly larger oxygen uptake. By regression analysis it was
shown that the patients suffering from left ventricular failure had
a significantly lower oxygen uptake that normals for the level of ventilation
achieved. The effects of the selected dose of 15 mg/70 Kg. were
qualitatively similar to those recorded in the normal subjects who
received the same dose. The fractional depression in ventilation and
oxygen uptake was significantly greater than in normal subjects. Even
after administration of morphine patients with left ventricular failure
continued to exhibit rather large respiratory minute volumes and a lower
oxygen consumption than would be expected in normal subjects for the
level of ventilation achieved. The drug also increased oxygen uptake
in these patients, the increase being apparently greater than that which
occurred in normal subjects who received 15 mg/70 Kg. The changes in
CO^ output were also related, in the main, as in normal subjects, to
increased CO^ formation consequent upon the increase in oxygen consumption.
The changes in P^CO^ were also probably related mainly to increased CO^
formation, though, owing to the limited number of observations this
could not be rigorously demonstrated. Arterial oxygen tension decreased
markedly in two of the three subjects in whom this was measured. Arterial
pH fell in all three patients, remaining on the alkaline side of normal in
two and falling to acidotic levels in the third.
In contrast to the normal group, an initial increase in ventilation
after drug administration to these patients invariably occurred but the
rather large mean increase in ventilation at the first post drug minute is
only just statistically significant.
Normal Subjects Treated with Soluble Phenobarbitone
Soluble phenobarbitone in the doses used produced marked
drowsiness and a slight, though very definite effect upon respiration.
The observations show that the drug has a specific effect in depressing
the respiratory frequency. A compensatory increase in tidal volume
occurs very rapidly so that respiratory minute volume is not necessarily
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depressed by the drug except in the early post drug period when such
depression appears invariably to occur.
The effect upon oxygen consumption also is very slight but
nevertheless real. The mean depression in the group of approximately
2% is similar to the change in minute ventilation. By regression analysis
this small change in oxygen uptake has been shown to be very significant.
Thus phenobarbitone has been shown to be a metabolic depressant drug in
1
its own right. The drug did not cause a significant decrease in carbon
dioxide output in the group - though it did so in one subject. Such changes
in CO^ output as occurred were related entirely to changes in ventilation.
£vidently( the change in oxygen consumption is too small to be reflected
in changes in carbon dioxide- output.
Changes in arterial pH and P CO? were slight and insignificantSL 6
even in the subject who experienced a significant fall in ventilation.
There is no evidence that the drug produces hyperpnoea or has
other stimulant effects. In particular it depresses rather than stimulates
oxygen consumption. The respiratory effects of the drug differ from
those of morphine in that it appears to have no depressant effect upon
the tidal volume and that compensation for the depressant effects upon
the respiratory frequency is very rapidly achieved. Arterial carbon
dioxide tension has been largely unaffected)partly no doubt because of
the insignificant effect upon respiratory minute volume and partly because,




These results have* for the first time* established in quantitative
terms the potency of the respiratory depressant effects of morphine in
man* The relationship of this depressant effect to the dose of drug
has been shown to be linear within the ordinary therapeutic range
of dose in man* and not logarithmic* as was apparently the case in some
animal studies (Wright and Barbour* 1935; Barlow* 1933). This
difference might have been due to the larger doses used in laboratory
species. Despite the individual variation in response which is present*
the dose/effect regression relationship illustrated in Figure 4 would
appear to be a good predictor of the respiratory depressant effects of
ordinarily used doses of the drug. The results also suggest strongly*
though ndt/' conclusively* that the respiratory depressant effects level 7
i i
off at a dose of 15 mg/70 Kg. Such a plateau of effect would be
consistent with the results reported by Kokka* Elliott and Way (1965)
in rats.
The purpose of the present discussion is to assess the
significance of the effects demonstrated in the foregoing sections with
the objects particularly of explaining the mode of action of the drug*
to consider how, if at all, the respiratory apparatus might compensate
for these rather marked effects upon respiration, and, to examine
any implications which these results might carry in regard to the
clinical use of morphine.
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Mode of Action of Morphine as a Respiratory Depressant Drug
The observations recorded make it clear that the primary effect
exerted by the drug is upon the tidal volume. This may be the only
respiratory depressant effect evident and may occur in the absence of
significant change in minute ventilation or respiratory frequency.
A dose of 5 mg/70 Kg. has been noted to cause a significant depression
in tidal volume with a slight and non*significant increase in the
respiratory frequency. Individual subjects treated with this dose almost
invariably experienced a fall in tidal volume, usually not associated
with any significant change in respiratory frequency and, not
necessarily accompanied by any depression, significant or otherwise,
in respiratory minite volume. In the other treatment groups, as noted
previously, the earliest respiratory effect - extending approximately
over the initial 14 minutes following drug administration - is a dose
related depression in tidal volume. These observations thus establish
that the basic mechanism through which respiration is affected is by
means of a depression in the tidal volume. In this respect morphine
differs from soluble phenobarbitone which, in doses producing marked
drowsiness, depressed respiratory frequency and, usually, caused
tidal volume to increase.
Doses of morphine greater than 5 mg/70 Kg. markedly depress
respiratory frequency and it seems likely that the effects of the drug
upon tidal volume and respiratory frequency are additive. This isdiown
by the fact that, although the tidal volume tends to increase somewhat
during the later poet drug period in the 10 and 15 mg/70 Kg* groups
the effects upon tidal volume remain throughout* in all treatment groups
depressant. This additive effect is^probably responsible for the linear
relationship between minute volume depression and dose of drug* the
rather steep slope of the regression line* and* in part explains why
morphine is so potent a depressant of respiration.
If the effects of the drug upon tidal volume and respiratory
frequency were linear over any considerable period of time after
administration* it is evident that morphine would be too dangerous a drug
for widespread routine clinical use. Fortunately* this is not so.
The effect upon tidal volume* although without doubt the primary
respiratory effect of the drug* is linearly related to the dose administered
only during the early post drug period. Thereafter*in the 10 and 15 mg/
70 Kg. groups and probably also in the 20 mg/70 Kg. group* compensatory
mechanisms which increase the tidal volume* or at any rate* inhibit
any further decline are clearly in evidence. It is* further* likely that
these compensatory mechanisms operate from a very early period. Thus,
the mean tidal volumes over the 60 minute post drug period in the 10 and
15 mg/70 Kg. groups are* in fact* larger than those of the 5 and 20 mg/
70 Kg. groups. Respiratory frequency is most depressed by 15 mg/
70 Kg. One explanation of these relationships would be that the breath
volume and the respiratory frequency are not only separately influenced
by the drug but also react separately in compensation.
It follows, therefore, that the effects of morphine upon breath
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volume are seen in least mixed form in the later post drug period
after 5 mg/70 Kg. The primary changes in tidal volume and respiratory
frequency in all other treatment groups are. to a considerable extent,
attenuated by the compensatory increase which occur in both.
It is desirable to consider whether the respiratory depressant
effects of morphine are due to the effect of the drug upon the state of
alertness or whether these two are unrelated. The measured respiratory
effects of soluble phenobarbitone - a drug which in all cases induced
moderate to marked drowsiness - suggest that drug induced drowsiness
would not per se cause any marked depression of ventilation. In any
event, this drug has a fairly specific, though rather slight* depressant
effect upon the respiratory frequency. Thus, the respiratory effects of
soluble phenobarbitone are in no way comparable with those of morphine.
The respiratory changes which occur during natural sleep or
drowsiness provide interesting data for comparison with the effects of
morphine. It has been known for some time that respiration is depressed
during sleep. Magnussen (1944) first showed that during sleep alveolar
carbon dioxide tension increased and the respiratory minute volume fell.
Many other workers have subsequently shown that ventilation is significantly
depressed during sleep or drowsiness, that alveolar or arterial CO2
tension is increased fcnd that the ventilatory response to carbon dioxide
is diminished (Robin, Whaley, Crump and Travis, 1958; Reed and
Kellog, 1958; Birchfield, Sieker and Heyman, 1959; Biilow and Ingvar,
1961; Biilow, 1963).
Ingvar and Billow (1963) and Billow (1963) showed very conclusively
by continuous monitoring of ventilation, F^CO^ and of the state of
wakefulness by E.E.G., that changes in the state of wakefulness are
very rapidly reflected in changes in ventilation and 1^ CO^- While,
during the steady state of normal alertness, only minor changes were
found in ventilation and P^. CO^, fhe former immediately fell and the latter
increased when the state of alertness was depressed.
Oxygen consumption was also markedly depressed during sleep
in one study (Robin, Whaley, Crump and Travis, 1958). However, in
another study (Billow, 1963) the reported changes in oxygenuptake were
more variable.
The measured changes in ventilation and arterial or alveolar
carbon dioxide tensions reported during sleep by authors publishing
detailed observations, as compared with the waking state have been
summarised in Table 31. These may be compared with similar changes
following the administration of morphine in the present study (Tables
11, 17; Figs. 2, 3, 26). With the exception of the report by Birchfield,
Sieker and Heyman (1959), the depression in minute ventilation has been
greater during sleep, and the increase in PaC02 or PACO£ comparatively
less than that recorded following administration of morphine. In
the only report providing readily accessible data (Robin, Whaley,
Crump and Travis, 1958) the depression in oxygen uptake has been
considerably greater during sleep than that recorded following any dose
of morphine used in the present experiments.
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Birchfield* Sieker and Heyman (1959) and Billow (1963) both
report a marked fall in tidal volume during sleep associated with a
slight average increase in the respiratory frequency. In the former
study the tidal volume fell markedly in each subject during sleep* the
respiratory frequency usually showing a slight increase and* only rarely
declining.
Billow (1963) noted also that the transition from wakefulness to
uninterrupted sleep was never abrupt and during this period respiration
and E.E.G. Evidences of alertness fluctuated somewhat. This recalls
the situation existing during the initial 14 minute post drug period when
ventilation and oxygen uptake are somewhat unstable in all treatment
groups.
It is thus evident that there are striking resemblances between
the primary respiratory changes induced by morphine and those which
occur as the result of sleep. In both states there is a marked fall in
ventilation caused primarily by a depression in the tidal volume. This
is associated with an increase in P^CO^. The respiratory minute
volume depression during sleep has* in the reported studies* usually
been appreciably greater than those caused by morphine in the present
study and the increase in alveolar or arterial carbon dioxide ttaxision
rather less* having regard to the degree of respiratory depression.
This difference is probably related to the fact - demonstrated for the
first time during the present experimental- that morphine increases oxygen
uptake and, in consequence, endogenous CO^ formation. The evidence
indicates that these usually decline during sleep. An unstable
transition state is also common to both conditions.
These changes are, in each instance, entirely different from
those which follow administration of soluble phenobarbitone. Thus,
the state of sedation per se has nothing to do with the respiratory effects
of morphine. These latter apparently relate to the activation of
mechanisms which normally operate during sleep so that, under morphine
narcosis, respiratory depression becomes dissociated from sleep - a
circumstance which accounts for some of the unique properties of the
drug.
These primary effects of morphine are exhibited in unmixed
form only during the later post drug period after a dose of 5 mg/70 Kg.
The effects caused by the larger doses, consisting of the additive
effects of depressant influences upon tidal volume and respiratory
frequency do not resemble the respiratory charges seen during any state
of drowsiness or sleep. Indeed, they do not resemble the respiratory
changes attributed to any family of drugs mentioned in the literature.
The above conclusions are strengthened by consideration of the
relationship between the depression in the state of alertness caused by
morphine andthe corresponding changes in ventilation and oxygen uptake.
The state of alertness was depressed by morphine in every
subject. Usually, overt signs of drowsiness appeared within five
minutes of drug administration, though occasionally a longer interval
elapsed. From the written records kept during each experiment
Tables 32 and 33 have been prepared. These attempt to relatedthe
changes in alertness, to the dose of drug administered and to changes in
ventilation and oxygen consumption. Although it appears that the
larger doses do cause a somewhat greater depression in the state of
alertness, this relationship is by no means striking. Computation of
2
Chi is, unfortunately, not strictly permissible because of the small
numbers expected in each cell^.
In Table 33 the changes in ventilation and oxygen uptake have
been placed in ascending order of magnitude of depression with the
corresponding rating for alertness underneath. There appears to be
no obvious relationship between these changes and the depression in
the state of alertness as recorded.
2
Chi so computed = 5.735, with 6 degrees of freedom- P = .50,
nearly.
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Significance of Hyperpnoea Following Morphine
The initial hyperpnoea which occurs after doses of 5 and 10 mg/
70 Kg. will now be discussed. There is little doubt that this is an
authentic drug effect. This may be inferred from the very striking
inverse relationship to the dose administered (Fig. 10) by the absence
of the slightest trace of such an effect after the administration of
soluble phenobarbitone, and. the almost invariable occurrence at this
time, in all treatment groups - whether or not hyperpnoea occurs -
of sensory symptoms, mainly paresthesiae involving the head, upper
extremities and upper portion of the trunk. It seems likely that
factors other than the dose administered contribute to the increase
in ventilation during the initial post drug period. The relationship,
albeit slight and statistically non-significant, to the variability of the
control ventilation and, particularly, the fact that hyperpnoea occurred
in all patients with left ventricular failure in contrast with its rarity
among normal subjects treated with the same dose - these suggest
that respiratory instability during the control period probably
influences the response.
Hyperpnoeaafter morphine administration has been occasionally
noted, usually without comment, by other workers. Among the normal
subjects reported in the present study, the phenomenon has been
regularly associated with an increase in oxygen consumption. There
seems little doubt that this initial stimulant effect must be the cause
of the increase in cardiac output not infrequently noted immediately after
administration of morphine (Drew, Dripps and Comroe, 1946; Fejfar,
Bergmann, Fejfarova and Valach, 1957).
Since morphine is a potent liberator of histamine (Feldberg
and Paton, 1950; Nasmytii and Stewart, 1950) it would be useful to
consider whether this substance might be responsible for the phenomenon
The time of onset - approximately 15-20 seconds after injection - would
be consistent with an histamine effect. Also, histamine causes over-
breathing and increased cardiac output and oxygen consumption (Lindeli
Soderholm and Westling, 1964). However, if histamine released endo-
genously were the cause of these events, the effects should be related
to body stores of histamine and not at all to the dose of drug. It is
possible that this is not a crucial objection. If the drug depresses breath
volume in its own right and concurrently released histamine which
increases ventilation, it is possible that the latter effect might be
dominant at lower doses and that the former might prevail after the large
doses. This cannot be ruled out, though the argument is rather
unconvincing. Would histamine stores be larger in persons with less
stable ventilation, for example, patients suffering from left ventricular
failure ?
Could this initial hyperpnoea be truly part of the respiratory
effects of the drug? This could well be the case. The initial effects of
the drug are clearly exerted at a very sophisticated level of respiratory
control - the master which fixes the breath volume. Possibly the drug
in its initial impact upsets the orderly handling and processing of data;
so that facilitatory and inhibitory impulses whether deriving from
physiological causes such as pulmonary congestion in heart failure
I
or histamine release after morphine* or from psychological causes
such as anxiety* J. for a brief period undamped. Of interest in
this connection is the observation of Seed, Wallenstein, Houde and
Bellville (1958) that the magnitude of drug effect appeared to be inversely
proportional to the alveolar Pdefining the position of their control
curve.
These notions are* of course* somewhat speculative but are
useful working alternatives to the rather inadequate hypothesis of
histamine release.
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Morphine as a Stimulant Drug
The evidence obtained in the present study that morphine has
stimulant properties will now be reviewed. Apart from the initial period
of hyperpnoea referred to previously, in some subjects associated with
very transient feelings of apprehension, there were no overt evidences of
drug stimulation in any subject.
The regression methods applied in the previous section provide a
method of separating the changes in oxygen uptake caused by changes in
ventilation from those due to other* causes. The estimates of r^ (Table 15)
indicate that under the experimental conditions approximately 35 - 50 7° of
variation in oxygen uptake is due to ventilation. Clearly, therefore, a
drug with the potent effects upon ventilation described in the preceding
sections should have caused a considerable fall in measured oxygen uptake.
Contrary to this expectation, it has been shown that the decline in measured
oxygen uptake has been very small, and, paradoxically, greatest in the group
which received the smallest dose. This discordance between changes in
ventilation and changes in oxygen uptake has been stressed by Krueger (1955).
The present study has shown that this can be satisfactorily explained.
The results suggested that the effect of morphine, in the doses
used, was threefold. First, it must be assumed from the regression
relationship (Table 15), that the drug depressed oxygen uptake because of
the depression in ventilation it produced. Secondly, there was an independent
depressant efect, presumably due to central "sedative" effects, which,
however, could oe showu to have occurred only during the later post-drug
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period after 5 mg/ /0 kg. Thirdly, doses of 10, 15 and 20 mg/?0 kg stimulated
oxygen uptake, at least during the later 45 minutes of the post drug period,
independent of any effects attributable to the change in ventilation. The analysis
suggested.that this last named effect is dose related. Consequently, because
of these simultaneously occurring and opposing effects, the net effect of
morphine in doses of 10, 15 and 20 mg/70 kg was no more than a slight fall in
the measured oxygen uptake (Table 11). These opposing actions would explain the
discordance between the change in ventilation and the change in oxygen uptake,
and thus the paradox that the smallest dose administered caused the greatest
depression in oxygen uptake. Further, in the 5 mg/70 kg group, an increase in
oxygen uptake occurred only during the initial 9 minutes of the post drug period,
when there occurred also, for part of this period, an increase in ventilation.
Proof that morphine stimulates metabolism does not rest solely on the
foregoing analysis of the changes in measured oxygen uptake after drug adminis¬
tration. The measured changes in carbon dioxide output and arterial PCO^
provide excellent collateral evidence in support. Thus, it was shown that while
changes in carbon dioxide output were, in part, and as would intuitively be expecte
related to the decline in ventilation, regression analysis demonstrated that there
was, simultaneously, an apparent increase in CO output which was independent
c*
of any changes due to the depression in ventilation. These observations are
best explained by the assumption that an increase in endogenous CO^ formation
occurring simultaneously with the decline in ventilation, limited the measured
fall in carbon dioxide output. Further, the present study has shown that the
measured increase in PaCG after morphine is more closely related to the
c
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afore-mentioned increase in metabolism than to respiratory depression . The
control regression relating arterial PCG and alveolar ventilation (Pig. 29)
clearly indicates how little arterial carbon dioxide tension would have increased
if the drug had no greater respiratory depressant effects^ than those demonstrated.
The notion that morphine increases oxygen uptake, though seemingly
novel, is consistent with certain other reported observations. As pointed out
in the review of the literature, a measured increase in oxygen uptake has,
on occasion, been recorded after morphine administration, both in man and
jn laboratory species. The effects of morphine upon body temperature, which
have been fully reviewed by Reynolds and Randall (1957) are also consistent
with the view that morphine, in some species, causes an increase in heat
production. However, the net effect upon body temperature and heat production
in man and in most laboratory species, has, in the majority of studies reviewed,
been a variable decline. These ^>parently contradictory findings reported in the
literature could be explained, in part, by the three-fold effect of the drug upon
f
metabolism demonstrated in the present study.
The hyperglycaemic action of morphine, which has long been known to
occur in man and in laboratory species (Reynolds and Randall, 1957) would also
be consistent with the hypothesis that the drug is a metabolic stimulant.
There remains to be considered how the increased metabolism induced
by morphine might be achieved. Firstly, it is possible that these effects, like
those upon respiration, are centrally mediated. There are other known effects
*
See pages 105 - 107
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of the drug, which appear to involve stimulatory rather than depressant functions,
namely, the release of ACTH and of anti-diuretic hormone, both of which appear
to be centrally mediated (de Bodo, 1944; Nasmyth, 1954). Nevertheless, it is,
on present information, very difficult to explain how the drug might simultaneously
depress some systems and stimulate others. It may be of relevance, however,
to point out that some central nervous system may be of relevance, however, to
point out that some central nervous system lesions produce simultaneous depression
of one type of function and exaltation of another - for example, the co-existing
voluntary motor deficit and increase in muscle tone noted after lesions of the
pyramidal tracts and in paralysis agitans.
Another possibility is that endogenously released histamine may be
responsible, in part, for the metabolic effects of morphine. In experimental animali
morphine is known to be a potent liberator of histamine (Feldberg and Paton, 1950;
Nasmyth and Stewart, 1950). Although liberation of histamine has never been shown
by direct measurement to occur in man, such liberation is likely. At any rate,
certain phenomena occurring after administration of the drug, namely, conjunctival
and palpebral erythema, puruitus, borborygmi and flushing of the face and upper
part of the trunk, are consistent with histamine effects. Further, histamine causes
hyperpnoea, increases measured oxygen uptake in man (JLindell, Soderholm and
Wealing, 1964), and is known in laboratory species to stimulate adrenal medullary
and cortical activity (Evans, Nasmyth and Stewart, 1952, Nasmyth, 1954). It is
thus possible that the early hyperpnoea observed in many patients and the dose
related increase in oxygen uptake may, in part, be attributable to histamine
endogenouslv released by the drug* However, since histamine is very
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rapidly destroyed in the body, such release would not explain the sustained
increase in metabolism recorded after the larger doses.
The peripheral vaso-dilatation so regularly produced by morphine
would be a source of heat loss. Even though body temperature has frequently
been reported to be lowered by the drug (Reynolds and Randall, 1957), the
heat loss so caused might well induce a compensatory increase in metabolism.
It cannot be stated whether or not this does occur. It would be useful to find
out whether any increase in metabolism occurs after administration of vaso¬
dilator drugs devoid of narcotic effects, for example papaverine; and, also,
whether attempts to minimise heat loss would affect the increase in oxygen
uptake caused by morphine. It would be important too to restudy in man, the
effects of morphine upon body temperature since it is not known whether the
recorded effects are to be attributed to a central action on temperature regulation
or to increased heat loss secondary to peripheral vaso-dilatation.
In conclusion, it must be admitted that, while the inference that morphine
increases oxygen uptake and endogenous carbon dioxide formation has been fully
Supported by the data presented, a satisfactory explanation of the manner in
which this is achieved must await the acquisition of additional data. In particular,
it would be important to study, in the human, other indices of metabolic stimulation
particularly changes in blood sugar and free fatty acid levels, and, to measure
directly changes in adrenal medullary and cortical function after administration
of morphine to human subjects.
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Significance of the stimulant effects of morphine
It is evident from the observations presented that morphine# in
doses greater than 5 mg/70 kg# exerts a sustained stimulant effect upon
metabolism pari passu with its depressant effects upon respiration.
Consequently# the former effect must# to some extent# antagonise the
latter and there is much evidence that this occurred. For example# it
has been shown that further depression in tidal volume was arrested and
some increase occurred in the 10 and 15 mg/70 kg groups. The apparent
levelling off of the effect upon respiratory minute volume at 15 mg/70 kg
is likely also to have been due to this antagonism between the two
independent drug effects. Miller# Gilfoil and Shideman (1955) working
with rabbits and Kokka# Elliott and Way (1965) working with rats also
report a similar tendency for large doses of morphine to become decreasingly
effective in depressing respiration.
Thus# it appears conclusively to have been shown in the present
study that morphine is its own antidote# so far as respiratory depression
is concerned. It is an astonishing and unique situation that the same
drug should, as entirely independent effects, depress the state of alertness
and respiration and stimulat e metabolism.
The idea that morphine produces a mixture of depressant and
stimulant effects which antagonise each other was first foi'mulated by
Tatum, Seevers and Collins in 1929- These workers pointed out that,
while monkeys treated with very large or moderate doses of morphine
frequently died in convulsions or depression respectively* animals treated
with intermediate doses appeared to fare better. From this it was inferred
that in these surviving animals the stimulant effects "pretty well" counter¬
balance the depressant effects* thus serving as an antidote. As a result
of experiments on a variety of laboratory species Tatum, Seevers and
Collins concluded that 'morphine has a dual effect consisting of a strange
mixture of simultaneous stimulation and depression on different parts of
the central nervous system.' They suggested that manifestations of
stimulation were referable 'directly or indirectly to increased activity
of the cord and certain regions of the brain (miosis, vagal slowing of the
heart and, after larger doses, marked direct or indirect reflex excitability
of the cord).' They made the important point from their own experiments
that the experimental animals (rabbit, cat, dog) die after a period of
convulsions and that the depression caused by the smaller doses is not of
sufficient depth to cause death.
Neither the experiments of Tatum, Seevers and Collins (1929)
nor others reported in laboratory species are comparable with those
reported in the present study. The doses of morphine used were massive
by comparison with those ordinarily used in man or administered during
the present series of experiments. The marked overt signs of stimulation
noted in laboratory species were not witnessed in Our own studies nor
have such effects been documented in the literature in human subjects.
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Nevertheless* the views of these workers appear to be essentially
correct. In so far as the effects of the drug in man are concerned* the
position may be restated as follows. Morphine* among its other effects*
independently depresses respiration and the state of alertness and
stimulates metabolism. The respiratory depressant and the metabolic
effects are each related to the dose administered. These stimulant effects
upon metabolism could well be responsible for the compensatory changes
in tidal volume and respiratory frequency which were shown to occur after
administration of doses in excess of 5 mg/70 kg. They might also be
responsible for the apparent - probably real - tendency for the depression
in respiratory minute volume to level off at 15 mg/70 kg* and would presumably
also antagonise the depressant effects upon the state of alertness.
It must not be thought that the stimulant effects upon metabolism
are solely responsible for limiting the degree of respiratory depression
caused by the drug. Other intrinsic central mechanisms must presumably
also exist - these appear to be very effective in limiting the respiratory
depression caused by soluble phenobarbitone.
While some part of the increased oxygen uptake caused by morphine -
particularly that during the early post drug period - may have been secondary
to adrenal medullary stimulation from released histamine* this cannot
account for the sustained increase in metabolism which was recorded after
all doses larger than 5 mg/70 kg. It is very probable that, like the
respiratory depressant effects, this stimulus to increased me tabolism is
161
centrally mediated. Nasmyth (1954) and Brigge and Munson (1955) have
reported good evidence that* in rats* the drug acts centrally to cause
release of ACTH. It is also known to act centrally upon the hypothalamo-
hypophyseal system to inhibit water diuresis (de Bodo* 1944). It is to be
noted that all these effects of morphine relate to interference with a very ^
t.
sophisticated control mechanism. Possibly* this might apply also to its ^
/
analgesic effects. There is no peripheral cr medullary mechanism
which would adequately explain any of these effects and no hypothesis
based on some single locus of action would fit the facts. Although the
observed effects of morphine appear to differ from one another in quality
and direction* it is not necessary to postulate a different mode of action
centrally for each of these effects individually.
Similar apparently contradictory effects of established central
nervous syttem lesions are the rule rather than the exception and there
seems no reason why this should not also occur with the temporary and
reversible lesions of drug intoxication. For example* the statement that
'lesions of the basal nuclei frequently depress voluntary motor function
while stimulating muscle tone and involuntary activity' is, formally true,
but, as it happens to be known, valueless in practical terms.
These considerations perhaps indicate why the search for analgesic
members of the opiate family of drugs which are free of respiratory depressant
properties or addiction liability has been entirely unsuccessful. It is to be
feared that the search may be as hopeful as that for perpetual terrestrial motion.
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Mode of Action of Morphine in Patients with Left Ventricular Failure
The respiratory and metabolic effects of morphine in the group of
patients suffering from left ventricular failure will now be evaluated. As
a group these patients exhibited a larger respiratory minute volume and
oxygen consumption prior to drug administration than normal subjects.
There was evidence of some degree of respiratory instability but they
were metabolically no less stable than the normal group.
Despite a considerably larger respiratory minute volume during the
control period the oxygen consumption was only slightly greater than that
of the normal group. It was shown by regression analysis that the oxygen
uptake in the group of patients suffering from left ventricular failure was
significantly less than that of the normal group in relation to the level of
ventilation achieved (Fig. 34, 35). Since the oxygen cost of increased
ventilation and the work of breathing at rest are greater than normal in
patients with aongestive cardiac failure (Cherniack, Cuddy and Armstrong.
1957; Hoeschen, Gold. Cuddy and Cherniack. 1962), the energy expended
on pulmonary ventilation must, therefore, be a considerably greater proportion
of the total energy requirements than is normally the case. This
observation is consistent with the theoretical calculations of Otis, Fenn
and Rahn (i960).
The effects of morphine in this group of patients consisted of, (1) the
relief of dyspnoea as a subjective sensation (despite the persistence of
relatively high levels of respiratory minute volume), (2) a marked fall in




There can be no question of the effectiveness of morphine in
relieving the discomfort of dyspnoea and* probably* no ether family of
drugs will achieve this end as efficiently.
Although the decline in ventilation is significantly greater than
that which occurred in normal subjects vho were treated with the same
dose of drug, tachypnoea -with relatively large respiratory minute volumes
persist in these patients (Table 24; Fig. 32).
The changes in oxygen consumption cannot be considered as
qualitatively different from those occurring in normal subjects. The net
decline in oxygen uptake is significantly greater than that which occurred
in the normal subjects treated with the same dose. This is* no doubt* to
be explained by the significantly greater decline in ventilation. In this
group also* the drug stimulates metabolism. The increase in oxygen
uptake attributed to the drug as an independent effect is apparently greater
in this group than in the normal treatment group.
/
As in normal sutgects also it seems likely that the increase in
oxygen consumption contributes appreciably to the increased arterial
carbon dioxide tension after morfhine.
Patients with left ventricular failure treated with morphine would
benefit by the reduction in the energy requirements for breathing. While
the drug stimulates metabolism* the net effect is a decrease in oxygen
consumption consequent upon the marked fall in ventilation. In patients
suffering from acute pulmonary oedema the fall in oxygen uptake would,
of course* be even greater than that recorded in the present study. Thus
the drug decreases, very considerably, the proportion of total energy
requirements devoted to maintaining pulmonary ventilation. While
patients will, no doubt, benefit from this reduction, it is not known whether
this will necessarily contribute appreciably to relief of pulmonary
congestion.
It is poaible that patients with marked tachypnoea such as is seen
in acute left ventricular failure might derive immediate benefit from the
decline in minute ventilation caused by the drug. Rowe. Castillo and
Crumpton (1962) reported that in human subjects active hyperventilation
caused significantly reduced coronary blood flow with reduced coronary
sinus oxygen tension - findings which they interpret as indicating probable
myocardial hypoxia. Yamamoto and Maclver (i960) reported also that
sustained high levels of ventilation induced by continuous CO^ infusion in
rats caused pulmonary oedema and heart failure.
Be that as it may. some saving in energy expended has been achieved
at a price which has now to be evaluated. The fall in ventilation and, even
more, the increased CO formation consequent on the me tabolic effects of
M
morphine will cause a marked increase in P^CO^. This occurred in the 3
patients in whom arterial gas tensions could be measured and, presumably,
would invariably occur. Many patients with left ventricular failure.
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particularly those severely dyspnoeic, would have a low or low normal
P CO prior to drug administration so that dangerous levels of P CO
8> M M
and of arterial pH after morphine would probably not be common (Fig. 30).
It is of some historical interest that Fraser (1923) suggested that this
increase in CO^ tension from hypocapnic levels might itself improve
cardiovascular function in patients with cardiac dyspnoea.
There seems no doubt# however, that significant or even marked
hypoxaemia would develop in patients treated with morphine alone. Whether
or not this is an acceptable price to pay vo uld depend upon the aetiology of
heart failure and upon the other therapeutic measures concurrently offered.
In patients with left ventricular failure secondary to myocardial infarct or
ischaemic heart disease marked hypoxia would probably be considered
unacceptable. It would be safer to offer such individuals small doses which
would relieve dyspnoea but not reduce ventilation markedly. The
concurrent administration of oxygen and digitalis would in any case be
recommended.
In each of the patients studied# a moderate or marked increase in
ventilation occurred immediately after administration of morphine. It
has been recorded previously that there is reason to think that respiratory
instability during the control period may predispose to the occurrence of
post drug hyperpnoea. If this surmise is well founded - as it appears to
be - it follows that the majority of patients in left ventricular failure,
particularly those with acute pulmonary oedema, will exhibit some
hyperpnoea after an appropriate dose of morphine. It seems probable that
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this initial stimulatory effect of the drug is responsible for the increased
cardiac output reported by Fejfar, Bergmann, Fejfarova and Valach (1957)
which these authors mistakenly attribute to a specific action of the drug in
patients with low cardiac outputs.
Could this marked initial stimulation contribute to improved cardio¬
respiratory function? The changes which occur at that time may well
convey the impression of dramatic clinical improvement and it is by no
means improbable that such improvement does in fact occur. This initial
period of hyperpnoea coincides with the flushing of the face and upper
extremities which occurs in all subjects treated with morphine intravenously
whether or not overbreathing is present. Hyperpnoea, peripheral vaso¬
dilatation and increased cardiac output during the first minute or two
following intravenous administration could conceivably contribute significantly
to lung drainage. Because of the greatly increased ventilation hypoxia,
where present before administration might be reduced or, at any rate, its
inevitable later development is postponed. Thus, time is purchased during
which other more slowly acting measures can be offered.
The rapidity with which patients who do benefit improve after
administration of morphine intravenously suggests that this may be the
chief contribution of the drug to clinical improvement. Other drug effects,
particularly the relief of tachypnoea and the consequent fall in the energy
requirements for breathing no doubt help over the longer term. Nevertheless
the price exacted must be balanced against this saving in oxygen
requirements - particularly the inevitable hypoxia.
It is necessary* once more* to stress the point that the clinical
use of morphine in left heart failure has new been rigorously evaluated.
Such evaluation is needed* particularly since measurements of pressure
changes in patients with acute pulmonary oedema after administration of
the drug do not always show improvement (Scebat and Lienegre* 1949;
Fejfar* Bergmann* Fejfarova and Valach* 1957; Finlayson* JLuria*
Stanfield and Yu* 1961).
Nevertheless* it is to be expected that morphine wll continue to
be used in the treatment of left ventricular failure and particularly in the
acute type of this disorder. The results of the studies here reported
suggest that the improvement to be expected derives mainly from the
initial stimulant effect upon ventilation associated vi th probable peripheral
vasodilatation and* in many cases presumably an increase in the cardiac
output. Moderately and severely dyspnoeic patients will no doubt benefit*
in the longer term* from the reduction in the energy requirements of
breathing and from the rapid relief from potentially dmgerous effects of
hyperventilation itself. Because of the inevitable hypoxia and because
other more specific and effective therapy is usually available* the large
doses of morphine recommended by traditional teaching (Hamilton* 1955)
should probably be avoided. On the basis of the observations on normal
subjects, it would appear that doses in excess of 5 mg/70 kg should
probably not be offered to patients suffering from left ventricular failure.
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QENERAE CONCLUSIONS AND CLINICAL IMPLICATIONS
While the experiments described in the foregoing account have
solved some problems relating to the effects of morphine in man,
other questions have, perforce, been left without clear answer.
The results reported explain the fact - suggested by clinical
experience - that morphine, despite the potency of its clinically
unwanted effects, is a comparatively safe drug. In antagonism to the
additive effects upon the breath volume and respiratory frequency, the
drug fortunately produces simultaneous effects limiting the respiratory
depression which occurs after ordinary therapeutic doses so that this
does not attain the degree which commonly occurs during natural sleep.
Even the very large doses which were routinely used in the past would
probably not cause dangerous respiratory depression in fit persons
because of the flattening of the dose/effect slope which almost certainly
occurs above 15 mg/70 kg . Another reason for the conxparative
safety of the drug would be that, at the selective altered levels of PaCO
M
and breath volume, efficiency of homeostasis is probably not impaired
after ordinary therapeutic doses.
On the basis of these results there would be theoretical reasons
for supposing that the analgesic effects of morphine are mediated in a
manner similar to its respiratory depressant effects. In that evant,
it would seem that the optimal dose of the drug for clinical relief of
pain would be of the order 5-10 mg/Kg. Larger doseae, while not
likely to carry any significant iisk to persons with normal pulmonary
function are probably wasteful. In recent years it would appear that
the 10 mg. analgesic dose has in practice become a standard for
routine use.
A very important result of the study has been the demonstration
that increased levels of arterial carbon dioxide tension after morphine
are related mainly to the action of the drug as a metabolic stimulant
and in relatively slight degree only to the decline in ventilation. This
observation would explain why the drug, which does not in normal
individuals depress minute ventilation more than occurs during natural
sleep, can be dangerous to patients suffering from chronic pulmonary
insufficiency. Since such individuals have difficulty - due to
established anatomical or functional changes - in eliminating carbon
dioxide, the increase in endogenous formation caused by the drug
will frequently lead to dangerous levels of P CO, and a consequent
a «
fall in arterial pH to acidotic levels. That hypercapnia and respiratory
acidosis rather than primary respiratory failure is the cause of death
in many of these patients treated with morphine is suggested by
published clinical descriptions (Samuelsson. 1952). It is noteworthy that,
almost invariably, the deaths reported in this publication occurred
several hours after the administration of ordinary therapeutic doses of
the drug.
In cardiogenic shock also* when a marked metabolic acidosis
is frequently present (Mackenzie, Taylor, Flenley, McDonald* Staunton
and Donald* 1964; Mackenzie* 1965)* the use of morphine may well cany
potential dangers. However* there do not appear to be any clinical
reports bearing on this point.
The observations on patients suffering from left ventricular
failure offer* for the first time, a plausible working hypothesis based
on quantitative data. Previous experiments on the effects of morphine
in patients suffering from left heart failure - the great majority of
modern studies having been performed on patients with mitral valve
disease - have been essentially negative. The present study has
recorded a modest but very definite advance in two respects. First*
it has shown the necessity for a full evaluation of the role of morphine
in the clinical management of patients suffering from left ventricular
failure; and, secondly* analysis of the continuous measurements
recorded has focussed attention upon three possible mechanisms through
which clinical improvement, when this occurs, might be mediated.
Most of the objections raised by Krueger (1955) to the generally
held opinion that morphine depresses the respiratory 'centre' have been
met by the results of the present study. Krueger stressed* in
particular, the fact that the respiratory depression caused by morphine
was always less than the change in oxygen consumption in laboratory
species and in man. He was also puzzled by the occurrence, in some
reported experiments, of an increase in respiratory minute volune and
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oxygen consumption. These observations are all adequately explained
by the results of the present study. Another point to which Krueger drew
attention was the fact that repeated doses of morphine administered to
laboratory species cause, not further respiratory depression, but
stimulation. This is fully explained by our demonstration that morphine
is a potent metabolic stimulant and is, in fact, a striking retrospective
confirmation of one of the main findings of the present investigation.
Krueger was led to conclude that morphine depressed respiration - when
this occurred - by depressing metabolism. It is evident, however,
that this hypothesis cannot be correct, since it has been conclusively
shown in the course of the present investigation that the drug has
independent and opposite effects upon respiration and metabolism. In
retrospect it would appear that many of the equivocal observations in
the past are to be attributed to the practice of administering morphine
in repeated doses during the same experiment.
An historically Interesting consequence of the present work is
that it has been possible to restate the "dual action" hypothesis of
Tatum, Seevers and Collins (1929) in relation to man. While the concept
of a true dual action appears not to be accurate, the conclusion of
these workers that morphine is its own antagonist appears, so far as
respiratory depression is concerned, to be essentially correct. It
is strange that data in support of their ideas have not previously been
obtained from observations on human subjects.
It may seem curious that, throughout this report, no mention
\
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has been made of one of the common respiratory effects of morphine,
namely, the induction of periodic or Cheyne Stokes breathing. This
omission has been deliberate |md for the following reasons. In the
present study obvious disturbances of the rarpitatory rhythm have been
noted in the spirometer records only among subjects who received 10
or 15 mg/70 Kg. morphine. In some of these subjects periodic
respiration resembling classical Cheyne Stokes breathing developed
for varying periods of time. At other times and in other subjects
other types of irregular breathing appeared. Similar disturbances
were not seen in any of the subjects treated with 5 or 20 mg/70 Kg.
Analysis of these disturbances of rhythm is likely to be a difficult
problem not capable of solution by the methods used in the present
investigation. This problem may be stated in concise form as follows.
What is the effect of morphine upon the respiratory cycle and how does
this compare with the effects of other drugs and with changes occurring
physiologically, for example, during drowsiness and sleep.
Changes in the respiratory cycle cannot be explored adequately
by the simple technique of breath ennumeration because, while this
provides an estimate of the mean length of the respiratory cycle, other
variables, for example, the individual cycle lengths, the length of
non-breathing periods or pauses and their relationship to changes in
the individual breath volumes, cannot be estimated in this way. It is
evident that the solution of this problem will require further analysis
and, perhaps, additional data. The writer has undertaken some preliminary
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work by the method of treating successive individual breath volumes as a
continuous time series on the simple assumption that inequalities in
the duration of individual cycles can be ignored. Under very steady
conditions there is a slow oscillation of low amplitude about a mean value
so that) in this sense, periodic breathing is a normal phenomenon of the
waking state. This periodicity is essentially unaffected by morphine in
a dose of 5 mg/70 Kg. - confirmation, incidentally, that the primary
effect of the drug is upon the breath volume and not upon the respiratory
cycle. It was found, however, that when less than very steady conditions
prevailed - as assessed by the variability of the individual breath volumes
- the duration of the cycle length cannot be ignored. Analysis will
therefore involve more extensive work than could be undertaken within
the limits of the present project.
Although the studies with soluble phenobarbitone were designed
to provide more rigorous experimental control for the main project*
the results are a useful addition to the rather scanty literature on the
respiratory effects of barbiturate drugs. They show very definitely
that the rather mild respiratory depressant effects of soluble phenobarbitone
are produced by an entirely different mechanism, both from those caused
by morphine and from those which occur during natural sleep. The view
that barbiturates are potent respiratory depressant drugs (Goodman
and Gilman, 1965) does not seem to have been borne out by the results
of the present study. However, rather similar results have been
published by Eckenhoff. Helrich and Hege (1955) for Seconal and by Keats
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and Beecher (1952) for pentobarbital sodium. In the former study the
drug produced no very definite changes in respiration or PaCO^ in
the three subjects studied. In the latter* minute volume and respiratory
i
rate* measured in 15 subjects* fell by about two and a half per cent and
oxygen consumption by about five per cent one hour after drug
administration - findings not very dissimilar from our own. Curiously*
in this latter study the respiratory sensitivity to carbon dioxide* as
measured by conventional methods* \tfas increased by the drug* despite
the definite respiratory depression revealed by the other d&ta.
Finally* the results fully justify the critical attitude shown
during the review of the literature towards the use of CO^ response
curves as a measure of drug action. It is evident that the failure to
make orthodox measurements of respiratory variables, particularly in
relation to time* would have resulted in the loss of very valuable
information. The data further cast doubt upon the supposition that
morphine causes any change in the sensitivity of the respiratory apparatus
in any meaningful physiological sense. Indeed, it would appear
doubtful that the study of CO^ sensitivity curves* as at present computed,
serves any useful experimental purpose.
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Table 1
Personal Particulars
Normal subiects in the treatment groups










Reason for admission to
hospital
5 mg/70 kg morphine W.B. 23 170 56.5 1.64 Renal colic
F.G. 35 187 71.4 1.94 Peripheral sensory neuropathy
w 'i.;,
V V « —« 55 170 74.5 1.85 Hypertension
Recovered left kemiparesis
G. k. 46 178 66. 3 1. 82 Duodenal ulcer
M.W. 46 169 69.8 1.80 Chest pain of uncertain causation
(myocardial infarct excluded)
J.H* 37 170 67.5 1.77 I Hiatus hernia
10 mg/70 kg morphine A.W. 40 177 72.5 1.89
1
j Myocardial infarct (two weeks
before study)
v 4 . H. 54. 1,5 75.5 1.82
i
Hype rtension
| G.F. 30 173 65. 5 , 1.77 Cnronic duodenal ulcer
vv » .J • 32 180 80.0
!
1.98 1 Hiatus hernia
Anxiety symptoms.
A. McK . 49 187 70.1 1. 93 Hype rtens ion.
Vv ah. 31 171 65.4 1.76
|
' For investigation of vomiting
| Mild dejjressive illness
J.N. 47 17 2 74.0 1 I.80 ; Hypertension
R.M. 32 177 62.0 I. 81 ; Ureteric calculus
I. 5,
(female)
32 18 2 84. 0 2. 04 ; Hiatus hernia
15 mg/70 kg morphine J. R.. 45 170i i 0 71.1 1.87 Duodenal ulcer
J. P. 65 174 71.8 1.85 Prolapsed intervertebral disc
J.G. 42 186 84.7! > 2. 08 Myocardial infarct (3 weeks
previously)
A. Ivi. 49 174 74. 5 1.89 Hype rten s ion
Transient left-sided weakness
\'r n
J * Zvicxs.« 41 173 69-9!>1.82 Spastic paraparesis
Cervical disc protrusion
/ *
A.N. 65 171 69.5 1.31 Myocardial infarct (4 weeks
previously)
H.S. 52 174 8i. 5 1.97 Hype r tens ion
Recovered cerebrovascular
accident (Brain stem)
V7.I. 62, 175 76.15 1.91 Cerebellar cortical degeneration
G.N.
(female)
62 152 41.0 1. 32 Dpilepsy (minor attacks)
20 mg/70 kg morphine J . R » 42 171 68.5 1.80 1 Pyrexia of unknown origin
C.R. 62 167 90.7 1.93 1 Spastic paraparesis
Cervical spondylosis
J • -i—'. 53 170 66.8 1. 76 Epileptiform attack
W. F. 40 173 o7.8 1.80
|
Viral pericarditis (3 weeks
previously)





220 mg (3.4b mg/kg) G.M. 38 171 63.5 1.74 . iinxiety symptoms
220 mg (3. 64 mg/kg) A. McD 60 177 60. 5 1.75 s For investigation of epigastric pain
255 mg (3.15 mg/kg) A.. M. 44 171 81. 0 1 Q2JL • / h* | Myocardial infarct (2 weeks
previously)
212 mg (3.14 mg/kg) J.C. 62 175 67.6 1.82 Transient right upper limb
weakness
Patients in left ventricular failure
given morphine 15 mg/70 kg
A • O • 61 173 70. IE 1.32
t
Ischaemic heart disease
Recent rx.iyo cardial infarct
D. McA 30 168 68. 5 1.77 Hype rtens ion
R.McI. 60 169 o5. 0 1.73. Hype r ten s ion
A.M. o2 165 59. 2 1. 64 Ischaernic heart disease
E. S.'
(female)
7! 165 55. 0 1.59 Myocardial infarct
A. G.
(female)
60 154 68.7 1. 67 Hypertension
r
Table 2
Statistics relating to age- Control (pre-drug)
Observations in and •variability in control ventilation and oxygen consumption



































































































Totals - All normal
Treatment groups




















4.155(3,24) 2.936(3,24) 1.089(3,22) 1.170(22,3) 1.810(3.24)
F values .025 > P >
.01
.1 > P > .05
.
Tfl8l6 3
MINUTE VENTILATION, RESPIRATORY RATE, TIDAL VOLUMES, 0„ UPTAKE AND CC„ EXCRETION (DIIPIIU1D AIR)


















































































































































































































































































































































































































































































































































7 . V- '' „ '
TABLE 4
MINUTE VKNTILATIO N» RESPIRATORY RAT 35^ T 1 D A l V 0 L i! H 2 3t Og UPTAKE AND C 0^ B K C R >'-> T ION {.HXFilial) AIS)
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K I 8 U T S VEST I L AT 10 N, EE3PIEATORY EAT S,
H8ASURSHSKT3 DURING S0CCS33 IYS FOUR
T IDA L V 0 L U M B St 0V} UPTAKE AND C 0_ ISC88TI08

















































































































































































































































































































































































































































































































































































































































































































































































































































MINUTE VENTILATION, RESPIRATORY RATE, TIDAL VOLUMES, Og UPTAKE AND C Og EXCRETION (EXPIRED AIR)





Measurement Control Periods Control Post Drug Periods
1 2 3
_!









































































































































































































































































































































































CHANGES I N M SHOTS TSHTILA7I0N, SUPISATOR?
>2
A T TIDAL VOLUME
02 UPTAKE AND COg EXCRETION AFTER 5ag/70Ife MORPHINE
2
Minute Ventilation L/k B.T.P.S. Respiratory Rat© Breaths/®in. Tidal Volumes 1. B.T ,P.S. Og Uptake L/»in./»2 S.T .P.D.
NAME CONTROL POST DRUG CHANGE •t* VALUE DEGREES OF
FREEDOM
CONTROL POST DRUG CHANGS *t* VALUE DEGREES OF
FREEDOM
CONTROL POST DRUG CHANGE 't' VALUE DEGREES OF
FREEDOM























































































-.232 2.000 58 12.42 t .61
(2.11)
12 *13 * *3S
(2.60)


























- ' /v ****
3.022


























(1) Just short of 5% level of significance
*
***
significant change .05 > p > .02
significant Change .02 > p > .01
significant change .01 > p > .001
**** significant change p < .001








CHANGES I II MINUTE VENTILATION, EE SPIN A TORT RATE, TIDAL VOLUMES,
02 UPTAKE AND COg EXCRETION AFTER 5ag/7QK& MORPHINE
Respiratory Rata Breaths/®in. Tidal Voliaaas I. B.T 00 Uptake L/ffiin./®2 S.T.P.D. <*>2 Excretion L/isin. S.T.P.D.
CONTROL POST DRUG CHANGE 't* VALUE DEGREES GT
FREEDOM
CONTROL post mm CHANGE »t' VALUE DEGRESS OF
FREEDOM



































































































































































(1) Just short of 5% level of significance i:-■.
* significant change .05 > p > .02
** significant change .02 > p > .01 - • ; ' '-i
*** significant change .01 > p > .001
**** significant change p < .001
Other ' t' values are not significant at 5% level. .• -A • J; - •' v. ' •'
timp a
CHANGSS II N I It II T S ( « I I I I I I I « I, 1ISHIIJ0H! EATS, TIDAL IOLIIIS,
|









NAME CONTROL post mm
......
^
CHANGS •t' VALUE DEGRESS OF
FREEDOM
CONTROL post mm CHANGS 't' VALUE BSGREB3 OF
FREEDOM
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CHANGES II MINUTE VENTILATION, USHIIIOII HATE, TIDAL VOLUMES,
!
Cv, UPTAKE AMD COg EKEETIOS AFTER Iteg/TOKfe MORPHINE





CONTROL POST DRUG CHANGS »t* VALUE DEGREES OF
FREEDOM
CONTROL POST DRUG CHANGS'
,—_. , . , „ "
. ■




POST DRUG CHANGE *t* VALUE DEGREES OF
FREEDOM
CONTROL POST DRUG CHANGE
V































































































































































CHANGES IN MI HUTS VENTILATION, R K S P IH A T C # E A T TIDAL VOLUMES,
C2 UPTAKE AND CO? EXCRETION AFTER 5mg/70Kg MORPHINE
-
t., .
Minute Ventilation IVM3 DTPS Respiratory Rat© . - Breaths/Min. Tidal VoIukq L BTP3
< °2 L/M"/»in, STPD C02 Excretion I/Min. STPD
NAME CONTROL POST DRUG CHANGE 't' VALUE DEGRESS OF
FREEDOM
CONTROL POST DRUG CHANGE
,
't' VALUE DEGREES OF
FREEDOM






CONTROL POST DRUG CHANGE »t* VALUE DEGREES OF
FREEDOM
CONTROL POST DRUG CHANGE *t* VALUE BEGUM" : OF
FREEDOM
J.R. 5,092'- ,0005 4.530-.0420 -.582 0.210 58 18.25-,31 15.00-.16 -1.25 3.469 58 .5717^.0107 ,5512-.0033 -.0205 2.200 58 .1570-.0035 .1456^.0018 -.0114 2.815 13 ,2053^.0035 .2283-.0029 - .022 , 3,548:-'i 13
J.P. 4.016-.142© 3.007-.0538 -.919 7.124 58 11.90-.43 10.03-.16 -1.88
:
4.803 54 .5983-.0255 .5663"t.0105 -.032 1,306 58= ,1227-.0017 .1139^.0022 -.0088 1.913 13 .2017-.0037 . 1783-.0042 -.0234 2.647 13




51 .3426^.0034 .3850-.0054 +.0424 3,855 51 .1230-.0025
'
, 1255-.0025 +.0025 . .472 13 ,1317-.0019 .1266-.0037 -.0051
■ j
.671 i:
W.I, 4.607-.0490 3.558-.0342 -1.139 15.646 53 18.91-,44 14.94~.178 -3.97
"
9.370 .50 .4697-.0063 .4503^.0042 -.0194 2.153 5£ .1357^.0017 .1234^.0015 -.0123 3.785 13 .2290^.0027 .1868^.0023
• -- V <f!-
• 1 J
-.0422
|- • ;.o -;i
0.866t i:
J.McK . 5.363-.0098 4.805-.0469 -.498 49.602 58 17,42-.40 16.54-.14 -.825 2.53 58
'
,
.5351-.0089 .5221^,0034 -.013 -1.615 58 , 1517-.0044 .1473^.0019 -.0044 1.00 13 .2120.- .0029
•; • -<,V . s.~:
l.P4l988t.0018 -.0132 3,350 13 )
A.N. 5.035-.0524 4.163-,0588 -.872 7.207 58
'
21.83-.41 18.50- .25 —3.33 6.253 86 - .4008^ .0058 ■ .4016^.0061 + .0008 .084 58 .1180- .0013 .1157-.0020 -.0023 .780 18 .1607-,0032 -.0110 2.315
. ' . • ' •; -
3
J .0. 4.104-,0612 3.721-.0454 -.383 3.985 58
'











1.069 13 ,2003^.0002 .1898^.0022 -.0103 2.370 13
A.M. 4.451^.0899 3.889-.0349 -.562 6,787
■
58 19.07-.51 18.00t.23 -1.67 3.163 S3 .4231—.0073 ,4076- .0055 -.0155 1.348 5f , 1290-*0023 f " +i1313-.0013
•• ' ' •
+.0023 ,821 13 .1993^.0035 .1931^.0035 -.0062 .850 13




.1317^.0025 + .003 .571 13 .22ot,0015 .2065-.0032




CHANGES IN MINUTE VENTILATION, RESPIRATOR
Og UPTAKE AND COg EXCRETION AFTER
- - -*$-
Minute Ventilation I/2T BTP3
—
r. .




Tidal Vol?®© L BTPS
NAME CONTROL
"




post drug CHAKG3 't' VALUE DEGREES OF
FREEDOM
CONTROL POST 1UG CHANGE ♦t* VALUE DBQKE
FRSI
J.R. 5 ,Om~ .0085 4,530- .0420 -.562 6.210' 58 IS.25-.31 15.00+-,16 -1.25 3.469 58 .5717i.0107 .5512i.0038 -.0205 2.200 58
J.P. 4.016-.1429 3.097-.0538 -.919 7.124 58 11.90-.43 1o.c2i.10 -1.88
-
4.803 54 .5983i.0255 .5663i,0105 -.032 1.306 56
C.D, 4.357-.0753 3.649-.0486 -.708 6.834 57 10.18-.30 12.7li.15 -3.47 10.321 51 .3426-.0034 .3850t.G054 +.0424 3.855 56




.50 . .4697-.0063 .4503i ,0042 -.0194 2.153 56
i- '■>
J.McK . 5.383-.0098 4.865-.0469 - .498 49.602 58 17,42^.40 16*54*.14 -.825 2.53 58 .535li,0089 .522li,0034 -.013 | -1,615
! ■ •' •
56
A.N, 5.035-.0524 4,163-.0588 -.872 7.207 58
L









58 14.17i.J4 ■ 14.5oi.14 4" ,83 1.114 58 .5369^.0051 .5275-,0062 -.0594
s • •' u
4.677 56
A.M. 4.431-.0899 3.889-.0349 -.562 6,787 58 19.37i.51 18.00i.23 ■ -1.67 3.163 58 .423lt.0073 .407ai.0055 -.0155 1.348
i' , • •'
5*
H.3. 4.980-.0352 3»836-.0710 -1.084 7,385 53
— 1 "3
19.Ogi.30 14.73i.22 -4.35 9.205 88 .5158^0132 .5318-.0091 + .016 .825 U
f ft A ? *, f I !M I- VCIUHIS,
fPi/V&tiR o H * m * n n
Oa Wptfttee l/Ma/»in . STPD • COg Excretion VXi«, SfPD
d t*
OM
CHANGS CONTROL POST MUG CHANGS *t* TALCSwm mm *t* VALUE DEGRESS OF
FRKEDOH FXSKDGK
y\m~ Mm attt^.GOM -,0114 1,815 13 .2053-.0035 .2283-.0029 -.022 3.548 13







,4T3 13 .1317-.0019 .1286-.0037 -mm : *» 11
aw&mm \ •>- -,£113 3%m 13 .2290-.0027 .1868-,0033 -.0433 ■* ««ti£*-«®W 13
%m&mu
i











































-*J OTH 1 ^
»
TRfeLfc VP
CHANGES IN MINUTE VENTILATION, RESPIRA







, 2L/M BTPS Respiratory Rate - Breathe/Min. Tidal Volume L BTPS 02 Uptake L/M2 STPD
NAME CONTROL POST DRUG CHANGE •t' VALUE DEGREES OF
FREEDOM
CONTROL POST DRUG CHANGE 't' VALUE DEGREES OF
FREEDOM
CONTROL POSTDRUG CHANGE 't' VALUE DEGREES OF
FREEDOM











































































CHANGES IN MINUTE VENTILATION, RESPIRATORY RATE, TIDAL VOLUMES,
02 UPTAKE AND C02 EXCRETION AFTER 20mg/70Kg MORPHINE
Respiratory Rate - Breathe/Min. Tidal Volume L 8TPS 02 Uptake L/M2 STPD COg Excretion L/Mln. STPD




CHANGE •t' VALUE DEGREES OF
FREEDOM




CONTROL POST DRUG CHANGE
!




































. . / '
1.548 ..13'
'






































-.0062 .967 13 .- >;*
Table 11
Fractional Changes in Respiration, Oxygen consumption, and carbon dioxide output after morphine, in normal subjects and subjects in left ventricular failure














5 mg/70 kg 6 -.0423 + .0177*
(.0434)
























9 -.0230 + .0152
(.0455)
• ' 'r ' : '"<■
-.0303 + .0157****
(.0472)













': / 8.754 (3,24) 4.789 (3,24) 1.364 (3,24) (1) 6.843 (22,3) (1) 1.909 (22,3)
(F value) 'i. P < .001 .01 > P > .001 P > .2





(2) -.0975 + .0159
(.0744)
jjj» jjj jjj
(3) -.0326 + .0113
(.0590)
[3) 1.0199 + .0074**
(.0380)


















(1) Variance within is greater thnh between groups
(2) 10, 15 and 20 rag/70 kg groups pooled.
(3) All treatment groups pooled.
Table 12





Fractional changes during periods specified Mean +_ S.E.
fS.D.)
1 12 1,-3 I, - 4






. .1230 + .1522
(.3730)
10 rag/70 kg normals
*
















20 mg/70 kg normals .4 -.1045 + . 0300s!5
(.0599)






Combined 5 and 10 rag/

















(I) Change just short of significance at. .(Ml level.
TABLE 13


















Common Regression - All groups
-.209
5, 10 and 20 mg /


















(1) Of the regression constant -fe
(2) Standard deviation from regression
(3) Slope of regression line with attached standard error
(4) Slopes not homogenous .05 > P > .025
Table 14
Fractional changes in tidal volume during initial four periods following drug administration (25ta to__44th minute of standard protocol)
FRACTIONAL CHANGES IN TIDAL VOLUME
Treatment Group No. of Subjects £5 - 29' 25 - 34'.. 25 - 39'. . 25 - 44 * I

























20 rag/70 kg 4 -.1301 + .0304*
(.0SQ8)









(1) 3.093 (3,23) 2.548 (3,23) 1.690 (3.23) 1,225 (3,23)
F values
.1
,!■> P > .05 P = .2 P > .2
_ .. ,
(1) F = 1.829 <2,18)
(.2 > P > .1) if
5 mg/70 kg group
is excluded.
TABLE 15
O Uptake / Ventilation





















.0998' + (.0088 + .0030)
.0368 f (.0109 + .0021)
4. 252
4. 074













.0566 + (.0175 + .0030)
.0729 +' (.0151 + .0030)
4. 746
4. 355













. 0073 + (.0264 + . 0044^
.0500 + (.0196 + .0023)
4.645
3.943













.0539 + (.0178 r .0050)
(2)














.0618 + (.0160 + .0018)
.0758 + (.0141 + .0014)
4. 684
4.178
(1) Significant slope difference among subjects (.025 > P > ,01)
(2) Slope not significant







r y a + b C .B. X S
yx


















Post Drug^ 62 .701 .112 .0309 7 {.016?^
.0024)
4. 355 , 0034
IS mg/70 kg
(9 subjects)
Control 34 .848 -.0088 t(.OfS +
.0026)
4.645 .0027
-.0106 J; .0011 ****





Control 14 .741 .121 .0081 + (.0216^
.0051)
S.186 .0033
-.0046 ± .0030 *
Post Brug^ 38 .703 .114 .0435 *(.0156
.0029)
4.500 .0020
All groups Control 104 . 880 .114 .008u * {.022l ♦
.0013)
4. 634 .0035
Post Irug^ 30S .814 .1083
■<>




(I) slopes not homogenous (z) initial 3 post-drug observation* excluded from, calculation
\ % % ¥7
• r> '10 155 sum! ^ t £ % % 1 % %$? IlkQ' ItllliVUl; :'Jfcllj3i?.4T^ A.¥ £ I A f T- % it - •< z t%/ZZ»£- ~ - - - - ~ X.
W I t « % % 1 "& 'V $ Ki t' % 1 «fe Ml M, & lfc UPM X? t!, UJ UK <33
%■' ¥«5*ir ant M »4fM
^) •uHnnp* 'inr#l. ;«rti^S.IF5tf*».% *1. ^
l{rj) •■Jtth:: w, pi jlai* nJtart <>•* Hi- ;tff* IS
Table 18
Alveolar ventilation, cleat! space ventilation^ dead space volume (physiological) and PaCO^ at suc.-c-ssiva 4 glante Intervale •- normal subjects and subjects
In left ventricular fatlure
I
Subject
CONTROL PERIODS p 0 3 T » sue P EUOD s
Dose of Drug ItOK
1 2 3 i 2 4 5 6 7 8 9 10 11 12
Normal subjects
5 Kg/TO kg F.G.
♦
VA 2.877 2.910 2.747 2.853 2 .862 2.730 3.024 2 .782 2.676 2.850 2 .828 2.903
i
2.703 2.00) 2.864
i % 0.989 1.079 1.311 0.314 0,353 0.960 1.077 1.090 1.132 1.044 1.101 1.198 1.427 1.451 1.373
% 0.0825 0.0814 0,0831 0,0835 o.osso 0.0711 0.O706 0.0727 0.0742 0.0696 0.0722 0.0737 0.0804IV" 0.0866 0.0820
PaCO 43 43 46 41 42 43 42 43 44 42 43 42 ■ 455 46.5 45.5
M.W. *A 2.748 3.08O 2.569 5.572 2.960 2.873 2.371 2.604 2,398 2.805 2.470 2.814 2.670 2.556 2.875
vD 1.280 1.397 1.303 2.437 1.654 1.368 1.348 1.440 1 .152 1.435 1.075 1.610 1.309 1.190 1.432
VD 0.0883 0.0822 0.0900 | 0.1133 0.0894 0.0867 0.0856 0.0944 0.0922 0.0938 0.0811 0.0901 0.0883 0.08SQ 0.0889
PaCtV> 41 37.5 41.0 32.5 39 39.5 43.5 44 42.5 42 42.5 44.5 42 12.5 43
G.R. VA 2.842 2.915
i
2.808 2.915 2.639 2.335 2.573 2.851 2.513 8.788 3.007 2.873 ■; }2 .714 2.790 2.816
*D 1 ,331 1.321 1.411 1.444 iAm 1.300 1.245 1.198 1.259 1.260 1.424 1,322. A.235 1.200 1.219
VD 0,0819 j 0.0813 0.0863 0.0802 O.OS45 0.0912 0.0874 0.0841 0.0868 0,0890 0.0934 0.0912 0.0352 0.0857 0.0813
PaCX)2 43 45 45,5 45.5 48.5 47.5 46.5 47 48.5 47.5 47.5 47 — 17.5 47 46
W.B. k 3.597 3.632 3.373 4.334 3.218 2.380 3.241 2.941 3.164 3.915 S.X05 3,309 3,184 2.864 2.928
v
x>
1.152 1.151 1.157 0.926 1.030 1.049 1.121 1.217 1.33C 1. .268 1.180 1.287 0.869 1.075 0.926
VD 0.0768 0.0921 0,0890 0.0805 0.0841 0.0323 0.0787 0.0854 0.0902 0.0823 0.0774 0.0780 0.0095 O.O80O O.072S |
PaCOs 38.25 37.5 37.5 34.2 38.5 40.75 40 41 33.5 36 39 38.5 37 .75 36 38.5
|
to £1: # '-»» 9 2.572 2.986 3.862 2,714 2.605 2,631 2.000 2.525 2.581 2.545 2.495 2.427 2.480 2.46C-
i
2.480
VD 1.5-19 1.558 1.533 1.431 1.525 1.433 1.492 1.491 1.508 1.609 1.600 1.105 41.533 1.515 1.549
*
% O.1016 0.0989 0. ICS2 0.0962 0.1000 C.C913 0.0395 0.097ft 0.0689 0.1038 0.1049 0,0892 0.0989 0.0962 0.0968
PaC02 44 43.5 44 43 46.5 45.5 47 47 47 47 48 47 47.3 17 48
10 jag/70 kg O.F. vA 3.340 3.725 3.746 3,774 3.084 3.262 3.072 3.235 2.882 3.174 . v
VD 1.024 1.850 1.845 2.130 1.615 1.571 1.484 \1.735 1.713 1.889
VD O.G8G2 0.0881 0,0802 0.0757 0.0751 0.0757 0.0838 <10338 Q.0955 0.0994




VA 2.379 3.SIS 3,711 3.237 2.998 3.CSS 3.148 3.330 3.188 3.445 3.377 3.169 3.941 2.915 2.836




- ■ . - . ••_•. -> - %'• '*t-.; ffM. vD , 0.1007 ...0•1290 _ syfial22IL' ■. i^O.1321 0.1228,..-,. 0,1316 0.1337 0.1394 ;'fi;'«>.1318 ^
43.5
0.1539
*P.W n-oo v.' <.»— o *> 37.5 38 41.3 _jM> ii-S 40 38.5 3G .5 39.5 -13.5
15 ms/70 kg H.S. Ta '3.048 3.125 3.OK) 2.210 2.226 2.332 2.578 2.721 2.800 2.400 2.863 2.935 2.751 2.651 2.828
Vy> _1.947 1.884 1.859 j 1.343 1.1S5, 1.176. .J 1.389 x.j ..J.374.^ M, 1.495 ^L1.396 _ 1.382 1.246 * 1.130 1.173
1 • VD 0.1025 O.G954 0.10G5 O.OS53 0.0878 0.0797 O.0868 0.0904 0.0949 0.0980i . 0.0888 0.0817 0.0807 O.OS38 0.0959
' "■
■ ■ I ' v . IWJOft 42 40.5 '10.5 44.5 :f -15.5 44.5 44.5 44.5 45 : 47 44.5 42.5 42.5 43 44
A .9.
*"
VA 3.ISO 2.924 2.313
1
2.561 2.454 2.557 2.554 2 .GOO 2.623 2.506
i - . .
2.562 2.593
■ 1.619 1.368 1.303 1.421 1.135 1.195 1.239 1.990 1.267 1.343 1.370 1.359
VD 0.0702 0.072O 0.0746 0.0693 0.0646 0.0646 0.0638 0.068S ,, 0.0687 0.0746 0.0794 0.0788
. ' • •5> • > '•!
PaCOg 41 41 42 j 43.5 46.0 45.5 47.0 47.0 46.5 c 48 48 48.5
]
20 iag/7G kg W.F. e-'
••




VD 1.997 2,195 1.820 1.716 1.420 1.546 1.505 1.581 1.634 1.867 1.799 1.696 1.9C2> * 1.835 1.857
VD 0.0378 0.0944 0.0800 O.OS17 0.C77S 0.0788 0.0783 0.0772 0.0811 0.0817 0.O889 O.O807 0.0789 0.0928 0.0906
PaCOr> 42 42 40 ! 42.5i 43.5 42.5 42.5 45.5 45 45.25 45 45.25 45■; -r. ' i" 45 45
c.r. 3.277 3.XOO 3.079 2.509 2.639 2.888 2.864 2.762 2.773 2.913 '3 2.957 2.921 2.734 2.710 2.698
V9 1.732 1.784 1.706 | 1.503 1.567 1.333 1.370 1.500 1.399 -■ 1.357 1.425 1.486 . 1.603 1.542 1.666
VD 0.0949 0.1005 O.0975 1 0.0859 0.0995 0.0874 O.0843 O.0909 0.0823 O.0798 0.0838 0.0874 0.0329 0.0949 0.1010
PaCOg 42 41.5 41.5" | 43.5 46 45 45 46 45 45.5; 45 15.5 48.5 48.5 48
« n
m- ■
*« «k ftOffi n .in*?** I rt *>nr. ft QA Ol n <vo V- ■» /lot ft <vra <-> OUR V-- *> . **4 2.940 3 .045 S.098 " 3.GSC a.au
•*3. a
Table 19
Regression Statistics PaCG / Alveolar ventilation - Normal Subjects
Ct *"















Common Control^ -.507 21 .8731 41.689 47.809 - (1.938 + .719) 3.157 2.695 .02 > P
> .01




3.057 .01 > P
> .001
10 mg/70 kg Post Drug -.362 15 1.7234 42.347 50.433 - (2.537 + 1.685) 3.188 -1.950 +^
1.049
1.506 . 2 > P
> .1
15 mg/70 kg Post Drug -.400 18 1. 3081 45.333 52.961 - (2.958 + 1.599) 2.579 -3.10b +
.399
1.850 .1 > P
> .05




1.497 . 2 > P
> .1
Common Post-
drug regression -.350 124 1.3544 44.152 51.074 - (2.456 + .591) 2.819 4.156 P < . 001
(1) 10 mg/70 kg group excluded because of significant slope difference
(2) Post Drug adjusted mean compared with 10 mg/70 kg control estimate
Table 20
Regression Statistics Alveolar ventilation/PaCQ Normal subjects
u
Treatment Group Degrees ofFreedom
S
yx
Y a + (b + S.E.) X Remarks
Pooled Control 21 .2283 3.157 8.6807 - (.1325 +
.0492)**
41.689
5 mg/70 kg Post drug 50 . 2250 2.770 5.8219 - (.0697 +
.0238)***
43.786 Post drug slope not significantly different
from control. Post drug adjusted mean
significantly less than control (.2157 + .0618).
10 mg/70 kg post drug 15 . 2548 3.188 5.3773 - (.0517 +
.0356)
42.347 Post drug slope is significantly smaller than
own control slope.
15 mg/70 kg post drug 18 .1768 2.579 5.0270 - (.0540 +
.0292)
45.333 Post drug slope not significantly different
from control. Post drug adjusted mean
significantly less than control (.1653 _+ .0941).
20 mg/70 kg post drug 38 .1152 2.847 3.7476 - (.0201 +
.0187)
44.808 Post drug slope significantly different from
control slope (. 05 > P > .02).




MINUTE VENTILATION, RESPIRATORY RATE, TIDAL VOLUMES, UPTAKE AND C Og EXCRETION (4MPSM1D AIR )
MEASUREMENTS DURING SUCCESSIVE FOUR MINUTE PERIODS BEFORE AND AFTER MORPHINE 15mg/7QKg




Subject Measurement Control Periods Control • Post Drug Periods
S •A •
Ht. Wt. 1 2 3 Values 1 2 3 4 5
r.- ■ ■
6 7 8 ^ 9 10 11 12
61 yrs M Minute Ventilation 4.533 4.481 4.220 4.413 4.882 3.881 3.896 3.511 3.896 3.557 3.557 4.158 3.850 4.081
!
3.434 3.821
Respiratory Rate 19.25 16.25 16.25 17.25 17.50 13.75 12.25 11.25 11.75 9.33 10.25 12.25 10.25 11.25 10.25 9,50
A.O. Tidal Volumes .436 .495 .494 .4752 .496 ,492 .596 .575 .580 .630 .611 .609 ,658 .658 ,580 ,662
1.82sq.m. 0 Uptake .130 .136 .127 t .1310 .140 .125 .128 .116 .132 .116 .126 .131 .128 ,135 .114 * *136
173cms. 70Eg CO Excretion .162 .167 .162 .1637 .189 ,155 .161 ,147 .168 .158 .157 .180 .163 ,182 .149 ,169
30 yrs. M Minute Ventilation 8.660 8.726 8.550 8.646 7.969 7.i33 7.397 7.529 7.198 6.449 6.560 6.164 S .296 6.207 6.383 6.097
Respiratory Rate 27.50 26.25 26.00 26.58 26.25 20.50 23.50 23,25 24 .00 22.75 19.75 20.75 22.75 4 19.50 22,50 22.75
D.McA. Eidal Volumes .557 .577 .571 .568 ,514 ,472 .558 .565 .546 .490 ,579 .511 .487 .506 .480 .452
1.77sq.m. 0 Uptake .176 .184 .177 .1790 .185 .168 .182 .185 .172 ,167 .182 .169 .164 ,158 .154 .148
168cms, 68.5Kg COg Excretion .283 .285 .279 .2823 .276 .245 .266 .279 .258 .233 ,265 .241 S .243 ,240 .244 .227
•
60yrs, M Minute Ventilation^ 4.561 4.432 4.465 4.485 3.707 3.284 3.639 2.737 3.329 3.217 3.667 2,911 3.426 4.052 5.210 3.763
Respiratory Rate 16.00 15.75 16.50 16.08 16.25 14.25 13.25 12.75 12,75 13.50 14.50 14.00 14.50 13.50 12.75 14.50
R. Mcl. Tidal Volumes ,480 .441 .458 .4592 .382 .387 .462 .345 .440 .414 .430 .343 ,407 .479 .673 .421
1.73sq.m. 0 Uptake .125 .116 . 126 .1223 .098 .113 .120 .090 .110 .101 .113 .082 .115 .128 .127 .103
169cms. 65Kg
'
COg Excretion .178 .166 .171 .1717 .137 ,138 ,158 .114 .145 .136
- • •.
.157 .113 .147 .179 .204 *143
62 yrs. M Minute Ventilation 7.365 7.058 6.986 7.137 6.582 6.107 5.274 5.703 5.868 5.300 5.109 5.180 5.156 5.465 6.582 6.915
Respiratory Rate 27.00 26.50 26.00 26.50 28.75 27.50 21.50 21.25 23.25 20.25 20.75 19.75 20.50 21.00 23.25 26.50
A.M. Tidal Volumes .533 .441 .412 .4619 .372 .371 .408 .427 .424 .424 .407 .421 .414 .434 .474 .434
1.64sq.iu. 0 Uptake .149 .142 .147 .1460 .130 .140 .132 .135 .131 .127 .115 .123 ; .123 .116 .142 .137
165sq.m. 59Kg CO Excretion
A
.215 .203 .204 .2073 .180 .173 .166 .180 .177 .170 .152 .163 .162 *165 .211 .198
71 yrs. F Minute Ventilation 7.860 8.100 8.247 7.968 5.579 4.193 5.264 &.720 5.053 5.544 5.193 5.036 5.019 5.176 4.497 5.193 :-
Respiratory Rate 34.50 32.75 32.50 33.25 25.75 17.75 20.50 19.00 19.50 19.50 19.00 18.25 19.00 18.75 14.25 18.75
E.S, Tidal Volumes .371 .392 .409 .3905 ,336 ,379 ,407 .491 .407 .454 .426 .433 .411 .457 .473 ,441
1.59sq.m. 0 Uptake .104 .110 .113 .1090 .094 .092 .107* ,106 .094 .104 .096 .098 .089 .100 .086 .104
165cms. 55Kg COg Excretion .137 .145 .147 .1430 .106 .100 .122 .130 .112 *123 .120 .119 .112 .122 .106 .126
60 yrs. F Minute Ventilation 7.123 7.056 6.148 6.776 8.246 3.615
it
3.165 3.961 3.879 3.728 3.973 3.757 3.973 3.890 3.807 4.305
Respiratory Rate 20.75 20.00 18.25 19.67 20.00 17.50 16.75 18.25 20.25 19.75 22.50 21.50 22.50 21.00 22.50 21.75
A.G. Tidal Volumes .602 .597 .576 .5918 .672 .345 .330 .356 .332 .322 .301 .310 .294 .312 .308 *353
1.67sq.m. 0_ Uptake .156 .161 .158 .1583 I .153 .115 .140 .163 .159 .153 .149 .147 . .,147 v .146 .141 .137
154cms. 68.7Kg CO Excretion
A
.229 .224 .204 .2190 .244 .116 .121 .154 .151 .146 ,158 .152 .160 .157 .154 .168
Table 22
Control values in Normal Subjects and Patients vvith Left Ventricular
Failure
NORMAL SUBJECTS
All Normals Normals in 15 mg/70 kg Patients in Left Difference betv/een means
Measurement Mean + S. E.
m T
-








(3) - (1) (3) - (2)
Ventilation 28 4.674 + .1095
(.5796)
9 4.677 + .1573
(.4717)
6 6.571 + .7217
(1.7681) 1.897** 1.894*
Respiratory Rate 28 16.52 + .57
(3.01)~
9 17.28 + 1.01
(3.02)"
6 23.22 + .85
(2.09)
670**** 5.94***
Tidal Volume 28 .5252 + .0157
(.0832)
9 .4938 + .0300
(.0901)
6 .4911 + .0307
(.0752)
-.0341 -.0027
Oxygen Uptake 26 .1376 + .0030
(.0154)
9 .1312 + .0048
(.0145)





26 .2724 + .0053
(.0270)
9 .2023 + .0112
(.0037)
6 .1978 + .0204
(.0501)
sO0•1 -.0045
Age 28 45.32 + 2.20
(11.64)
9 53.66 + 3.32
(9.95)




Minute Ventilation 28 .0738 + .0076
(.0404)
9 .0585 +.0089 "
(.0268)
6 .0927 + .0178
(.0436)
.0189 .0342




6 .0312 + .0046
(.0114)
.0037 .0036
n = number of subjects
Table 23
Changes in PaCK, PaCQ, and arterial pH after 15 mg/70 kg morphine in patients




Changes in PaCO^ Changes in arterial pH
Control Post drug Control Post drug Control Post drug
























A.G. 82.33 + 1.45
(2.52)











CHANGES I » MINUTE VENTILATION, RESPIRATORY RATS, TIS A h V O L U M §» O UPTAKE AND COg EXCRETION I K P A T I S NTS KITH LEFT VSSTRICDl AOB FAILURE
A F T S R lSttg/70% MORPHINE
NAME CONTROL
£51nut© Ventilation











CONTROL ' POST DRUG g&AlEfX ♦t! VALUE .DEGREES OF
FMSDGB




CONTROL POST DRUG CHANGE 't'VALUE DEGREES OF
FREEDOM
C0_ Sxcasaiioti
2 Afy . ■ ■ ..
CONTROL POST DRUG C»ANGS *t' VALUE DEC- • ' ' OF
FT ■:»+"

















































































































































































CHANGES IN MINUTE VENTILATION, RESPIRATORY RATE, TIDAL VOLUME, 0„ UPTAKE AND C0o EXCRETION
ct 2
AFTER I5mg/70Kg IN PATIENTS WITH LEFT VENTRICULAR FA I L U RE
DOSE SUBJECT
Minute Ventilation
ACTUAL CHANGS FRACTIONAL CHANGE
Respiratory Rate
ACTUAL CHANGE FRACTIONAL CHANGE
Tidal Volume
ACTUAL CHANGE FRACTIONAL CHANGE
0? Uptake
ACTUAL CHANGE FRACTIONAL CHANGE
CO iExcretion




L/sq.m. Breatb/min, L. B.T.P.3, l/min./sq.m.
S.T.P.D.
1/min. S.T.P.D.
-0.534 -.1210 +5.57 -.3229 + .120 +.2532 -.0039 -.0298 +.0011 +.0067
D.MCA. -1.864 -.2156 -3,58 -.1347 -.055 -.0968 - .0095 -.0531 -.0309 -.1095
r.mel. -0.906 -.2020 -2.20 -.1368 -.027 -.0595 -.0140 -.1145 -.0241 -.1404
a.m. -1.367 -.1915 -3.65 -,4235 -t045 -.0966 -.0162 -.1110 -.0325 -.1568




, - ■ +'
-.239 -.4037 -.0125 -.0790
■
■- ' + ' i { " ; ■ ■:
- .0622 - .2840
Table 25
Fractional Lepreasioa in Respiration, Oxygen Uptake and Carbon
Dioxide Output, in Patienta with Loft. Ventricular Failure (6 subjects)
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. 868 t .066*
(.1619)
P > .3


















Regression Statistics Oxygen Uptake/Ventilation in Patients with Left Ventricular Failure







Y a + (b + S.E.) X Groups tested f Difference
+ S.E.
1. Control . .
Regression* '
.620 19 .0039 .1362 .0550 + (.012*4**
.0036)
6.568 1-2 -.0212 +
.0024****
2. Post Drug .715 47 .0074 .1291 .0553 + (.0154 + 4.779 1 - 3 -.0368 +
Regression .0022) .0024****
3. Control - . 650 105 .0049 .1369 .0618 + (.0160 + 4.684
all normals .0018)




Comparisons between Soluble Phenobarbitone and Morphine Treatment Groups
Measurement





n Mean _+ S .E.
(S.D.) n Mean Hh S.E.
(S.~D.)
Ventilation 28 4.674 +. .1095 4 4.482 + . 3759 .1923 7.5
(.5796) (.7519)
Respiratory- 28 16.52 + .5689 4 17.96 +1.60 -1.44 .4 > P > .3
Rate (3.0102) (3.19)
Tidal Volume 28 .5252 + .0157 4 .4529 + .0400 .0723 .2 > P > .1
(.0832) (.0800)
Oxygen 26 .1376 + .0030 4 .1190 + .0019 .0186* .05 > P > .02
Uptake (.0154) (.0038)
Carbon dioxide 26 . 2124 + .0053 4 .1834 + .0067 .0290* .05 > P > .02
output (.0270) (.0133)
Age 28 45.32 + 2. 20 4 51 + 5.92 -5.68 .4 > P > . 3
(11.64) (11.83)





































































































































































































MINUTE VENTILATION, RESPIRATOR-7 RATE, TIDAL VOLUMES, 0? UPTAKE, COg EXCRETION (-B"!I IH[ R 9 D 'A I »-)
MEASUREMENTS DURING SUCCESSIVE FOUR MINUTE PERIODS BEFORE AND AFTER SOLUBLE P H E NO BARBITONE










Post Drug Periods V
















































































































































































































































































































































































olteoobarbitone at 4. 9. 14 and 60 minutes following riru;> administration
P E RIOT OY£ R W H I C H M E A S U R E D
Item 0-4' 0-9' 0 - 14' 0 - 60'






-. 0211 2 « 0288
(.0576)


































Changes in PaCO and pH alter soluble phenobarbitone
Subject
Changes in PaCO^ Changes in pH
Control (1) Post Drug (2) Control (1) Post Drug (2)














7. 328 + . 001
(.005)










12 post drug observations
Table 31
Changes in Ventilation and PaCQ^ and P CO during sleep reported by various authors^
11 35 1 " jrx. ' 2' L 1" '













13 -.2653 + .0412 (.1486) 3.545 + .455 (1. 508) -.2154 + .0703
Birchfield, Siekei"^
and Heyman (1959
11 -.0872 + .0281 (.0933) 4.091 + .625 (2.071)
Biilow and Ingvar^
(1961)
4 -.2316 + .0154 (.0308) 2.00 + .561 (1.122)
Billow (1963)^ 12 -.2059 2.1 + 0.3
Biilow 12 -.2647 3.8 +0.4
(1) Statistics calculated from reported data, except where otherwise indicated
(2) Statistical parameters not calculable from reported data
(3) Ventilation and PaCO measured at different points in time
Table 32






+ ++ +++ +t++



























barbitone 36', 2', 3' 1 • 1
it.
2
+ Definite drowsiness throughout all or most of post drug period
+t More marked drowsiness; eyes closed from time to time for short periods
+t+ Eyes closed most of the time for some part of post drug period
++++ Eyes closed most of the time for all or nearly all of post drug period.
Table 33
5 mg/70 kg group State of Drowsiness related to fall in ventilation and oxygen uptake
M.W. F.G. G.R. J.H. W.B. W.E.
Change in Ventilation + .0118 +.0061 -.0447 -. 0641 -.0715 -.0956
Change in state of
alertness +++ ++ +++ ++++ +++ ++
Time of onset of
drowsiness 1' 17' 3.5' 1' 2' 6'
M. W. G.R. W.B. W.E. F.G.
Change in oxygen
uptake -.0087 -. 0113 -. ol47 -.0427 -.0486
Change in state of
alertness +++ +++ +++ ++ ++
Time of onset of
drowsiness 1' 3.5' 2' 6' 17'
Table 33 (contd.)
10 mg/70 kg group State of alertness related to fall in ventilation and oxygen uptake
W.D. A.W. W.H. J.N. R.M. A.McK. I.S. G.F. W.J.
Change in ventilation -.0207 -.0647 -.0702 -.0874 -.0915 -.1077 -. 1118 -.1143 -.1397
Change in state of
alertness ++++ ++ ++ ++ +++ + + +++ ++++
Time of onset of
drowsiness 5' 2' 3' 3' 16' 3' 7.1' 4» 3'
W.H. Z.S. A.W. W.D. W.J. A. McK. G.F. R.M.
Change in oxygen
uptake +.0423 +. 0119 +.0029 -.0013 ©Ho•1 -.0286 -.0614 -.0951
Change in state of
alertness ++ ++ ++++ ++ ++++ +++ +++ ++
Time of onset of
drowsiness 3' 2.1' 2' 5' 3' 3* 4' 16'
15 mg/70 kg group State of alertness related to fall in ventilation and oxygen uptake
J.McK. J. C. J.R. A.. M. C.D. A.N. H.S. J.P. W.I.
Change in ventilation -.0929 -.0955 -. 1104 -.1263 -.1625 -.1732 -.2177 -.2288 -.2425
Change in state of
alertness 1 + ++++ + + ++ ++++ ++++ ++ +++ ++++
Time of onset of
drowsiness 52' 4' 3' 10' 7.5' 15' 1' 0.5' 1'
H.S. C.D. A. « hi • J.C. A.N. J.McK. J.P. J.R. W.I.
Change in oxygen
uptake +. 0233 + .0203 +.0178 + .0147 -.0195 -.0290 -. 0717 -.0726 -.0906
Change in state of
alertness ++ ++++ ++ ++++ ++++
•
+ ++ ++++
Time of onset of




-J32' 1.5* 3' P
Table 33 (contd.)
20 mg/70 kg group State of alertness related to fall in ventilation and oxygen uptake
J.D. C.R. W.F. J.R.
Change in ventilation -.0961 -.1293 -.1581 -.2308
Change in state of alertness ++++ ++ ++ ++++
Time of onset of drowsiness 3.5' 4' 5' 2'
C.R. J.D. W.F. J.R.
Change in oxygen uptake +.0304 + .0141 =.0325 -.0487
Change in state of alertness
I
++ ++T+ ++ ++++
Time of onset of drowsiness 4' 3.5* 5' 2'
